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Abstract
High-throughput technologies in biomedical sciences, including gene mi-
croarrays, supposed to revolutionise the post-genomic era, have barely met
the great expectations they inspired to the biomedical community at first.
Current efforts are still focused toward improving the technology, its
reproducibility and accuracy. In the meantime, computational techniques
for the analysis of the data from these technologies have achieved great
progresses and show encouraging results.
New approaches have been developed to extract relevant information out
from these results. However, important work needs to be further conducted
in order to extract even more meaningful and relevant information.
These techniques offer great possibilities to explore the overall dynamic
held within a living organism. The potential information contained in their
output can reveal important leads at deciphering the interconnection, in-
teraction or regulation influences that can exist between several molecules.
In front of an increasing interest of the scientific community toward the
exploration of these dynamics, some groups have started to develop solu-
tions based on different technologies to extract these information related to
interactions. Here we present an Artificial Neural Network-based method-
ology for the study of interactions in gene transcriptomic data. This will be
applied and validated in a breast cancer context.
This manuscript will discuss the methodological optimisation to identify
biomarkers of interest from high-throughput transcriptomic technologies;
and it will show how the algorithms were brought forward to identify the
potential relationship that may exist between the markers identified. It will
illustrate and highlight the robustness of the methods by discussing some
examples of application in different breast cancer studies.
The present thesis will show that despite the great difficulty to obtain
gold validation to prove the robustness of the approach; it has been possible
to identify some relevant features able to highlight the promises held by this
preliminary development of the method. The results obtained by trying to
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identify the correlated component within an artificial dataset suggest some
interesting ability of the approach. Additionally, when applied to the van’t
Veer dataset (van’t Veer et al., 2002), the list of selected transcrpits held
two different isoforms for two different genes, and the method identified the
strong correlation between the 2 forms. Finally, the results involving the
transcripts for DTL, TK1 and CDC45L have been shown to overlap with
the result of a similar work from Gevaert et al. (2006) on the van’t Veer
dataset using a different method involving a Bayesian network with Markov
blanket.
Ultimately, this thesis will try to discuss the advantages or limitations
as well as the potential application and future hopes around the methods
introduced.
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Chapter 1
Introduction
1.1 The challenge of biomarker identification
The latest development in genomics and proteomics research have be-
gun to open the door for the future generation of medicine. One poten-
tial to lead to personalised medicine where the hope would be to provide
early, fully customised and adapted therapy for a particular individual to
a particular condition or disease. In the first place, this involves an early
detection/diagnosis of the disease, but yet it is just one part of the chal-
lenge. Another is to clearly identify the characteristics of the conditions.
Several diseases are known to present high heterogeneity (e.g. breast cancer
is known to have several types and even several subtypes (Kapp et al., 2006;
Perou et al., 2000)). Not only does this heterogeneity exists for the disease,
but combined with the natural biological variation from one individual to
another, it results in very different phenotypes and types of behaviour. As
a consequence different responses occur from one patient to another for a
similar disease under a similar treatment. Therefore, early and accurate
phenotyping and identification of the sub-types of the disease can reveal
crucial information relevant for subsequent treatment and prognosis, and
ultimately patient outcome.
One of the first requirements for patient-tailored treatment is to ob-
tain early and adapted diagnostics for diseases with high incidence in the
population such as cancer. It is well established that an early diagnosis
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Figure 1.1: Evolution of incidence and mortality rate of female breast cancer in Great Britain from 1975
to 2009 (source: Cancer Research UK)
will greatly increase the prognostic outcome for a patient, by managing the
disease and providing appropriate treatment in the early development of
the disease, and subsequently preventing it to reach a critical development
(e.g. metastatic stage in cancer). This has been clearly proven over the
years with the improvements of screening techniques such as mammogra-
phy for breast cancer. Figure 1.1 highlights this fact as it shows a clear
drop of mortality rate around 1989 in England, whilst incidence is slightly
increased. The evolution of incidence is mainly explained by the worlds first
national breast screening programme set up in England in 1988. However,
the drop in mortality rate observed can also be attributed to the early suc-
cessful treatments with Tamoxifen on ER positive patients in the late 80’s.
These screening techniques have proven their efficiency by diagnosing early
and asymptomatic breast carcinomas and subsequently allowed to provide
treatments earlier in the disease evolution to a larger cohort of women, con-
sequently leading to a drop in the mortality rate. Nevertheless, they only
rely on visual and microscopic observation through pathological methods,
and then can only pick tumours that have already evolved to a later stage
or grade. As a result, the following step for earlier detection of malignancies
needs to be carried out at the molecular scale. This is the whole interest of
biomarkers.
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Although there is no real consensus among the scientific community or
health organisations to precisely define a biomarker, two of them can be
noticed:
• A characteristic that can be measured and evaluated as an indicator of
normal biological processes, pathological processes or pharmacologic
responses to therapeutic interventions National Institutes of Health
(NIH) Biomarkers Definitions Working Group, 1998).
• Any substance, structure or process that can be measured in the body
or its products and can influence or predict the incidence of outcome
of disease. (World Health Organization (WHO) International Pro-
gramme on Chemical Safety)
However, for these two definitions, a key expression in common is : “can
be measured ”. A biomarker is a characteristic or a molecule that can be
measured and/or quantified with any instrument or method. Therefore, if
the biomarker is to be involved in a potential future assay, or diagnosis
tool, the accessibility to the marker needs to be relatively easy (from blood
stream or urine). Finding biomarkers using invasive tissue based approaches
can not be easily transferable to routine clinical aspect. Consequently, an
ideal biomarker would be any peptide, protein or generally a molecule easily
accessible via body fluids (such as blood or urine); and that would only be
detected in affected patients and not in healthy individuals (Chatterjee and
Zetter, 2005; Lane and Crawford, 1979; Linzer and Levine, 1979), hence
with a sensitivity of 100%. However, a biomarker is only as good as its abil-
ity to accurately identify true positive cases and to distinguish as well true
negative ones (i.e. not only the sensitivity is important but the specificity
is key too) (Diamandis, 2004b).
One of the earliest markers to be used as a biomarker for cancer was Car-
cinoembryonic Antigen (CEA) described in 1965 by Dr. Joseph Gold for
the prediction of colon cancer (Gold and Freedman, 1965). He found that
CEA, normally present in foetal tissues, was also present in blood stream
of patients with colon cancer (Chatterjee and Zetter, 2005). This particular
antigen had been found later to be an indicator of breast cancer prognosis
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outcome and treatment response (Krieger et al., 1984; Park et al., 2008) as
well as CA 15-3 (Chatterjee and Zetter, 2005; Ebeling et al., 2002). It is
later, in 1979, that one of the best known cancer marker, tumour protein
53 (p53), is almost simultaneously identified by different groups of Arnold
Levine, David Lane, and Lloyd Old (Deleo et al., 1979). This protein will
be reported to have key role in Deoxyribonucleic Acid1 (DNA) damage re-
pair and tumour suppression which will open new direction in breast cancer
research (Levine et al., 2004). Still in the focus of breast cancer markers,
it is only a decade later that the most important step is accomplished in
the identification of 2 major genes for breast cancer management, when in
1994 Mark Skolnick et al. discovered the breast cancer, 1 (BRCA1) gene
(Miki et al., 1994) and Mike Stratton et al. identified the breast cancer, 2
(BRCA2) gene (Miki et al., 1994). BRCA genes are believed to be responsi-
ble for about 80% of inherited cancers, and women with BRCA1 mutations
have about 85% risk of developing breast cancer for lifetime (Antoniou et al.,
2003; King et al., 2003).
We can cite as well that a marker can not only be a molecular entity,
but can be an index calculated from a combination of factors describing
a sample for several types of outcome. It is the case of the Nottingham
Prognostic Index (NPI) which allows the stratification of a population by
calculating an index value, this value gives insight about the 5-year survival
chance for an individual after surgery removal of breast carcinoma (Haybit-
tle et al., 1982). The NPI is based on the tumour grade score (G) according
to the modified Bloom-Richardson grading, tumour size(S), and number of
positive lymph nodes score (L) (1 for no node, 2 for 1-3 nodes, 3 for more
than 3 nodes). Multivariate analysis found these 3 parameters as important
to be involved in the NPI, and the expression is :
NPI = G+ L+ (0.2× S) (1.1)
1DNA is the long-term storage nucleic acid holding the genetic information of a living
organism contained within the nucleus of its cell(s) for eukaryotic organisms.
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Biomarkers have three main application domains:
• Diagnostics
• Prognostics
• Prediction of therapeutic outcome
Nowadays, the early diagnosis of diseases and their reccurence remain
the most frequent use of biomarkers. However, future hopes are to im-
prove the other 2 areas of application. With new biomarkers, accurate tests
and predictive models could provide clinicians and patients with accurate
prognosis and prediction of response to treatments (Chatterjee and Zetter,
2005). A more precise phenotyping of tumour characteristics would give an
insight to which sort of therapeutic strategy had a chance of success. Thus,
maximising the therapeutic and consequently prognostic outcome for the
patient.
However, considering all this hope, the path leading toward personalised
medicine still is a long and difficult one, and the biomedical community is
still facing important challenges to achieve this objective (Ginsburg and
McCarthy, 2001). The current lack in accurate and reliable biomarkers for
critical diseases (e.g. cancers) remains a crucial challenge for the biomedical
and the bioinformatics community, and the identification of new biomark-
ers still requires a tremendous amount of work (Rifai et al., 2006). So far,
only classical methods, mainly based on the judgment of the pathologists
(involving an obvious element of subjectivity) are being employed to char-
acterise the clinical state of a patient regarding a disease, an infection, or
the grade of a disease. The discovery of new biomarkers could then allow for
a quicker, more reliable and efficient method of diagnosis for these patholo-
gies. Furthermore, such biomarkers could provide new potential targets for
future therapies.
This task is made difficult mainly by the high heterogeneity of some dis-
eases, furthermore, diseases are almost always multifactorial (Barabási and
Oltvai, 2004). Therefore, it can be worthless focusing on a single biomarker,
and it should be recomended to consider a panel of biomarkers, a fingerprint
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which results in providing more reliable and accurate models.
In this thesis we show that it is possible, not only to extract relevant in-
formation and accurate biomarkers from high-throughput technologies such
as microarray technology, but literally distill out from the data even more
information regarding the whole dynamic in place within the sample at
the moment of extraction, collect deeper information and assess how the
relevant biomarkers studied may be co-expressed, and therefore interact
somehow. This is possible as we know that the system studied are highly
complex and dynamic, and therefore hold this information.
1.2 Breast cancer
Cancer is a generic term to designate diseases affecting the regulation
of the cells’ cycle, growth and migration. It has been found they involve
important changes in the genetic information contained in the cells; and
it has been shown that these genetic mutations can lead to the appari-
tion of oncogenes (which enhance cell proliferation), and the silencing of
cell proliferation regulation genes or tumor suppressor genes (Hanahan and
Weinberg, 2000). When the highly regulated behaviour of the cell division is
corrupted, they proliferate in an anarchic way, they expand without dying,
and invasion can eventually lead to the death of the individual.
A large focal point of this research has been to cancer, and in particular
breast malignancies. The reason for this is mainly due to the fact that 120
women out of 1,000 in the UK population have a lifetime risk to develop a
breast cancer (source: breast cancer UK), as a consequence a large amount
of information as well as samples have been collected and stored during
years for the purpose of prospective study. These databases can then pro-
vide valuable information and datasets to further develop, test and validate
approaches and models developed by scientific research. Besides, this can-
cer is known to be highly heterogeneous, several types and subtypes exist,
with different outcomes, treatments and prognosis for each of them (Sørlie,
2009). That makes this cancer a real challenge for the biomedical commu-
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nity to find appropriate diagnosis tools, biomarkers to characterise the type
of breast cancer. Characterising this type early in the development of the
disease would help finding which treatment should give the best outcome
(and which would not) and therefore apply directly a therapeutic solution,
tailored to the patients’ tumour phenotypes, that have optimum chances of
maximising the patients’ benefit.
Breast cancer has a high incidence in western countries, every year 45,000
women are diagnosed with breast cancer in the United Kingdom, 12,000 will
die from it. It is the second cause of death from cancer for women in the
UK. And one woman out of nine will be diagnosed with breast cancer in
her lifetime (source: cancer research UK).
One of the main difficulties encountered by researchers in breast can-
cer is the high heterogeneity of the disease. This cancer can exist in many
different types and sub-types. First of all, the cell type of the origin of
the cancer (ductal or basal) makes it very different. Thereafter, several
subtypes can exist regarding the status of the cells for oestrogen or pro-
gesterone hormones, or Her2 protein (Bertucci and Birnbaum, 2008; Sørlie
et al., 2001, 2003). Greater understanding of underlying molecular events
can result in a more accurate choice of therapeutic strategies thus favouring
better results and outcomes for the patients at the end of the curing process.
1.3 The interest in Systems Biology
It is becoming clear that the era of reductionism (i.e. the removal or
filtering out of important variables) is potentially limited with respect to ge-
nomics and proteomics information derived from histological systems in bi-
ology and biomedical sciences (van Regenmortel, 2004). Until lately, reduc-
tionism was still the current paradigm in biology and biomedical sciences.
However, it appears clearly now that such a way of researching starts to
show some limitations (Gierasch and Gershenson, 2009). Therefore, the sci-
entific community is beginning to consider a more comprehensive approach
toward life science : Systems biology (Ahn et al., 2006). According to Ahn
and coworkers, system biology is the study of biological processes from a
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wider point of view, considering the overall dynamics of the parts to form
an entity.
So far research groups have mainly focused their work toward biomarker
identification, however it clearly appears that identifying single markers is
highly reductionist and has reached its limits in terms of predictability, and
more particularly in terms of understanding the biological relevance of a
particular marker. Therefore, it was sought to investigate further to, firstly
identify not only a single marker, but a combination of markers able to
accurately discriminate together the population between two or multiple
classes; and secondly identify potential interaction that may exist between
the markers contained in a dataset. Indeed, by looking only at potential
single biomarkers, we try to model a real-world system that is non-static,
but completely dynamic and highly complex, as most of these markers are
interacting with each other, as stated by Barabási & Oltvai (Barabási and
Oltvai, 2004) :
It is increasingly clear that a discrete biological function can only
rarely be attributed to an individual molecule.
While the identification of a panel of genes or proteins is an important
work, investigation of interactions within a panel of contextually relevant
genes associated with a given clinical question has the potential to eluci-
date biological function and identify functions and interactions that asso-
ciate with the disease, thus studying "interactome"2 of a given disease. The
study of the interactome offers the further potential for identification of new
disease specific pathways that may be used to identify therapeutic targets.
When one considers the study of the interactome an issue of complexity
arises. If one were, for example, to consider a whole genome, the num-
ber of interactions would be massive. For example, in an Affymetrix array
one would find in the order of 600 million potential interactions. Clearly,
2The term interactome has been firstly described in 1999 by sanchez and cowork-
ers as "the complete repertoire of interactions potentially encoded by the genome of an
organism" (Sanchez et al., 1999).
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interpretation of this is impossible due to complexity. In order to study
the gene interactome in a reasonable fashion it is necessary to first define
the context of the question. In an earlier study, our group developed a
method of screening genes in the context of a given question (Lancashire
et al., 2008). This reduces the parameter set to a manageable size while ad-
dressing the context of the problem allowing one to analyse the interactome.
In addition, it is now believed that the paradigm governing the idea of
transcriptional regulation as a simple on-off switch is no longer acceptable,
and scientists should rather consider it as a more complex system, similar
to a complex logic circuit, where several inputs may have contradictory
influence toward the expression of a gene (Duggan et al., 1999; McAdams
and Shapiro, 1995).
This thesis will describe a novel approach simultaneously considering
all of the genes in a set identified to be predictive of metastasis in breast
cancer explored previously by the van’t Veer study (van’t Veer et al., 2002).
This is achieved by the development and comparison of a series of Artificial
Neur Network (ANN) models that each of which use all available inputs to
predict a single omitted input. This is repeated for all single inputs within
the set. By examination of the weights and predictive performance of each
model, a matrix of interactions can be determined. The advantage of this
approach over others is that the multi-factorial consideration of each in-
put allows determination, for a given pair of parameters, the magnitude of
interaction, whether it is inhibitory or stimulatory and whether the inter-
action is bi or unidirectional. Once the process is achieved, filtering out the
non-significant interactions with a certain decision threshold will ultimately
result in an interaction map giving insight on what is relevant.
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1.4 Types of data used and analysed
Metabolic changes occurring due to a disease should have impact on the
presence (qualitative) and abundance (quantitative) of particular molecules
that can be monitored within samples such as serum or urine (Claudino
et al., 2007). Nowadays, the development of the new “omics” technologies
enables researchers to massively monitor the comprehensive profiling of sev-
eral types of molecules (e.g. DNA, Ribonucleic Acid (RNA)3, MicroRNA
(miRNA)4, and subsequently compare different samples to identify any sig-
nificant qualitative or quantitative alteration occurring between a cohort of
control samples and a cohort of samples carrying a particular disease; or
between two stages of a same disease.
These technologies require multi-disciplinary teams to firstly produce
and then decipher the vast amount of highly complex data produced at the
end of a Microarray (MA) experiment in order to extract the maximum
relevant knowledge (Duggan et al., 1999).
The research described in the present manuscript focused on several
types of data to analyse, genomic MA data in particular. Although, some
other types of data have been analysed too, such as Mass Spectrometry
(MS), flow cytometry or environmental data, they won’t be further discussed
here, for concision and consistency purposes.
1.4.1 Microarrays for genomic profiling
Statistical analysis of the genomic profile of an individual can lead to
the discovery of a pattern of genes, or fingerprint, associated with a disease
or phenotype of interest. Therefore, assessing the gene expression profile for
an individual could not only be exploited as a valuable diagnostic or phe-
notyping tool, but could enhance our knowledge of the particular dynamic
3RNA is a nucleic acid-based molecule existing outside of the nucleus of the cells.
Several types exist, inluding rRNA, tRNA, miRNA, etc... The most abundant and im-
portant is messenger RNA (mRNA) that plays a role of intermediaite between DNA
molecules and protein or peptide products.
4miRNAs are small RNAs (15-20 pair base) believed to play a regulatory role in
transcription of DNA.
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within the system of a given disease. MAs are a powerful and accurate
new technology that potentially allow the detection of hundreds of thou-
sands of genes contained in a biological sample within a single experiment
(Lancashire et al., 2009a). As a consequence, MAs have the perspective to
draw the whole map of the human genome and massively discover genes
of interest related to a particular phenotypes, ultimately leading to impor-
tant clinical developments for patient care and management (Lander, 1999).
MA techniques were directly derived from Southern blotting techniques
developed in 1975 (Southern, 1975). Edwin Southern’s method relied on
the hybridisation of DNA fragments, previously migrated by electrophore-
sis, using probes to detect the migration of the DNA sequence of interest.
The evolutions from Southern’s technique combined to the development of
cDNA libraries (Schena et al., 1995) triggered the development of DNA
MAs. These evolutions consisted firstly in the use of non-porous surface,
such as glass, which allowed their second evolution: miniaturisation (Lan-
der, 1999). As a consequence, spotting cDNA probes onto a solid surface in
microscopic wells, the MAs are able to simultaneously measure the expres-
sion level of an important number of genes. The first real use of genomic
(DNA) MA was reported in 1995 by Schena and coworkers (Schena et al.,
1995). They described a method to measure the differential gene expression
of 45 genes in Arabidopsis thaliana, by spotting gene-specific cDNA probes
on a solid glass surface and presenting to them fluorescent labeled RNAs
from the organism.
Principle
The detection of presence and abundance of labeled nucleic acids mainly
relies on the principle of DNA/RNA hybridisation on the array, where two
strands of matching DNA/RNA pairs bind to each other. They consist of
a collection of very short sequences of nucleic acids chemically bound to a
solid surface. Each of these sequences (the probes) are complementary to
a sequence of a gene, therefore each probe represents a particular gene, or
a specific segment of a gene. As a result, if a particular gene is present in
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Figure 1.2: The different steps for a gene microarray experiment (Duggan et al., 1999)
the sample, the probe of the corresponding gene will appear as present by
fluorescence.
Methods
The process of MAs can be split into 4 main steps (Stekel, 2003), sum-
marised in Figure 1.2.
• Sample preparation and labelling
• Hybridisation
• Washing
• Image acquisition
The early stage of a MA experiment consists of the extraction of the
molecules of interest (RNA, cDNA, miRNA...) from the samples. The
molecules are then labeled as desired. An example of a labelling method is
fluorescent dye binding to the oligonucleotide with Cytosine 3 (excited by
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green laser) and Cytosine 5 (excited by red laser). Commonly, two samples
are used differently labeled with the cytosines (e.g. healthy and disease
subjects) (Stekel, 2003).
Once labeling is complete, the molecules are presented to the array,
where matching strands can bind to each other. Therefore, when labeled
DNA/RNA fragments from the sample match DNA probes, heteroduplexes
are formed by complementary base pairing (hybridisation) as described by
Watson and Crick (Watson and Crick, 1953), which shows the presence of
the gene targeted by the specific probe, and highlights this presence later
by measuring the level of fluorescence.
Eluting is a critical step, as only labeled molecules that bound to the
probes are needed, it is essential that non-bound molecules are washed out.
Finally, an image of the fluorescence emitted by the dyes still bound
to the probes is captured. The intensity of the fluorescence is then nu-
merically translated, which is supposed to be proportional to the binding
intensity and therefore to the level of expression of the gene corresponding
to the probe.
Limitations
However, one of the main limitations of this method is situated in the
advantage itself. The massive production of data provide a dramatic highly
dimensional dataset, which can barely be processed by conventional sta-
tistical methods. For example, with Affymetrix GeneChip 1.0 ST MAs
(designed to target all known and predicted exons in human, mouse and
rat genomes), each individual case studied contains information for approx-
imately 1.2 million exon clusters corresponding to over 1.4 million probesets
(Lancashire et al., 2009a). In addition, this issue, combined with the inher-
ent important biological variability commonly found in biological samples,
induces an important difficulty to identify key features within a dataset.
This clearly stresses the need for feature selection/extraction strategy prior
any deeper analysis.
More importantly other issues arose from a reproducibility aspect. For
a robust and non-questionable identification of important markers, the data
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analysed need to be reproducible within samples, between sample runs and
even across different instruments (Diamandis, 2004a). Technical solution
employed so far use replicates and filtering with averaging of samples to
assess the good reproducibility of the experiments. Lack of good repro-
ducibility projects suspicion onto any identified predictive signature, subse-
quently making validation and then clinical application difficult (Matharoo-
Ball et al., 2007c).
With this question comes as well the question raised by normalisation
methods. The question of normalisation is key and several methods have
been described so far. The lack of gold standards toward this normali-
sation issue reduces the chances to obtain highly reproducible and inter-
experimental studies, particulary when applying normalisation methods to
purposes it was not meant to (Lim et al., 2007).
Therefore, innovative analysis methods need to be applied to extract mean-
ingful information from the array.
1.4.2 Simulated dataset
Despite the obvious advantages of using well-characterised simulated
datasets for the testing of new analysis tools; clear precautions need to be
taken in order to address appropriately any analysis concerning this type
of dataset. Indeed, the recent editorial from Rocke et al. in Bioinformatics
(Rocke et al., 2009) commented that our lack in the knowledge of actual bi-
ological correlation between sample replicates, combined with the unknown
dependency between a biological state of a cell and transcript expression,
and the unknown changes from one state to another, makes artificial data
only valuable for development stage and unworthy for purely comparing
different methods.
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1.5 Nature of the problems
Although expression MAs have brought high hopes and expectations,
they have brought with them tremendous challenges too. They have been
proven to suffer from different limitations as previously discussed.
However innovative computational analysis solutions have been devel-
oped and have been proven to be effective and successful at identifying
markers of interest regarding particular questions. But few research has
been carried out to deeply explore the information hold by the complex-
ity of expression arrays which can provide a broader view of interaction or
regulatory pathways and networks (Bar-Joseph et al., 2003).
1.6 Statistical methods for biomarker identifi-
cation
The real interest in MA experiments is in the analysis of multiple expres-
sion experiments in order to identify similar patterns of expression (Quack-
enbush, 2001). Although, multiplying the number of expression arrays ulti-
mately leads to an increasing amount of data correlating with an increasing
complexity; thus requiring robust methods to extract the relevant infor-
mation from them. Computer based methods are then needed to decipher
this complexity, and extract as much meaningful information as possible.
Several methods exist for this purpose, some of them (i) are derived from
the field of classical statistics, such as clustering techniques or regression
analysis. Other methods (ii) come from the more advanced field of ma-
chine learning approaches ranging from Support Vector Machines (SVMs)
to Bayesian Networks, and including ANNs.
We will briefly introduce here the most common methods employed to
handle genomic MA data, previously discussed, before focusing on ANNs
in the following chapter, the approach chosen for this Ph.D. project.
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1.6.1 Standard statistical approaches
Classical statistics used to be gold-standard methods for the analysis
and classification of genomic MA data in the early years of MAs. This
section presents some of these methods.
Clustering methods
Historically, clustering (and particularly hierarchical clustering) was the
first approach adopted by scientists in order to analyse results from MA
technologies. These approaches group the samples (or the genes in the
transposed fashion) together in clusters on the basis of their distance in the
expression space (Eisen et al., 1998). Several algorithms for the measure of
this distance exist, and generate the diversity of clustering techniques.
One of the most commonly applied clustering technique for genomic MA
experimental data is hierarchical clustering. The method introduces a
measure of distance between the samples (or the genes in the way round),
and groups them in clusters according to this distance, repeating this itera-
tively until all the samples have been used. The distance basically represents
how close the objects to analyse are to one another. The most common dis-
tance measure is euclidian distance, but others may be used such as the
Manhattan distance or Maximum Norm.
Finally, the samples are organised and grouped in a phylogenetic tree-
like structure, allowing a rapid visual interpretation of the results (i.e. 2
samples with similar gene expression patterns have a small distance, and
fall into the same cluster). As a result, genes with similar biological func-
tion may fall into the same cluster or different clusters with short distance.
Different methods exist to determine the hierarchy of the clusters, amongst
them the most famous are Single-linkage, Complete-linkage, Average-linkage
or Weighted pair-group average. This method has been widely applied in
many famous studies in breast cancer (Perou et al., 2000; van’t Veer et al.,
2002) mainly because it is a simple method with a quick and easy visuali-
sation of the results (Quackenbush, 2001).
Contrary to hierarchical clustering, k-means clustering assigns the
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objects (either samples or genes) within clusters without looking at the
relationship that might exist between them (Quackenbush, 2001). It parti-
tions the data space in a predetermined number of clusters (k) and randomly
assigns the objects to one of the clusters. An average expression vector is
calculated for each cluster from the expression vector of the objects they
contain, and is used to calculate the distance between the clusters. The
objects are then iteratively moved to other clusters, each time recalculating
the new distance obtained. Objects are moved until optimal distance is
reached (i.e. the distances, either inter or intra-cluster, are less consistent).
Alternative implementation of the algorithm allows assignment of a seed
object (sample or gene) for each cluster, using it in a semi-supervised fash-
ion (with a priori knowledge). On the hypothesis of k = 2 groups (e.g.
controls versus disease) with the extreme expression patterns assigned to
each cluster, it is possible to assess in which class individual samples would
fall, and how closely.
Self-organising maps (SOMs), or Kohonen maps, named after the
statistician Teuvo Kohonen who developed this method (Kohonen, 1989),
are a form of cross-combination of clustering techniques with the field of
ANNs, and can be seen as an unsupervised neural network (Törönen et al.,
1999). Similarly to k-means clustering, this approach creates groups and
assigns the genes to each group based on their similarity to their reference
vector (Quackenbush, 2001). The difference with k-means clustering stands
in the organisation of the groups and in the calculation of the reference
vector for each of them. Here the groups are represented by a grid of nodes
defined by the user and geometrically arranged in a k -dimensional space
(Tamayo et al., 1999), commonly a two-dimensional space for easy visual-
isation (c.f. Figure 1.3). Firstly, the groups are randomly set with their
respective vectors. Then the algorithm iteratively selects a gene at random
in the data space and calculates the distance (with respect to the distance
metric system chosen) with the closest group. Then the groups are moved
toward this particular gene inversely proportional to their distance with it
by adjusting their reference vector (i.e. the closest group has its reference
vector the most adjusted, and the farthest, the least). This adjustment
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is given by the following expression, with the position of the group N at
iteration i being fi(N), and at the following iteration, the data point P is
selected with its nearest group NP :
fi+1(N) = fi(N) + τ(d(N,Np), i)(P − fi(N)) (1.2)
The learning rate τ gives the rate that decreases with the distance of
the group N with NP . This process is repeated over a number of iterations
i (20,000 - 50,000).
Figure 1.3: Principle of Self-Organizing Map. a) Example of a SOM consisting of a 4 × 4 matrix of
neurons. b) The weight vectors (+) of neurons are first initialised with random profiles. c) Intermediate
configuration during the learning process where weight vectors are moving towards the data profiles (O).
d) Finally, weight vectors come to represent groups of data profiles. (Törönen et al., 1999)
Mangiameli and co-workers compared the robustness of SOMs with hier-
archical clustering (Mangiameli et al., 1996) and demonstrated that SOMs
were performing better for the analysis of what they called "messy data".
The choice of geometric configuration for SOMs, or k-means clustering,
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is driven by the user, thus introducing an element of subjectivity. Addi-
tionally, this application of cluster analysis to class prediction have been
criticised (Simon et al., 2003). Therefore, it is suggested to rely on another
source of information, such as Principal Component Analysis (PCA), to en-
lighten this choice of number of clusters that best represents the data space.
Principal Component Analysis
PCA is a method of choice for dimensionality reduction in datasets (Lan-
cashire, 2006), a particular issue when studying gene MA data, as the num-
ber of genes studied P far exceeds the number of samples n (P >> n). It is
an exploratory multivariate statistical technique used to simplify complex
data space (Raychaudhuri et al., 2000) by translating the data space into
a new space defined by the principal components, relating to the variance
(shape) of the data. These principal components are orthogonally arranged
linear combinations of the original variables identified by the method and
that can explain most of the variation observed within the dataset, which
can be due to redundancy of information in the data space (Raychaudhuri
et al., 2000). As a result, it is difficult or even impossible to link the principal
components to the actual variables of the original dataset, making it diffi-
cult to identify the important genes in the system studied for the microarray
experiment (Lancashire, 2006). This limitation stresses that PCA is only
a data reduction tool and highlights the need of supplementary analysis tool.
All these techniques are usually qualified as unsupervised methods since
they do not require any subset of data for which outcome is known in order
to construct a model based on the known examples, although this is not
entirely true since some clustering techniques are supervised (as mentioned
earlier) (Eisen et al., 1998).
Classical unsupervised methods have been proven to suffer from several
issues. Cluster techniques, and particularly hierarchical clustering, have
been mis-employed for class comparison and class prediction and have been
proven to be non-effective for that particular matter (Simon et al., 2003;
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Tamayo et al., 1999) as well as PCA (Tan et al., 2005). The choice amongst
the different clustering techniques, combined with the different distance
measurement methods introduce an element of subjectivity and result in the
production of different outcomes of the analysis (Quackenbush, 2001). But
their main pitfall stands in their inability to cope with high-dimensionality.
In high-dimensional space, it would be likely that for a pair of adjacent
objects falling into the same cluster there would exist dimensions in which
those points fall far apart from each other. Thus, techniques using distance
functions with all input features may lack effectiveness (Domeniconi et al.,
2004). However, some groups apply these techniques as a simple preliminary
step for feature selection, prior to deeper analysis of the dataset, using
machine learning approaches (Liu et al., 2005b).
1.6.2 Machine Learning and supervised approaches for
classification and prediction problem
These methods are mostly used for their predictive ability. They can
classify individual samples to groups they belong to, thanks to their expres-
sion profile and genomic expression patterns. This is an important step for
allowing the stratification of patients and be able to accurately predict, for
instance, their tumour phenotypes in the case of cancers.
K-Nearest Neighbours
K-Nearest Neighbours (KNN) is one of the most simple approaches for
general non-parametric sample classification (Vadrevu and Murty, 2010).
This method considers the comparison of expression profiles with an un-
known class to other ones for which the class is known. The class for the
unknown sample is then determined to be the same than the class for the
sample with the most similar profile and for which class is known. This
method follows three steps for the classification of a new sample with an
unknown class:
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• Assessment of the gene expression profile for the sample studied.
• Identification of the nearest known samples thanks to a distance mea-
surement (usually Euclidian distance).
• The class of the sample is determined by the class of the nearest
samples.
This is achieved by considering two important factors :
• k : the number of nearest samples to look at.
• l : the acceptable margin for classification to be successful.
As a result, the class of the sample to be classified is determined only
if l of the k nearest samples are of the same class; if not, the sample class
remains undetermined. Then, if k = 3 and l = 3, the algorithm only consid-
ers the 3 nearest neighbours (k) and the class of the sample to be classified
is determined only if the 3 of them (l) are of the same class (Stekel, 2003).
KNN algorithms have been shown to have good classification perfor-
mances for a wide range of real-world data (Xiong and Chen, 2006). How-
ever, they can suffer from major disadvantages, mainly due to poor ef-
ficiency with high-dimensionality and noise in the dataset (Vadrevu and
Murty, 2010).
KNN have been also applied for class prediction problem with gene MA
data in breast cancer studies. Miller and coworkers compared the per-
formances of several supervised training methods (including KNN, Linear
Discriminant Analysis (LDA) and SVM) for the prediction of p53 (mu-
tant versus wild type) in breast cancer survival on different datasets (Miller
et al., 2005). They observed that, despite very similar prediction accuracy
(between 84.9% and 85.7%), KNN performed with slightly higher speci-
ficity5 (95.3%) than SVM (94.3%) and LDA (84.6%). However, LDA was
found to have higher sensitivity6 (79%) compared to KNN and SVM (53%).
5Specificity is a statistical measure of the ability for a test to classify the proportion
of negative cases correctly identified by the test as such.
6Sensitivity is a statistical measure of the ability for a test to classify the proportion
of positive cases correctly identified by the test as such.
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Linear discriminant analysis
LDA attempts to separate the data into two sub-groups by calculating
the optimal linear line that best split the population. Calculation of this
discriminating line is conducted by taking into account sample variation
within similar classes, and minimising it between classes. As a result, any
additional sample has its class determined by the side of the discriminating
line it falls.
LDA can outperform other linear classification methods as LDA tries
to consider the variation within the sample population. Nevertheless, LDA
still suffers from its linear characteristic, and often fails to accurately classify
non-linear problems which is mostly the case in biomedical sciences (Stekel,
2003). This is the reason why non-linear classifiers are recommended.
Support Vector Machines
SVMs are a form of supervised learning approach for non-linear model-
ing(Vapnik and Lerner, 1963). They are an evolution of LDA in the sense
that they work by separating the data into 2 sub-groups with a straight line
or an hyperplane.
In the common example of a two-class classification problem, SVMs
firstly attempt to find a linear "‘maximal margin hyperplane"’ able to ac-
curately discriminate the classes (Dreiseitl et al., 2001). If no such linear
hyperplane can be found, usually due to the inherent non-linearity of the
dataset, the data are mapped into a high-dimensional feature space using
kernel functions in which the two classes can now be separated by a hyper-
plane which corresponds to a non-linear classifier (Furey et al., 2000). The
class of an unknown sample is then determined by the side of the hyperplane
it falls.
SVMs are one of the most popular classification tool in the biomedical
community, and have a strong competitive interest with ANNs. However,
no evidence has clearly demonstrated that SVMs perform better than ANNs
for medical prospect (Lancashire et al., 2009a).
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1.7 Alternative interaction inference algorithm
Considering the tremendous promise expression arrays hold for a com-
prehensive understanding of the molecular biology in living systems, some
groups have recently started to focus their research into the investigation
and exploration of the potential gene interactions and relationships assess-
able with expression array data. Different approaches have been described,
and some of them are discussed in this section.
Bar-Joseph and coworkers presented a paper describing a technique using
DNA-binding data to infer potential gene regulatory networks (Bar-Joseph
et al., 2003), arguing that it is necessary not to consider only expression data
but a combination with other sources in order to overcome the variability
from post-transcriptional modifications.
Hart et al. in 2006 tried to implement an ANN-based gene regulatory
network inference method, which they applied to yeast cell cycle (Hart et al.,
2006). Contrary to the method presented here, the group trained the ANN
only to predict a set of cell cycle expression classes with a pool of 204
expression regulators in order to predict which of the regulators is predictive
of a class.
Another ANN-based application for gene-gene interaction modelling has
been described by Günther and coworkers (Günther et al., 2009), in which
they conclude that ANN-based methods are more reliable than logistic
regression at predicting gene-gene interactions. However, the study only
aimed at comparing the methods with simulation datasets for two-loci dis-
ease scenario.
Gevaert and coworkers developed a Bayesian network method with a
Markov blanket algorithm to investigate the connection between the genes
involved in the van’t Veer dataset (Gevaert et al., 2006). This is an interest-
ing application and will be useful to confirm some of the findings obtained
by the approach presented in this study.
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Several other groups made the choice of Bayesian networks for these
algorithms. It is the case of Jansen et al. who described an approach using
genomic data to predict protein-protein interactions (Jansen et al., 2003),
as well as Hartemink et al. and Needham et al. (Hartemink et al., 2002;
Needham et al., 2009).
Another effective method preferred by mathematician groups is based
on Ordinary Differential Equations (ODEs). Christley and coworkers pub-
lished in 2009 a paper based with this methodology for gene expression
data in which they incorporated a priori knowledge on gene interaction or
regulation, such as CHIP-seq data, in order to decrease the modelling error
(Christley et al., 2009).
Recently, Jupiter and colleagues presented a web-based tool named Star-
Net2 which aims to identify gene regulatory networks fromMA co-expression
data (Jupiter et al., 2009). However, this method only interrogates MA data
for correlation in a pairwise fashion.
Other methods such as likelihood approach (Liu et al., 2005a), random
walks (Chipman and Singh, 2009) or synergy networks (Watkinson et al.,
2008) can be cited.
These methods for gene regulatory networks inference have been re-
viewed by Schlitt Brazma (Schlitt and Brazma, 2007), and by Lee Tzou
(Lee and Tzou, 2009).
Beside these methods, a number of groups focused their studies on the
use of functionality to define interactions, particularly for protein-protein
interaction studies (Schwikowski et al., 2000; Shoemaker and Panchenko,
2007; Spirin and Mirny, 2003).
Also, literature-based tools seeking to compile every reported link be-
tween biomolecules have seen the day as well. Some well-known examples
are:
• Kyoto Encyclopedia of Genes and Genomes (KEGG) PATHWAY database
(Kanehisa and Goto, 2000).
• Ariadne Pathway Studio (Nikitin et al., 2003).
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• Ingenuity Pathway Analysis (IPA) (Ingenuity R© Systems Inc., www.ingenuity.com).
• GeneGo (GeneGo Inc., http://www.genego.com/).
The main disadvantage of many of these methodologies is that they
provide only limited information regarding the nature of the interactions. In
many cases only the presence of an interaction is considered. Furthermore,
when an interaction is considered, it is only in the context of the target,
and not considered as it is interacting with the whole gene marker pool.
In the approach discussed here, the overall panel of genes considered is
questioned iteratively for each gene as target, output to be predicted, so a
global interaction map can be extrapolated.
Bar-Joseph et al. argued that only expression data for gene regulatory
network inference should be avoided due to the variability induced by post-
transcriptional modifications, and a combination of data sources should be
preferred (Bar-Joseph et al., 2003). In the case of this research, the post-
transcriptional modifications are overcomed by modelling simultaneously
tens to hundreds of cases. And a particular care has been taken with the
integration of different sources of data, in order to avoid inconsistency and
biases from cross-platform technologies.
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1.8 Aims of the study
The biomedical technologies discussed previously provide a dramatic
amount of data to researchers who don’t always know how to handle such
quantity and complexity of information (Lancashire et al., 2009a). There-
fore, the questions are: what do they want out of these experiments, what
are the answers sought, and how can we maximise the gain from these pro-
ductive yet expensive technologies?
It has been demonstrated earlier in this manuscript that conventional
statistical approaches suffer from great limitations for the purpose of class
assignment and prediction. Hence, the analysis of the data from these
biomedical technologies, enhanced the field of computational intelligence in
biomedical sciences.
Several machine learning methdods have seen the day since then and
amongst them are ANNs (discussed in the following chapter). A number of
biomedical applications of ANN-based studies have been reported to be suc-
cesful (Drew and Monson, 2000). Comparison with other machine learning
methods have been conducted, and showed that ANNs perform similarly or
even better to other solutions like SVMs (Lancashire et al., 2009a).
However, these applications mainly aimed to identify signatures predic-
tive of particular questions, and even fewer intended to bring a step fur-
ther the analysis of the important information held within the experimental
dataset.
Therefore, it was sought within this research to :
• Develop new approaches for the analysis of highly-dimensional data
for biomarker identification using ANN techniques.
• Optimise the approaches for speed and accuracy in order to over-
come limitations of the data. These methods should allow quicker
and reliable results for the identification of biomarkers. In addition,
developing standalone solutions with the ability to be portable under
alternative systems, will allow smoother and faster application of the
methods.
• Develop new approaches for identification of interaction networks, par-
38
ticularly in the field of genomic technologies.
• Optimise these approaches for speed and accuracy in order to obtain
the most reliable results for the exploration of interactions between
markers.
• Application of all the approaches developed in breast cancer case stud-
ies, to potentially identify new predictive signatures for outcomes, and
new patterns of interaction or relationships between the identified el-
ements. Ultimately, identifying key metabolic changes between two
categories of populations could lead to breakthrough discoveries of
potential new treatment strategies.
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Chapter 2
Theories behind Artificial Neural
Networks and Stepwise
parameterisation
The following chapter will introduce the concepts and parameterisation
of ANNs. It will present a brief history and the basic principles around
ANNs and their architecture. The chapter will introduce as well the Step-
wise parameterisation of ANNs with its principles and algorithm. The chap-
ter will finally briefly present an application of the original implementation
of the Stepwise approach in a breast cancer study.
2.1 Artificial Neural Networks
2.1.1 Introduction
ANNs are commonly described as computational modelling systems.
They are a form of machine learning algorithms that can learn from patterns
(Khan et al., 2001; Lancashire et al., 2005b) in order to predict answers to
particular questions in complex data (i.e. non-linear, highly-dimensional
and noisy data). The models produced by ANNs have been shown to be
able to predict well for unseen data, meaning that ANNs have a reliable
generalisation ability (Lancashire et al., 2009a). Therefore they represent
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Figure 2.1: Schematic representation of the Artifical Neuron described by McCulloch and Pitts in 1943
(Rojas, 1996)
one of the most robust and reliable methods to handle complex data gen-
erated by the biomedical technologies discussed earlier (Drew and Monson,
2000).
ANNs are constituted by single elements, nodes named neurons in ref-
erence to the biological inspiration (discussed later). Figure 2.1 represents
an example of a single artificial neuron. A neuron j receives n inputs i with
their respective value x (the input vector) that has been scaled (usually
between 0 and 1 or between -1 and +1). Each of them is modified by the
weight w of the link between the input i and the neuron j. The neuron
calculates then the sum of the weighted values for all the x inputs (Bishop,
1995; Lancashire et al., 2009a).
vj =
n∑
i=1
(wjixi) (2.1)
The sum is then added to the bias value vj0 of the neuron j. The final
value is then passed through a transfer (or activation) function φ in order
to obtain a final non-linear output yj for neuron j.
yj = φ(vj + vj0) (2.2)
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The transfer function φ is commonly a sigmoid function of the form:
φ(v) =
1
1 + e−v
(2.3)
or an hyperbolic tangent function:
φ(v) =
ev − e−v
ev + e−v
(2.4)
So that we obtain:
yj = φ
vj0 + n∑
i=1
(wjixi)
 (2.5)
The output of a particular neuron can eventually become the input of
a subsequent neuron, and information is transmitted and, if appropriate,
altered until finally, this output is propagated up to the ultimate neuron of
the network and provide an overall output of the global ANN. This overall
output can be the predicted class of the current case for a two-group clas-
sification model often coded as 0 and 1 or as -1 and +1, or a discrete value
for a regression model (Lancashire et al., 2009a).
2.1.2 Historical Background
It is believed that the early stages of theoretical neurophysiology trig-
gered in parallel the preliminary works of neuromathematics and neuro-
computing between 1890 and 1949 (Basheer and Hajmeer, 2000; Nelson
and Illingworth, 1991). The preliminary descriptions of biological neurons
initiated the early research on the artificial neuron. The neuroscientist War-
ren S. McCulloch and the logician Walter Pitts (Hecht-Nielsen, 1988) firstly
described the concept of this artificial neuron (also known as the Threshold
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Logic Unit (TLU), or the “McCulloch and Pitts neuron”) in 1943 as a math-
ematical function derived from simulating the basic functions of biological
neurons (McCulloch and Pitts, 1943).
This work described a neuron and the input vector this one receives
(c.f. Figure 2.1). Mimicking the basic mechanic of the biological neuron,
the artificial neuron stated by McCulloch and Pitts is a binary element, i.e.
existing under two clearly distinct states y : activated or inhibited (positive
or negative, 1 or 0), with a threshold θ defining the state of the neuron.
The neuron receives signals from one or several (n) other input(s) (xi with
i = 1...n) (the input vector), and emits the signal toward others with its
output. Each input is weighted by a fixed value w (-1 or +1), which alters
the influence of the input. Therefore, signals from the input received can
either be excitatory or inhibitory and have the same importance. But if any
signal received is inhibitory (weighted as -1), it will not be further transmit-
ted; in other words, all the signals received need to be excitatory in order to
activate the neuron, so behaving as a "all-or-none" process: the equivalent
of the logic threshold function. The weighted sum of the input vector is
then calculated and the result compared to the threshold θ, resulting in the
following rule :
y =

1, if
 n∑
i=1
wixi
 ≥ θ
0, if
n∑
i=1
(wixi) < θ
(2.6)
Later in 1958, the psychologist Frank Rosenblatt formulated the concept
of the Perceptron (Rosenblatt, 1958) in an attempt to describe the percep-
tion (which gave the origin of the name for the Perceptron) especially in
retina (Kanal, 2004). The Perceptron stood as an evolution of the recently
born artificial neuron of McCulloch and Pitt integrated in the first neural
network. The concept of the Perceptron mainly relies on two things : the
weighted connections and its learning ability (Rojas, 1996). Initially, weight
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connections are stochastically determined, the learning process is achieved
by the alteration of the nodes or the weights of the interconnections between
the nodes of the network. For this purpose, a set of examples is used to
learn, or train the network. By adapting the weights (w) of the connec-
tions between the nodes, the Perceptron has the ability to identify inputs
or connections which provide stronger response toward the goal to achieve
(e.g. character recognition problems in the context of Rosenblatt’s work
(Hecht-Nielsen, 1988). Similarly than for a biological neural network, the
learning process involves a closer connection between the neurons involved
(i.e. a higher weight) for the particular function required according to the
Cell assembly theory formulated by the psychologist Donald Olding Hebb
earlier in 1949 (Hebb, 1949):
Let us assume that the persistence or repetition of a reverber-
atory activity (or “trace”) tends to induce lasting cellular changes
that add to its stability. When an axon of cell A is near enough
to excite a cell B and repeatedly or persistently takes part in
firing it, some growth process or metabolic change takes place
in one or both cells such that A’s efficiency, as one of the cells
firing B, is increased.
This theory initiated the whole field of learning rules in artificial neural
networks, brought forward with Rosenblatt’s Perceptron. However, efficient
at character recognition, this Perceptron was only able to model linear sys-
tems. Nevertheless, a growing interest in neurocomputing started at that
moment.
Contemporary to Rosenblatt, the field of Artificial Intelligence (AI) was
not gathering as much interest (i.e. funding) as the Perceptron due to this
fashion. This led to the publication of a book by the cognitive scientist
Marvin Minsky and the mathematician Seymour Papert, pioneers in AI,
(Minsky and Papert, 1969) which aimed to stress the limitations of the Per-
ceptron, especially their inefficiency at modelling non-linear systems. Most
of these limitations were already known by the community (Basheer and
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Hajmeer, 2000; Hecht-Nielsen, 1988), but they highlighted their importance
(Lancashire, 2006). This publication had a major impact and stopped the
works on the field of ANNs, with many researchers switching interest from
ANNs toward AI (Basheer and Hajmeer, 2000).
Interest in ANNs only reappeared in the middle of the 1980’s, initially
with the work of John Joseph Hopfield in 1982 (Hopfield, 1982) and 1984
(Hopfield, 1984) who introduced the Hopfield network. But it is admit-
ted that 1986 was the year of the regain of interest with a major break-
through for ANNs when Rumelhart, Hinton and Williams published their
work on the Back-Propagation algorithm (Rumelhart et al., 1986) initially
described by Paul Werbos in 1974 (Basheer and Hajmeer, 2000; Werbos,
1994), and which is an adaptation of Widrow and Hoff’s work on the Delta
rule (Widrow and Hoff, 1960).
Nowadays, ANNs are still widely employed in a broad range of applica-
tion domain, but as well on the theoretical aspect of neurocomputing. The
large interest in the use of ANNs can be easily assessed by checking the
number of daily publications or conferences organised around it.
2.1.3 Biological Neural Network homology
We have seen previously that early research in neuroscience and neuro-
physiology triggered and inspired the first scientists in the field of ANNs.
We will discuss here the extent to which the analogy between the biological
and the artificial world enabled this inspiration, bringing further the field
of neurocomputing.
McCulloch and Pitts in 1943 initiated the work on ANNs with artifi-
cial neuron inspired by the biological neuron (McCulloch and Pitts, 1943).
The word “neuron” comes from the greek neuron which means nerve, it is
the building element of the nervous tissue composing the most part of the
nervous system and almost exclusively located in the brain. The first de-
scription of a neuron is attributed to Santiago Ramón y Cajal in the late
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1890’s who was granted with the Nobel prize in physiology and medicine in
1906 (Jain et al., 1996) for this work. The nervous tissue is composed of
billions of these neurons which have various types and length according to
their function and location within the body (Basheer and Hajmeer, 2000).
Neurons are composed of three main parts: the core of the cell (the body)
is known as the soma; several extensions named dendrites ; and another
longer extension, the axon as shown in Figure 2.2. As for a regular cell, the
soma contains a nucleus that holds the genetic information in DNA, and
cytoplasm with the usual organelles.
However, the neuron is a unique and highly specific cell type, not only
because of its morphology (the axon of the same neuron can be as long as
one meter), but as well because of its physiology. The neuron is able to re-
ceive an electric signal on its dendrites, and if appropriate, it will transmit
this signal towards other neurons or cells via its soma and consequently its
axon. The transmission of the signal occurs at the extremities of the axon,
which can split in several strands. At these extremities are the synapses
which make the contact with the dendrites of the following neuron. The
real transmission from one neuron to another is made possible by these
synapses; when the signal arrives to the synapse, chemicals named neuro-
transmitters are released and travel through the synaptic cleft until they
reach the following cell. Once the neurotransmitters reach the cell’s mem-
brane of the receiving neuron, they are captured by receptors which will
eventually trigger and propagate an electric signal through this neuron de-
pending if the threshold of transmission for the neuron is met and depending
on the type of synapse (either inhibitory or excitatory) (Basheer and Ha-
jmeer, 2000; Jain et al., 1996). The process of transmission is orientated
with a presynaptic neuron and a postsynaptic neuron. The transmission is
made possible thanks to a local depolarisation.
Therefore, ANNs are inspired by the way in which the biological neural
network learns and processes information. Their concept simulates the be-
haviour of the biological neural network. Indeed, as discussed previously,
learning involves minor adjustments to the synaptic connections between
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neurons as described by Donald Olding Hebb (Hebb, 1949), biological neu-
ral networks are believed to learn by following this rule. The more a synapse
is used to transmit a signal toward a receiving neuron, the more reinforced
this synapse will be; in the conversely, the less a synapse is used, the weaker
it becomes, it could even eventually disappear. Similarly, the learning pro-
cess with ANNs is based on the interconnections between the processing
elements, the nodes that constitute the network topology, and learning oc-
curs by adjusting the intensity of the interconnection weights through a
number of iterations by presenting examples to the network (Basheer and
Hajmeer, 2000). Figure 2.2 represents both biological and artificial neurons
in a comparative manner.
Figure 2.2: Comparison of schematic artificial and biological neuron.
2.1.4 Architectures
Although, this work involved only MultiLayer Perceptron (MLP) ar-
chitecture, ANNs exist in several other form of architectures which will be
briefly discussed in the following section. It has been estimated that around
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50 different types of ANNs coexist (Pham, 1994). The architecture refers
to how the nodes of the network are organized, mainly the layers of nodes.
The choice of a particular architecture by the user will be guided mainly by
the type of problem to be solved (e.g. some ANNs are appropriate for data
modelling but not for perceptual problems (Basheer and Hajmeer, 2000)).
For the purpose of this manuscript the focus will be on ANNs in their most
commonly used form, the MLP, but other ANN based approaches exist; for
example radial basis function networks and recurrent neural networks.
Perceptron
The Perceptron as described by Rosenblatt (Rosenblatt, 1958) is the
most simple architecture of ANNs. It consists of a single artificial neuron
that processes information from n inputs and provide a response thanks to
an appropriate learning step. As Minsky and Papert pointed out in 1969
(Minsky and Papert, 1969), the major limitation of Perceptron is its inabil-
ity to model non-linear problems. This limitation triggered the work on the
evolution of the Perceptron: The MLP.
MLP
Improvement of the Perceptron has been brought by Rumelhart. The
Perceptron can stand as a particular case of a MLP; indeed the Perceptron
is a one-hidden node single-layer MLP. In the MLP, ANNs are organised
into several layers, with each layer having a number of respective neurons, or
processing elements, that constitute that layer (Figure 2.3). Simply put, the
majority of ANNs have a similar topology consisting of an input layer, one or
more hidden layers, and an output layer. The number of hidden layers and
the number of neurons in each layer is dependent on the complexity of the
problem, i.e. the number of input neurons. The input layer interacts with
the external environment to receive the input data as a vector of predictor
variables, each represented as a node. This information is passed through to
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Figure 2.3: Schematic representation of a classical single-hidden layer MLP with m hidden nodes.
the first hidden layer, and multiplied (thus modified) by a set of associated
weights. These products are summed and fed through a non-linear transfer
function (e.g. sigmoid, hyperbolic tangent) which scales and then produces
an output, similar to the axon of the neuron.
Other architecture
Several other architectures of ANNs are worth mentioning, but won’t
be discussed further in this thesis. They include Radial Basis Function or
Recurrent Neural Networks.
2.1.5 Learning rules
Learning rules are algorithms that define how the weights linking the
inputs to a neuron and two neurons with each other should be iteratively
adjusted during the epochs of the training process in order to get optimal
solution. The ultimate aim of the learning process is to find the optimal
set of weights that will provide a trained ANN able to give solution that is
the closest to the expected solution, in other words with the smallest error
(Rumelhart et al., 1986). ANNs must then be trained to efficiently compute
the gradient in order to be capable of accurately modelling a set of cases
49
and predicting their output. There are two major learning paradigms; su-
pervised and unsupervised.
Supervised learning algorithms
Supervised learning involves providing the network with a set of cases
that have values for the inputs as well as the known desired outputs. The
output of the network is then compared with the true output to calculate
error by assessing the network performance as learning progresses. The
interconnecting weights are initially randomised (e.g. [-1, 1]) so that pre-
dictions after completion of the first training cycle are essentially random.
One of the most popular forms of supervised learning, Back Propagation
(BP), compares the error between the true output and the predicted out-
put and then feed this error back through the layers of the network. The
weights are adjusted so that after completion of the next training cycle (or
epoch) the error decreases according to:
ωki(τ ) = ηδkxi (2.7)
Each weight update ωki at the current (τ th) cycle is updated in propor-
tion to the input value to which the weight is applied xi, the error in the
output of the unit δk and a constant known as the learning rate η (Bishop,
1995). The weight change of a neuron is proportional to the influence an
input had on the error during training and the learning rate is a constant
which controls the size of these weight changes. The larger the learning
rate, the faster learning will proceed; however too large a value may lead to
oscillation or non-convergence of the model (Basheer and Hajmeer, 2000).
Each time a pattern is presented to the network, the weights leading to an
output node are modified slightly during learning in the direction required
to result in a smaller error the next time the same pattern is presented,
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until a target error is reached or no improvement of the error is observed. A
momentum term α, may be applied to help prevent the network becoming
trapped in local minima, or being stuck along flat regions in error space.
This occurs with a slight alteration to the weight update rule by making
the weight update on the τ th iteration depend on the update that occurred
during the (τ − 1)th iteration:
ωki(τ ) = ηδkxi + αωki(τ − 1) (2.8)
This helps to speed up the time it takes for the network to reach con-
vergence by gradually increasing the step size of the search in regions where
the gradient is not changing. As with the learning rate, effectively choosing
values for these constants depends on the particular problem of interest and
experimentation is important here to find optimal values. In our own expe-
riences, a learning rate of 0.1 combined with a momentum of 0.5 has proved
successful (Lancashire et al., 2005a, 2008). The target error that needs to
be minimized is often determined as the total sum-of-squares based on the
difference between the output and target vector as follows:
 =
1
2
n∑
j=1
(dj − yj)2 (2.9)
where n is the number of cases, dj is the target network output for case
j and yj is the network predicted output for case j. Alternative error func-
tions also exist, such as the Mean Squared Error (MSE), or the maximum
conditional likelihood fitting, but will not be dwelt upon here. This learn-
ing process is an extension of the generalised delta rule, and is commonly
known as BP (Rumelhart and McClelland, 1986; Rumelhart et al., 1986;
Werbos, 1994).
It is crucially important that the data used in training the network
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should be reasonably large in order to contain all the information neces-
sary to be able to recognise which of the predictor variables are important
amongst the vast amounts of noise and individual variation that is expected
to cloud important information in complex -omics datasets. If the network
outputs fail to show good discrimination on an independent test dataset,
over-fitting may have occurred and training must be continued or repeated.
Over-fitting can occur when the number of parameters in a model exceeds
the number of cases. It is in essence a memorisation of the training data
(and any associated random noise) (Ransohoff, 2004; Simon et al., 2003).
In order for the network to be trained to a satisfactory level which main-
tains generalisation for new data, it is vital to employ an appropriate reg-
ularisation technique (discussed in a subsequent section). Once learning is
complete the weights are stored and can be used to predict future cases
in separate test datasets. Other learning algorithms have also been pro-
posed. These include (but are not limited to) QuickProp (Fahlman, 1988),
Resilient Backpropagation (RPROP) (Riedmiller and Braun, 1993) and the
Levenberg - Marquardt algorithm (Levenber, 1944; Marquardt, 1963).
Unsupervised learning algorithm
Unsupervised learning occurs when the network attempts to map the
inputs to outputs without any external assistance. Therefore the network
itself governs how it groups the cases based upon the input data. This
is sometimes referred to as self organisation, and Kohonens self organising
maps (discussed previously) (Kohonen, 1989) are the most popular form of
neural network-based unsupervised learning. Other forms of unsupervised
learning include PCA, independent components analysis, hebbian learning
and autoassociators.
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2.1.6 Regularisation
One of the main issues to solve with supervised learning is over-training
or over-fitting. Such a phenomena occurs if the network achieves too well
the tasks required for the training set, the examples used for learning. Con-
sequently, the trained ANN can only model data from the training set, and
poorly generalise for unseen cases (Lancashire et al., 2009a). Commonly the
main purpose of modelling is to simulate a real world system and therefore
a model is judged on its ability to generalise to new data. For ANNs, the
risk of low generalisation is mainly attributed to over-training of the model,
leading to over-fitting and subsequently poor predictive performance dur-
ing independent validation. Due to the fact that even a linear model would
over-fit in high dimensions, ANNs must be appropriately regularised during
training in order to achieve sufficiently high predictive performances. In
order to address this, regularisation techniques need to be applied during
training. Several options for regularisation exist and methods can be chosen
according to the type of data or generalisation performance that is required.
We will briefly discuss now some of the most common forms.
Weight decay
One of the simplest regularisation methods to implement is weight decay.
In weight decay, the error function includes a penalty term: for example,
the sum of squared weights and biases multiplied by a decay constant that
controls how much the penalty term should affect the resulting error func-
tion:
λ
n∑
i=1
w2i (2.10)
Since over-fitted models are more likely to contain unusually large weights,
this approach aims to penalise such large weights, in order to keep weight
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values smaller than they naturally otherwise would converge at, thus keep-
ing the activation of the neurons in the linear range (Bishop, 1995).
Resampling and early stopping
A common solution to address this issue is to stop the training process
once it has reached a satisfactory error level at modelling. According to
Ntzani and Ioannidis (Ntzani and Ioannidis, 2003), independent validation
is only conducted in about 10% of MA studies published. Given the fact
that these complex datasets are likely to be non-linear in nature, one may
not have prior information regarding the intricacies of the data. As such it
is vital to estimate the performance of these models on new data in order
to be confident that over-fitting has been avoided. It was stated earlier that
the BP algorithm should stop training once the network has achieved an
acceptable level, however, the question remains as to what is considered
to be an acceptable level, and what can be done to ensure that the model
will be capable of generalising to additional future cases. If training is
terminated solely on the basis of a set number of iterations the model is at
risk of over-fitting. The most universal approach to address this problem
is resampling. Typically in ANN-resampling approaches, the data is split
into different subsets, where a percentage of the total sample set is used to
train and optimize the ANN (the training set) and (sample size permitting)
the remaining are partitioned for validation during training (the validation
set) and external testing after the modelling is complete (the independent
test set). This validation approach will be referred to as Monte Carlo Cross
Validation (MCCV).
A common, yet efficient, regularisation technique known as early stop-
ping mechanism monitors the network error with respect to a validation
or test dataset. This process signals to stop training either when a pre-
determined number of iterations have completed, or when the prediction
accuracy of the model begins to worsen for the validation or test dataset,
a sign of over-fitting. The weights resulting in the minimum validation or
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test error are then selected. Once the network has completed the learning
process, it is further validated using the test data split, to give an unbi-
ased estimation of the networks likely performance on future unseen cases.
Examples of this approach can be found in (Lisboa and Taktak, 2006) and
(Basheer and Hajmeer, 2000).
Bayesian regularisation
The Bayesian regularisation approach involves modifying the target func-
tion (such as the sum of squared errors) in order to improve the models gen-
eralisation ability (Kelemen and Liang, 2003). The Bayesian regularisation
aims to smooth the cost function by adding to it a regularisation parame-
ter based on the sum of squared weights. To reduce bias, the weights and
variables of the network are assumed to follow a Gaussian distribution and
are assigned prior probabilities, optimised according to the Bayesian frame-
work of Mackay (MacKay, 1992). Network training then attempts to find
the trade-off between minimising the model complexity and model error,
as such minimising both the bias and variance (Kelemen and Liang, 2003).
Methods such as automatic relevance determination will identify and re-
move unnecessary parameters from the model since the Bayesian approach
provides an estimate for the entire distribution of model parameters rather
than a single optimal set of weights. Model comparison is based on highest
evidence, rather than cross validation, and as such Bayesian regularisation
maximises the data available as it does not require a validation set since
all the training data can be used for model fitting. A review of Bayesian
methods for supervised neural networks can be found in (MacKay, 1995),
and an example of its application in a MA study can be found in (Kelemen
and Liang, 2003).
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2.2 Stepwise approach principle
ANNs have shown remarkable abilities for data-mining and pattern recog-
nition as previously demonstrated (Bishop, 1995). However, data-mining in
the field of biomedical sciences remains highly challenging especially for the
analysis of genomic data. Genomic technologies (e.g. MAs) have triggered
a new era in biomedical research by allowing the simultaneous assessment
of the level of expression of many genes within a single experiment. This
era comes with its own challenges, mostly regarding the analysis of the data.
One of the main limitations for the application of ANNs in genomic tech-
nologies is that, despite their ability to cope with high dimensionality within
the data, they can still suffer from what is known as the curse of dimen-
sionality, firstly described by Bellman (Bellman, 1961) as the exponential
growth of the input space as a function of dimensionality. In other words,
the importance of a particular feature of genes can be hidden amongst the
vast amount of the other gene expression vectors. It occurs mainly when
the number of variables P is far higher than the number of cases n (P »
n), leading to a data space with noise and irrelevant inputs, consequently
leading to poorer performances of the model to unseen data, hence poorer
generalisation (Bishop, 1995). Recommended methods to overcome such an
issue usually involves the application of pre-processing procedures or feature
extraction algorithms (Bishop, 1995) as used for dimensionality reduction.
However, given the disadvantages and advantages of the approach, the idea
of independently testing each gene for the particular question, and subse-
quently test multiple combinations with the best performing single genes,
assessing and comparing their predictive performance, arise and gave the
opportunity to increase the gain of reliable information out from the data.
2.2.1 Stepwise algorithm
This approach consists basically in a wrapping method of a classical
ANN that enables identification of patterns within genomic data in an ad-
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ditive manner by finding the best individual variables performing the highest
to classify the dataset regarding the question studied and build the model
by iteratively adding subsequent variables to further improve the classifica-
tion. Initially, the approach uses each gene from the microarray experiment
as an individual input in the ANN, thus creating n individual models (n
being the number of genes studied in the experiment). Subsequently, the n
models are compared and sorted according to their predictive performances
for unseen cases (cases used in the Test subset from the MCCV). Thus,
we can rank each gene according to their modelling ability for the question
investigated on blind data. Then, the best input (i.e. gene) is selected
and further tested in 2-input models with the remaining genes, therefore
creating (n − 1) models. The best 2-input model is selected similarly, and
is further improved by testing its performances combined to the remaining
(n − 2) genes. The process is repeated until no improvement of predictive
performance of the model is observed or until it has reached an optimal level
of performance (Lancashire et al., 2008). The algorithm consists as follows
(Lancashire et al., 2005c):
1. Each of the variables is used as a single input in a one-input model,
creating the n single models.
2. Each model is then trained over 50 events of MCCV1, meaning that all
the samples were randomly reshuﬄed to ensure that all are considered
blind for a number of models, in order to improve the ability of the
network to generalise well for unseen cases.
3. The predictions and MSE across the 50 sub-models for test subset are
monitored and recorded for each single-input model, and these inputs
are then ranked based on their MSE.
4. The input within the model predicting the best (i.e. with the lowest
error) is then selected for the second step.
150 MCCV folds were found to be the number for which the models started to reach
consistency (Lancashire, 2006).
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5. At the following step, the input that performed the best in the previ-
ous one is used as the basis for two-input models.
6. The remaining inputs (n − 1) are then sequentially added to create
(n− 1) two-input models.
7. 50 sub-models are then trained for each of these two-input models,
and their performance is monitored as explained earlier.
8. The performances allow us to rank the best two-input model, and
select the combination of two inputs for the third step.
9. The process is repeated until no improvement in network performance
is observed, or if any early-termination condition is met.
A more detailed version of the algorithm is shown in Figure 2.4, and a
diagram in Figure 2.5.
This approach has been successfully applied in many different studies
conducting to key discoveries of reliable and validated biomarkers mainly
in cancer and especially breast cancer (Lancashire et al., 2008, 2009b).
Some examples of these applications will be discussed further in the present
manuscript.
2.2.2 ANN architecture for Stepwise parametrisation
Originally, the Stepwise approach consisted of a Visual Basic coded pro-
gram named “Stepwise ANN modelling” interfacing the Neural Networks
package of the software c©Statistica (StatSoft, Inc. (2004). STATISTICA
(data analysis software system), version 7. www.statsoft.com.). Despite the
numerous disadvantages of choosing to interface an external software, this
solution allowed the developer to initially assess the validity and robust-
ness of the approach without the heavy task to develop a complete ANN
software. Therefore, it was possible to define the optimal settings and pro-
cedures to obtain the most efficient and reliable approach for the analysis
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Figure 2.4: Schematic representation of the Stepwise algorithm
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Figure 2.5: Diagram depicting the principle of the Stepwise algorithm (in red are the models at each
step found to have the best modelling performance, i.e. the lowest modelling error, hence selected for
the subsequent steps).
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of complex genomic or proteomic data (Lancashire, 2006; Lancashire et al.,
2008).
The Stepwise approach is based on a single hidden layer MLP with two
hidden nodes using a BP learning algorithm. An early termination strategy
is employed in order to avoid over-fitting of the data on the training subset
with a maximum number of epochs of 3000, a window of 1000 epochs (i.e.
training stops when no improvement of the model is observed after 1000
epochs) and a MSE of 0.01. Learning rate is set at 0.1 and momentum at
0.5 for the BP algorithm. Initial weights of the network are randomly set
within a range between -1 and +1. A MCCV strategy is applied as well,
in order to ensure the good generalisation ability of the model obtained,
randomly splitting respectively 60%, 20% and 20% of the cases for training,
validation and independent test purposes. The MCCV is repeated 50 times
resampling all the cases in order to have them randomly affected differently
to the different subsets. The same settings were used for all the biomarker
discovery studies conducted during this Ph.D. project. However, some fur-
ther studies were carried out to assess how the methodology behaves.
2.3 Example of application of the original Step-
wise approach to a gene array in a breast
cancer study
2.3.1 Introduction
The study to be discussed here focused on the exploitation of a dataset
previously described and used in a study by van’t Veer and colleagues (van’t
Veer et al., 2002). This group firstly identified a set of 70 genomic markers
to predict distant metastases in breast cancer. Transposing such a signa-
ture into clinical routine then becomes challenging; the development of an
assay based on 70 gene transcripts would be really complicated, however
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it has been recently transposed into clinical aspect with the Mammaprint
assay from Agendia (Slodkowska and Ross, 2009). Therefore, it could be
interesting to reduce the number of markers to investigate, with a similar
or even better predictive ability. Using the ANN stepwise approach, it has
been possible to reduce the number of markers down to 9 able to predict the
outcome of distant metastasis for breast cancer patients with an accuracy
of about 98%. The results of that study showed that the expression of Car-
bonic Anhydrase IX (CA9) was able, as a single predictor, to predict the
metastatic events with an accuracy of 70%. The identified signatures were
subsequently tested against a second validation cohort of 295 cases (van de
Vijver et al., 2002). Here again, CA9 expression on its own was able to
predict metastatic outcome with an accuracy of 63%. Finally, investigation
of the protein expression of CA9 was conducted by immunohistochemistry
which was carried out on an independant set of samples. This work con-
tributed to (Lancashire et al., 2009b).
2.3.2 Materials and methods
Dataset and ANN analysis
The data were extracted from a microarray experiment in breast cancer
(van’t Veer et al., 2002). They were directly imported as a Microsoft Excel
format from http://www.rii.com/publications/2002/vantveer.html. It con-
sisted in a pool of 78 patients, with mixed ER status and no lymph node
positive cases, and with 24,481 values for each corresponding to the Log10
expression ratio of the genes. This particular dataset was chosen as it is
a well known and characterised dataset. However, this can be considered
as an historical dataset and therefore involves some pitfalls. Indeed, the
quality of the data relies on the quality of the technology back in that time.
Even more, the quality of the samples has to be replaced in the context, in
2002 the technologies for detection and diagnosis were not the same than
nowadays, as a result, the samples collected may present higher aggres-
siveness since the tumours may have been detected at a later stage in the
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development of the tumour.
The stepwise approach described earlier was applied in order to identify
the genes of importance regarding the question of distant metastasis. The
input vector was represented as analogue value with the log10 ratio of the
expression of each gene investigated. The output for the individuals who
presented a distant metastasis within 5 years was coded as 1, and 0 if no
evidence of metastasis was found within the five year period. A classical
architecture with MLP was applied in the ANN developed, with two hidden
nodes in the hidden layer, and a sigmoidal transfer function. Learning rate
was set at 0.1 and momentum at 0.5. Here again, overfitting of the ANN
on the training dataset was avoided using a MCCV approach that created
50 submodels, each with different random split of the cases in 3 different
subsets: 60% of the cases in the training set, 20% in the validation set, and
20% in the independent test set. Early stopping strategy interrupted model
development after 1,000 epochs without improvements, or when minimal
error of 0.01 was obtained.
Patient selection and tissue microarray
As mentioned in (El-Rehim et al., 2005), tissue microarray blocks con-
taining 555 breast tumour samples from patients involved in the Notting-
ham Tenovus Primary Breast Carcinoma Series were used for the validation.
The tissue samples were coming from tumour periphery avoiding necrotic
tissue. All the cases involved in the study were well characterised with com-
plete follow-up data with protein expression, pathology and clinical informa-
tion, including information on tumour reccurence, metastasis and survival.
Patients characterised with ER positive phenotype had received adjuvant
endocrine therapy whilst individuals with poorer Nottingham Prognostic
Index received chemotherapy. For CA9, the protein expression was further
validated on a separate cohort of 245 patients for which again, comprehen-
sive follow-up data was available, including histopathological information.
These patients were managed at the Royal Marsden Hospital, where they
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received therapeutic surgery followed by similar therapy as previously de-
scribed. For all tumour samples collected, grade and size were determined
by pathologists according to a modified Bloom-Richardson scoring system
(Bloom and Richardson, 1957) and the Tumour, Node, Metastasis (TNM)
staging criteria.
CA9 immunohistochemistry
The immunohistochemically stained tissue microarrays were scored by
pathologists blindly to the patients’ clinical and pathological information.
Staining was conducted in neoplastic cells of tumours and in stromal fibrob-
lasts. A previous study suggesting the involvement of CA9 in prognostic
outcome was the reason for the staining in stromal fibroblasts of this par-
ticular protein (Colpaert et al., 2003). Positive or negative staining in the
samples were recorded respectively as 0 or 1. No scoring was conducted for
altered tissues or tissue showing no invasive carcinoma.
2.3.3 Results
Model development
The analysis of the dataset by the stepwise approach identified a gene
signature of 9 genes able to predict with 98% sensitivity and 94% specificity
for prognostic prediction, with an Area Under the Curve (AUC) of 0.971
with Receiver Operating Characteristic (ROC) curve analysis. A summary
of the results at each step of the model development is shown in Table 2.1.
Following this development stage, the identified 9-gene signature has
been tested upon a different set of data consisting of 19 previously unused
samples (therefore completely blind to the model developed). This set in-
cluded 7 metastasis-free patients and 12 metastatic ones. The 9-gene model
succeded to correctly discriminate the 19 samples showing the relevance of
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Step Input added Gene name Description Cumulative Error Response
accuracy
1 NM_001216 CA9 Carbonic anhydrase IX 70% 0.44 Pos
2 Contig52778_RC EST 80% 0.38 Weak
3 Contig35076_RC EST 83% 0.38 Neg
4 Contig40557_RC FLJ13409 EST 87% 0.35 Pos
5 AB032973 LCHN LCHN protein 80% 0.4 Pos
6 AB004064 TMEFF2 Transmembrane protein 95% 0.23 Pos
with EGF-like and 2
follistatin-like domains 2
7 NM_006101 HEC/KNTC2 Kinetochore associated 2 95% 0.22 Weak
8 AF161451 HSPC333 HSPC337 96% 0.17 Neg
9 Contig33475 EST 98% 0.15 Weak
Table 2.1: The 9-gene signature identified at each step of the model development by the stepwise approach
the signature.
Response curve analysis for the 9 genes was also conducted to further
question the influence of each gene to the phenotype. This showed that
7 out of the 9 genes have a strong discriminatory response; in addition, 4
of them (CA9 being one of them) showed a positive relationship between
increased gene expression and higher probability of developing metastasis
(see Table 2.1). Conversely, 3 genes showed the reverse relationship, mean-
ing that a higher expression level of the gene resulted in a lower metastatic
risk. The 2 genes having weak response can still play a role in regulating
or modulating the other ones, which could explain why they appear in the
signature obtained by additive approach.
Validation of the signature
The application of the 9-gene signature managed to correctly classify the
population of 19 samples, thus showing the good generalisation ability of the
identified model, where the 70-gene signature identified in the original paper
misclassified 2 out of the 19 samples. A subsequent validation stage was ac-
complished using the NKI295 dataset (van de Vijver et al., 2002) including
a cohort of 295 patients to the 9-gene model identified. The Kaplan-Meier
analysis of the two groups obtained after the discrimination of the popula-
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tion by the signature showed significant difference for both overall survival
(P<0.001)2 and metastasis-free survival (P<0.001). The signature obtained
was able to discriminate the groups defined by the original 70-gene signature
from the van’t Veer study into prognostically distinct groups (P<0.001). On
the other hand, in a Cox regression model, using age, nodal status, Oestro-
gen Receptor (ER) status, tumour size, type of therapy and van’t Veer’s
70-gene signature, the 9-gene signature was a predictor of overall survival
(P = 0.012, Hazard ratio = 1.89) and metastasis-free survival (P = 0.003,
Hazard ratio = 1.92). In addition, CA9 gene expression showed a signif-
icant (P<0.001) positive association with tumours of basal-like phenotype
and an inverse association with luminal type cancers (P<0.001). Further
investigation followed to assess the feasibility of an immunohistochemically-
based assay transferable to routine clinical practice. For more details about
this and about the immunohistochemical validation of CA9 expression, the
reader is referred to the paper (Lancashire et al., 2009b) in Appendix I.
2.4 Discussion
The focus of this study was to develop an optimal yet minimal gene sig-
nature able to accurately predict the outcome of distant metastasis in breast
cancer patients using our regular ANN method coupled with the stepwise
approach with a previously published dataset (van’t Veer et al., 2002). The
original aim of this work was to at least be able to obtain a similar degree
of accuracy with the van’t veer study. The stepwise approach, specifically
designed to identify reliable biomarkers within complex datasets, was able
to identify a set of 9 genes with the ability to accurately predict (98% sen-
sitivity) metastatic outcome for breast cancer patients. Thus meeting our
goals to improve the original identified set of 70 genes predicting with an
accuracy of 83%, with a very smaller number of genes in the signature.
2P is an indicator of the statistical significance of the difference of the mean between
two variables over a population.
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The main gene identified was CA9, and was able, by itself to predict
70% of metastatic cases from the first cohort, and 63% from the NKI295
cohort (van de Vijver et al., 2002). The group of Carbonic anhydrases, in
which belongs CA9, is induced by the Hypoxia Induced Factor 1 α (HIF-
1α). They play a role in protecting cancer cell from death by neutralising
acidic conditions from hypoxia-induced glycolysis. In addition, it seems that
CA9 has a role in degradation of the extracellular matrix and induction of
growth factor, which could enhance cancer migration and invasion (Kallergi
et al., 2009). More details can be found in the published article (Lancashire
et al., 2009b).
2.5 Summary
This chapter focused on the ANN principles, theories and architectures.
Additionally, it showed the extension of the architectures, and how it can
be optimised for the purpose sought here: the identification of potential
new biomarkers from high-throughput data in biomedical sciences. In order
to highlight this, it finally discussed a successful application in a study
aiming to identify new, reliable and more importantly validated biomarkers
in breast cancer for the prediction metastatic events. The results obtained
in this example clearly showed the robustness of the approach presented
here. However, clear limitations occurred and the approach requested some
optimisation for more reliable and smoother applications.
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Chapter 3
Optimisation of the Stepwise
approach
This chapter will focus on the optimisation of the techniques discussed
in the previous chapter for the purpose of the identification of biomarkers.
We will detail how the optimisation was carried out, and how the improve-
ments were assessed. This optimisation step helped to improve the selection
step of important genes necessary for the interaction algorithm as it will be
further discuss in the following chapter. Finally, another example of appli-
cation of the newly developed stepwise approach will be discussed.
3.1 Stepwise approach optimisation
Although the program presented previously has shown great advantages,
this solution quickly showed some important limitations, mainly due to
the constraints of using an external software, not only because of the cost
issue for the licence, but as well as the maintenance or upgrading side (e.g.
the version 8 of c©Statistica was no more supporting cross-validation), and
unexpected crashes after about a day of process.
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3.1.1 Visual Basic software development
As a result, it was decided to develop an integrative and standalone new
application in Visual Basic able to build ANN MLPs, and able to integrate
several types of analysis. This software was developed in Visual Basic in the
first place, in order to obtain a fast stage of development and allow a rapid
validation and application stage, despite the poor speed of execution inher-
ent to Visual Basic code. The software used a classical single hidden layer
ANN MLP core, around which were wrapped several layers of algorithms in
order to use the Neural Network core in different ways. The further algo-
rithms incorporated into the new system, additionally to the Stepwise, at
that stage were :
• Sensitivity analysis is a well-known type of analysis that tests a
dataset by iteratively removing single elements to monitor how the
removal affects the predictive performance of the model. This perfor-
mance obtained is assessed and a ratio is given to the removed input.
• Cascade analysis iteratively removes correctly classified cases by the
ANN with all the inputs successively tested.
These ANN-based approaches have been successfully implemented in the
software and were working correctly. However, only the Stepwise approach
has been intensively applied to studies, and only this particular one will be
further discussed and described.
The software has been designed so that it can integrate any type of
algorithm to wrap around the ANN kernel of the software, therefore, any
idea can be quickly implemented as another layer around the core to use
the Neural Networks.
3.1.2 Application in C
Despite the great quality of the approach developed and presented in
the previous chapter, several improvements were needed in front of the
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limitations encountered during application stage. One major issue being
the poor speed of execution, which is the case for the solution presented
in the previous section. Therefore, it was considered a redevelopment of
the solution in a different and much faster language : C. Not only does
this language allow a faster speed of execution; but as well, its portability
makes it possible to apply the program in different environments such as
Linux or Unix. These environments are well known to have better speed
of execution, and more reliable memory management, a key issue in our
particular situation for massive data analysis.
The development stage of the application in C, was straight forward.
It revealed itself as a simple translation from Visual Basic to C, with no
major difficulty beside the usual memory management that can arise with
such code. Indeed, a careful management of the memory allocated needs to
be carried out as it usually is the pitfall of programming in C.
For an easy setting of the parameters needed by the Stepwise approach,
the strategy of an external parameter file was chosen. It is indeed easier to
alter the particular features of the parameters in a separate file read by the
main program, rather than altering them within the code and recompiling
the whole program everytime needed.
Finally, in order to obtain a more user-friendly program, and make it
available for biologists, a simple interface has been created in Visual Basic,
so that it is possible for scientists unaware of command lines to utilise the
software. Figure 3.1 present a snapshot of this interface. It allows the user to
quickly set the appropriate parameters, although they are set by default to
our regular settings. The user can specify the path where the file to analyse
is stored, and the folder where the results will be saved. When this is done,
the user can hit the "‘Run"’ button, the interface creates the parameter file
and launches the Stepwise program in C. Finally, this one starts to read the
parameter file, and can get started with the analysis itself. In addition, this
interface has been designed so that it was easy to implement some security
features (such as licence key).
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Figure 3.1: Screenshot of the Stepwise interface in Visual Basic
3.1.3 Monitoring improvements of optimised Stepwise
For the purpose of assessing the improvements brought by the optimised
software, a quick monitoring has been carried out. It mainly consisted of
assessing how the speed of processing improved with the newly developed
program, and if any improvements of modelling error could be observed.
The monitoring has shown some great improvements in terms of speed
and predictive error. Indeed, the time of process has been divided by up to 5
times, and the predictive error on the validation subset has been divided by
a factor 2 on average (from 0.379 to 0.184). This assessment was conducted
and determined by analysing the publicly available dataset from West et al.
for 10 independent repeats (West et al., 2001). This particular dataset had
been chosen as it is a well known, and it is been studied and used intensively
by the group. The signature used for the assessment purpose consisted of
recreating the predictive error ranking of the 7 markers previously identified
as the best predictors for lymph node status in breast cancer for 49 patients
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by prior analysis (Lancashire et al., 2008):
• AFFX-CreX-3_st
• M83221_at
• S79862_s_at
• U39817_at
• U63139_at
• M83652_s_at
• U30894_at
The predictive error on the validation subset (Figure 3.3) and the time
of execution to train the models (ranking the 7 genes by predictive error)
were then monitored over 50, 75 and 100 bootstraps (Figure 3.2). In short,
the monitoring consisted in the assessment of predictive error and speed of
execution for the stepwise to find the same rank of genes in the steps than
previously found and reported (Lancashire et al., 2008).
Figure 3.2: Time of execution for Statistica and the stepwise approach coded in C
On average it is now possible to run a 10-step stepwise analysis in the
same time as a single-step run with the previous software when interfacing
Statistica. We are then able to provide a quicker answer to biologists prob-
lems with a model and biomarkers of interests in a much shorter time period:
instead of speaking in week(s), we can now speak in day(s). In addition, the
average error, through different numbers of bootstraps have been compared
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between the stepwise in C and with Statistica. For the validation subset
(Figure 3.3), it clearly appears that a better and more accurate modelling
process is achieved with the Stepwise coded in C. This can be explained by
the choice of a sigmoid transfer function for the program in C rather than a
linear transfer function used by Statistica for the output node. In addition,
since this monitoring has been achieved on the validation subset, we can
argue that this improvement is not due to any sort of over-fitting reason, as
this subset is completely unseen during the training process of the ANN.
Figure 3.3: Comparison of the average predictive error on validation subset for different number of cross
validation folds (number of bootstraps).
3.1.4 MCCV repeats assessment
The survey has been conducted as well to asses the ideal number of re-
peats for MCCV to consider for an appropriate balance between a speed of
processing and a reliable modelling.
The results (Figures 3.2 and 3.3) showed that no real improvement could
be really observed after 50 folds and this number remains ideal to keep
an optimal balance between the time of execution and the development of
a robust model, with accurate predictive ability and good generalisation.
These results confirmed the results obtained by Dr. Lancashire previously
(Lancashire, 2006).
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Looping system
Several other improvements have been implemented. These include a
looping system, which simply repeats an analysis completely independently
to previous ones. This helps to run a Stepwise analysis over a number of
repeats without having to be in front of the screen each time it needs to be
re-launched for the user.
3.1.5 Output files
A clearer output filing system and summary file using American Stan-
dard Code for Information Interchange (ASCII) file format has been imple-
mented as well in order to clarify the output of the analysis. An overall
summary is now written at the end of the analysis to show to the final
user the overall results, for each step and each loop. Even details on each
bootstrap are recorded, in the way that if anything went wrong during the
training process, it is possible to have an insight into the development of
the model and track down where can be situated a problem that appeared.
3.2 Application of the optimised approach :
identification of miRNA signatures to pre-
dict ER, PR and HER2/neu status for
breast tumours
The study presented here refers to the discovery of significant validated
diagnostic markers for breast malignancies. There is indeed great interest
and efforts around discovery of new biomarkers for this particular form of
cancer. The high heterogeneity of phenotypes in breast carcinomas still
makes it one of the most challenging diseases in the clinical management
of the patients, especially from a diagnosis and therapeutic point of view.
Such heterogeneity tends to harden the work of clinicians who need accu-
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rate phenotyping of the tumours in order to provide the most precise and
efficient treatments and therefore to maximise the benefit from the therapy
for the patients. Highly divergent phenotypes result from a wide range of
different genotypes. Therefore, identifying the underlying genotypes (i.e.
genomic profiling) that can govern the mechanism of the subtypes in ma-
lignancies will lead to breakthrough discoveries ultimately leading to new
clinical management of patients.
3.2.1 Introduction
miRNAs have seen a growing interest lately, as shown by the increas-
ing number of publications during these years (Figure 3.4). They are now
recognised as highly abundant regulatory molecules and they can offer an-
other potential therapeutic strategy for malignancies, or a new prospect for
diagnostic tools for the characterisation and subtyping of carcinomas. Im-
portantly, miRNAs have been recently shown to be dysregulated in breast
carcinomas, and some miRNAs play a role in tumorogenesis, metastasis
and invasion (Lowery et al., 2008). Therefore comes the interest to iden-
tify miRNAs signatures of importance and monitor the correlation between
these signatures and the clinicopathological classification of the tumours
and the patients.
In the present study, it was sought to assess potential roles of several
miRNAs expressed in breast tumour tissue related to the ER, and status of
the patients. By identifying those miRNAs, we could then build a model
thanks to ANN modelling, in order to predict patients’ status according to
the level of expression of the identified miRNA signatures. Those identi-
fied signatures could then provide new insight in breast carcinogenesis and
breast cancer subtyping subsequently leading to potential new diagnosis
tools and treatments.
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Figure 3.4: Increasing number of publications concerning total miRNAs (in green) and miRNAs in cancer
(in red) between 2001 and 2009 (source: www.mirnatherapeutics.com).
3.2.2 Materials and methods
The samples were collected by surgically extracting breast tumour tis-
sue from patients during primary curative resection at Galway University
hospital, Galway, Ireland. The initial pool of patients consisted in 29 early-
stage invasive ductal breast cancer tumours (Table 3.1) used for microarray
miRNA expression experiment. A second cohort of 95 breast tumour sam-
ples, and 17 tumour-associates normal breast tissue specimen used as control
references (Table 3.2) were used for validation purpose with . Immunohis-
tochemistry determined the ER, PR and HER2/neu status for each patient
involved.
After extraction, the RNA samples devoted to microarray were Cy-dye
labelled and hybridised on LNA miChip microarray platform (Exiqon ver-
sion 7, 453 miRNA sequences). Slightly modified RNA extraction protocol
was employed for the samples devoted to validation with qRT-PCR. Prior
ANN analysis, preprocessing methods were applied to capture intensity level
of expression for miRNAs. The resulting data from the microarray were sub-
mitted to the genomic data repository platform Gene Expression Omnibus
of the (http://www.ncbi.nlm.nih.gov/geo/) under the accession reference:
GSE15885.
76
Patient Age Tumour Lymph node Grade Stage ER PR HER2 Subtype
(years) size (mm) status
1 49 23 Negative 1 2A P P N Luminal A
2 52 30 Negative 3 2A N N P Her2 overexpressing
3 57 45 Negative 3 2A N N P Her2 overexpressing
4 51 21 Negative 3 2A P P N Luminal A
5 68 15 Negative 3 1 P N N Luminal A
6 42 22 Negative 3 2A N N N Triple negative
7 54 26 Negative 3 2A N P N Luminal A
8 35 22 Negative 3 2A P P N Luminal A
9 50 16 Negative 3 1 N N N Triple negative
10 49 25 Negative 2 2A N N N Triple negative
11 59 20 Negative 3 1 N P N Luminal A
12 58 22 Negative 3 2A P P N Luminal A
13 58 18 Negative 1 1 N P P Her2 overexpressing
14 66 22 Negative 3 2A P P N Luminal A
15 56 17 Negative 1 1 N N N Triple negative
16 48 30 Negative 3 2A N N P Her2 overexpressing
17 60 26 Negative 3 2A P P N Luminal A
18 56 29 Negative 2 2A P P N Luminal A
19 50 3 Negative 2 1 P P N Luminal A
20 40 7 Negative 1 1 P P N Luminal A
21 40 6 Negative 2 1 P P N Luminal A
22 58 35 Negative 2 2A P P N Luminal A
23 64 34 Negative 3 2A P P N Luminal A
24 66 26 Negative 1 2A P P N Luminal A
25 84 16 Negative 2 1 N P N Luminal A
26 57 7 Negative 3 1 N P N Luminal A
27 68 35 Negative 3 2A P P N Luminal A
28 40 20 Negative 2 1 P P P Luminal B
29 49 35 Negative 3 2A N N N Triple negative
Table 3.1: Clinical and pahtological information for the original 29 patient cohort for microarray exper-
iment.
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Breast cancer clinicopathological characteristic Number of patients (n = 95)
Median (interquartile range) tumour size (mm) 23.5 (17.75 to 35.0)
Histologic subtype
Invasive ductal 80
Invasive lobular 13
Colloid/mucinous 1
Tubular 1
Tumour-associated normal 17
Intrinsic subtype
Luminal A (ER/PR+, HER2/neu-) 47
Luminal B (ER/PR+, HER2/neu+) 21
Her2 overexpressing (ER-, PR-, HER2/neu+) 11
Triple-negative (ER-, PR-, HER2/neu-) 11
Missing data 5
Grade
1 14
2 26
3 53
Missing data 2
Nodal status
Node-negative 50
N1 17
N2 17
N3 11
Oestrogen receptor status
Positive 62
Negative 32
Missing data 1
Progesterone receptor status
Positive 58
Negative 33
Missing data 4
Her2/neu status
Positive 32
Negative 59
Missing data 4
UICC stage
Stage 1 23
Stage 2a 29
Stage 2b 8
Stage 3a 14
Stage 3b 4
Stage 3c 8
Stage 4 9
Table 3.2: Clinical and pathological information for the the second cohort with 95 patients involved for
the independent validation using PCR.
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For this study, the ANN stepwise approach has been applied, using a
three-layer feedforward MLP with a BP algorithm and sigmoidal transfer
function as described in chapter 2. The data were initially normalised be-
tween 0 and 1 for each variable casewise. The individual miRNA intensity
values were presented to the ANN as input, and classes to predict (ER, PR
and HER2/neu) were presented to the output layer (coded as 0 for negative
and 1 for positive samples). The cross validation with an early termination
strategy was applied to the approach in order to avoid overtraining of the
model.
qRT-PCR quantification was performed to further validate the findings
obtained with the microarray experiment coupled with the ANN stepwise
approach. The relative quantity of miRNA expression was obtained with
the comparative cycle threshold method, or ∆∆Ct method. Analysis of
these results was performed using the Kolmogorv-Smirnov normality test.
3.2.3 Results
The analysis of the microarray by the ANN stepwise method allowed
us to identify fingerprints of miRNAs that can accurately predict status of
patients associated to ER, PR, and HER2/neu for breast tumour samples.
The predicted performances of the models developed are obtained by recre-
ating a complete ANN just using the identified miRNA signatures on the
same population of data. The lack of a second blind microarray dataset,
that would be best for validation purpose, was tackled by applying a MCCV
strategy for this model interrogation procedure on the original dataset. Fur-
ther validation of the signatures found were performed using qRT-PCR on
the second cohort of samples.
The most advanced model of miRNA signatures predicting for ER status
consisted in a pool of 6 miRNA transcripts (miR-342, miR-299, miR-217,
miR-190, miR-135b, miR-218). This model, when interrogated on the same
population of data and trained over 50 MCCV repeats, was able to discrim-
inate ER positive and negative phenotypes with a median performance of
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miRNAs fingerprints identified by stepwise analysis at each step for each status studied
Step miRNA mRNA Mean squared Median Responsetargets error performance (%)
ER
1 miR-342 - 0.132 83.3% (+)
2 miR-299-3p - 0.087 100% (-)
3 miR-217 - 0.07 100% (+)
4 miR-190 - 0.06 100% (-)
5 miR-135b - 0.057 100% (-)
6 miR-218 LAMB3 0.047 100% (+)
PR
1 miR-520g - 0.186 83.3% (-)
2 miR-377 - 0.129 83.3% (+)
3 miR-527-518a - 0.086 100% (-)
4 miR-520f-520c - 0.07 100% (+)
HER2/neu
1 miR-520d - 0.109 100% (+)
2 miR-181c Tcl1 0.086 100% (-)
3 miR-302c Cyclin D1 0.062 100% (*)
4 miR-376b - 0.05 100% (+)
5 miR-30e-3p Ubc9 0.047 100% (*)
Table 3.3: Fingerprints of miRNAs used in the expression signature at each step of model development
for ER status, PR status and HER2/neu status. A (+) in response signifies that increased miRNA
expression leads to increased probability of receptor positive status; on the opposite a (-), indicates that
increased miRNA expression leads to increased probability of receptor negative status; (*) means weak
response, possibly interacting to modify the response of other miRNAs.
100%.
The second model developed, to predict PR status, was found to be
most accurate with a set of 4 miRNAs (miR-520g, miR-377, miR-527-518a,
miR-520f-520c). This model was able to discriminate the patients regarding
their status for PR receptors with a median performance of 100%.
Finally, the third model developed was looking at the optimal miRNA
signature that could accurately predict the HER2/neu status of the patients.
The identified pattern of miRNA by the trained ANNs was composed by
:miR-520d, miR-181c, miR-302c, miR-376b, miR-30e. This signature as
well was able to identify with 100% median predictive performance of the
status, over 50 submodels run. These results are sumarised in Table 3.3.
The major advantage of an additive approach like the Stepwise algo-
80
Figure 3.5: Evolution of the predictive errors at each step of development for the 3 models (a: for
estrogen receptor status; b: for progesterone receptor status; c: HER2/neu status).
rithm presented here, consists in its potential to identify and further build
and improve a molecular fingerprint. Figure 3.5 clearly shows how the pre-
dictive error drops at each step until the developed model reaches an optimal
performance by iteratively adding new markers to the model. After optimal
performance is reached, no further improvement is observed.
Model interrogation
The identified miRNA signatures found to have a role for each studied
phenotypes were investigated for responses and population discrimination
ability. In order to identify how the outcome studied is behaving regarding
the level of expression for each of the miRNA included in the model, an
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Figure 3.6: Response curves of the miRNAs identified to be the best single predictor for ER status (a);
PR status (b); and HER2/neu status (c) (respectively miR-342, miR-520g, miR-520d).
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analysis was performed using each of the identified miRNAs. The analysis
consisted of presenting the values of the studied miRNAs from the signa-
ture as an input vector to the ANN that will predict the status of each
individual, repeated for each of the 3 models (see Table 3.3). Figure 3.6
only displays the results of the response analysis for the best single miRNA
for each of the 3 models. As a result, this figure showed that miR-342 has
a positive influence to ER status, meaning that there are higher chances
that an individual will present a positive status to ER when the intensity
of this miRNA is found higher. Similarly, for HER2/neu status, miR-520d
gives a positive response. Conversely, miR-520g is found to have a nega-
tive response, indicating that when its expression decreases, there are more
chances for the PR status to be negative.
Further interrogation of the developed models with the identified miRNA
fingerprints consisted of re-stratifying the population by predicting their sta-
tus according to the output obtained with the respective models. This way
of interrogating a particular model allows us to position any new individual
within the population structure and visualise how this new patient fits into
the overall population.
The 3 models were able to accurately classify the population accordingly
to the status of the individuals as shown in Figure 3.7. The model for ER
status, composed by 6 miRNA signatures, was able to perfectly distinguish
positive from negative status individuals, with a very clear threshold, show-
ing a great ability to accurately discriminate both populations. Moreover,
this model is able to consistently predict the ER status as nearly no varia-
tion is observed in the 50 different submodels developed. This is shown by
the error bars in the first population chart of Figure 3.7, which are obtained
by the confidence intervals positive and negative for each individual over
the average of the 50 submodels.
The third population chart shows again excellent discrimination ability
for the model of miRNA signature at predicting HER2/neu status of the
individuals. But this result needs to be considered carefully as only 5 out
27 patients present a positive phenotype. Therefore, although the model
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Figure 3.7: Population distibution of the model interrogation for the 3 models developed: the ER model
(a); the PR model (b) and the HER2/neu model (c).
presents good reproducibility with low error bars, since the population is
not balanced and only few individuals have a positive HER2/neu status, it
is difficult to conclude about the absolute robustness of the model.
Validation
Validation of the identified signatures was mainly conducted with qRT-
PCR by testing a subset of these identified miRNAs in the samples of the
second cohort. The results can be seen in Figure 3.8.
miR-342, identified as best single predictor for ER status, was investi-
gated by qRT-PCR, in order to identify its importance regarding the ER
status of the patients. The analysis revealed that no significant difference in
expression of miR-342 was observed between tumour and tumour-associated
normal tissue (P value=0.6 from paired t test). However, the analysis
showed that a significantly (P=0.04 from independent t test) higher expres-
sion of this miRNA was observed in ER positive tumour samples (n=62)
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compared to ER-negative (n=32). These results show that the expression of
the miRNA is not specific to the tumour tissue, but it is significantly higher
in ER-positive samples. In addition, it confirms the positive association
between this miRNA and the ER positive status (i.e. higher likelihood of
positive ER status with higher miR-342 expression level) obtained with the
response curve. This is validating the results obtained by in silico method.
Interestingly, miR-342 expression was also found higher for HER2/neu pos-
itive tumours (n=59) compared to negative tumours (n=32) (P=0.001 from
independent t test), where the ANN analysis for HER2/neu status identified
miR-342 at 62nd position out of 352 miRNAs studied.
Regarding PR status, miR-520g was found as best predictor using the
ANN approach. The expression of this miRNA was investigated as well for
validation by qRT-PCR in order to confirm the results. Similarly to the
previous one, the expression of this miRNA was found to have no signifi-
cant (P=0.228 from paired t test) difference between tumour and tumour-
associated normal breast tissue; however, significant (P=0.032 from inde-
pendent t test) increase of this expression could be observed in PR-negative
tumour samples (n=33) compared to PR-positive ones (n=58), confirming
here again the results obtained with the response curve analysis.
Figure 3.8: qRT-PCR Results for miR-342 and miR-520g for ER and PR status
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3.2.4 Discussion and conclusion
Molecular identification and subtyping of phenotypes in cancer is show-
ing an increasing interest for biomedical research. With this new focus,
breast cancer is even more seen as a highly heterogeneous disease each sub-
type having its own clinical, pathological and molecular specificity. There-
fore, the identification of the subtypes of the disease is critical to gain an
optimised treatment for the individual and subsequently maximised prog-
nostic outcome. Subclasses of breast carcinomas involve the status of ER,
PR and HER2/neu (Lowery et al., 2009):
• luminal-A subtype: ER+ / HER2/neu-
• luminal-B subtype: ER+ / HER2/neu+
• basal-like subtype: ER- / PR- / HER2/neu-
• HER2/neu-overexpressing subtype: ER- / HER2/neu+
Not only are these receptors key factors for tumour subclassification,
they also play a key role in the therapeutic strategy that will be employed.
Specific drugs to treat breast cancer have an effect on one of these re-
ceptors. As an example, ER signalling can be totally inhibited with pure
anti-oestrogen drugs such as fulvestrant. Moreover, the status of these re-
ceptors will have an impact on the response of the patient to a particular
treatment, for example, HER2/neu-positive tumours will be less responsive
to endocrine-based treatment (DeLaurentiis et al., 2005). The most chal-
lenging tumour subtype is the basal-like (or triple negative) as it usually
presents the most aggressive behaviour that comes generally with a poorer
prognostic outcome. Despite promising research of treatment for this sub-
type with platinum agents, -targeted agents or inhibitors, no effective spe-
cific treatment has been found for this particular subgroup. Therefore, it
is clear that ER, PR and HER2/neu receptors are key indicators for breast
cancer management although their regulation is very poorly understood so
far. This is the reason why we decided to investigate potential miRNAs
associated with them.
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The microarray profiling have been shown to be remarkably useful for
the assesment of the gene or miRNA expression of individuals. Despite the
robustness of this method, it is still barely applied to routine clinical prac-
tice, mainly due to the lack of reliable computational method of the data.
Classical statistical approaches have been proven problematic for such anal-
ysis (Lancashire et al., 2009a), mainly because of the highly dimensional
and complex data that emerge from a microarray experiment. Moreover,
several artifacts can still affect the outcome of such method (noise, exper-
imental variability, chip and samples variability...), subsequently leading
to poor performance of the models developed. A study by Michiels and
colleagues (Michiels et al., 2005) demonstrated that the outcome of a par-
ticular microarray experiment is highly dependent on the computational
analysis method employed and particularly dependent on the selection of
the training set of patients. This is the reason why ANNs were chosen for
this study. Their ability to cope with noisy, complex and highly dimen-
sional data, coupled with a robust Cross validation procedure, to overcome
the problem raised by Michiels et al., make ANNs a good choice for the
data analysis. They have already been successfully applied in a number of
contexts where markers of biological relevance have been identified, includ-
ing polycystic ovarian syndrome (Matharoo-Ball et al., 2007b), melanoma
(Matharoo-Ball et al., 2007c), prostate cancer (Matharoo-Ball et al., 2007a)
and breast cancer (Lancashire et al., 2008).
The study here focused on the identification of miRNA transcript sig-
natures predictive of ER, PR and HER2/neu status with microarray data
analysed by ANN-based stepwise approach. The breast tumour samples
selected for the study were early stages (stages 1 and 2a) without nodal
invasion. The stepwise approach succeeded to identify optimal miRNA sig-
natures able to accurately predict receptor statuses. Although the model
performed perfectly for the dataset, it is required to perform further vali-
dation on a larger dataset, using alternative methods like PCR.
The miRNA signatures identified for ER status (miR-342, miR-299,
miR-217, miR-190, miR-135b, miR-218), for PR status (miR-520g, miR-
377, miR-527-518a, miR-520f-520c) and for HER2/neu status (miR-520d,
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miR-181c, miR-302c, miR-376b, miR-30e) include miRNAs that have pre-
viously been identified as dysregulated in different cancers, including breast
cancer (Blenkiron et al., 2007; Mattie et al., 2006) and involved in the reg-
ulation of cell functions such as growth, apoptosis, migration and invasion
(Cheng et al., 2005; Grady et al., 2008; Huang et al., 2008). This confirmed
that the signatures identified are relevant in breast cancer context. In addi-
tion, confirmation by qRT-PCR of the results from microarray experiment
gave a validation of the findings. A set of 8 miRNAs was validated in the
same sample by stem-loop qRT-PCR, and a significant positive correlation
in sample-to-sample expression was found between the two techniques (qRT-
PCR and microarray). Moreover, qRT-PCR confirmed that the expression
of the top ranking miRNAs in ER and PR (miR-342 and miR-520g) was
related to the phenotypic characteristic of the patients in an independent
set of 95 tumour samples (see Figure 3.8).
miR-520g was found important in the PR signature as well as ranked
in the step 1 of the analysis for ER status. These results were validated
by the results from qRT-PCR. It appears that it is the first report of im-
plication of this miRNA dysregulation in breast cancer. However, it seems
that this miR-520g is computationally related to a number of genes involved
in breast cancer, such as ABCG2 (BCRDP) (Griffiths-Jones et al., 2008).
ABCG2 expression in cancer cells has been shown to confer a drug-resistant
phenotype and correlates with response to anthracyclines in breast cancer
(Huang et al., 2008).
The validation qRT-PCR results, as well as the literature review of the
miRNAs identified suggested then that these miRNAs are relevant and can
be significant in the context of the phenotypes of breast cancer studied here,
thus showing the robustness of the approach employed.
3.3 Summary
The Stepwise approach, despite the robustness of its original version,
suffered several issues and limitations. As a result, different aspects of
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the method needed improvements, optimisation and tests in order to satisfy
the expected robustness and accuracy at predicting models and fingerprints.
Following the optimisation stage, the robustness of the redeveloped solution
was illustrated by a successful study published in a peer-reviewed journal
which allowed the identification of a new predictive miRNA signature for
ER, PR and HER2/neu statuses in breast malignancies (Lowery et al., 2009)
(see Appendix II).
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Chapter 4
Interaction algorithm
development
This chapter will now discuss the main focus of this Ph.D. research: the
development and optimisation of a software solution aiming to infer net-
works of interaction/relationship that could exist between biomarkers using
an ANN based approach. It will introduce the main idea and basic princi-
ple, and will further develop the optimisation and assessment to select the
optimal algorithms and methods to extract the most accurate results.
4.1 Introduction
In the previous chapter were discussed some examples of applications of
the stepwise approach to identify signatures of discrete variables (regard-
less of their nature) able to accurately predict a particular outcome in a
disease. Although this approach has proven its robustness and reliability,
it is still simplifying a complex problem to answer a particular question. In
addition, although it is possible to identify a set of markers that seems to
cooperatively have an influence on the context investigated, it is impossi-
ble to answer how these markers may be connected to each other, and it
is impossible to explain why they seem to be involved in the same sort of
interaction, complex or pathway. As discussed earlier, understanding the
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system of a disease, its dynamic, requires to use a more comprehensive ap-
proach and consider the global system rather than just some key features.
In other words, we might have been able to identify several spots; so now,
how is it possible to join the spots one to another and try to explain how
they might behave between each other? We have previously seen that sev-
eral groups have been trying to answer these questions using different types
of approaches with different technologies. We are going to describe here a
method based on ANN technology able to infer the potential co-expression,
and therefore relationship, between several markers in a multivariate fash-
ion.
4.2 Theory and development of the method
4.2.1 Theory
It has been well established and discussed that correlating and co-expressed
molecules are highly likely to be involved in some sort of molecular com-
plex or pathway of any nature, including regulatory patterns (Barabási and
Oltvai, 2004; Quackenbush, 2001). Based on this statement, the primary
hypothesis of the development of the algorithm is :
If any of the markers (e.g. genes) contained in an expression
array of individuals have some influence on the expression of
other markers (either positive or negative), we might be able to
observe and monitor significantly correlating expression profiles
between these interacting markers through the population of in-
dividuals. In other words, the influence that one input has upon
the prediction of any other given input is proportional to the
relationship between the two.
Therefore, there might be other ways (in addition to investigating single
markers for prediction), to investigate in depth a dataset in order to ex-
tract such information. Moreover, with the huge quantity of data contained
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within a single expression array (in excess of 1 million exons on a single
chip), it might even be possible, with the expressions of all the interacting
markers, to recreate the whole interaction map of the markers contained
within the specific dataset in a particular context. We show here the de-
velopment of an algorithm based on ANNs able to indicate the potential
network of interactions between markers present in the dataset.
Such an algorithm could then stress the central role of key features within
the particular context of a given disease, providing then not only a greater
understanding of the system biology of the disease, but also new potential
therapeutic targets for future treatments.
Several groups have recently started to focus some research toward this
new scope as discussed in the introduction. Also, other alternatives so far
have been to compile all the existing literature about systems biology and
interacting molecules with several databases and softwares. This is the case
with Ingenuity, which is used in this project to validate findings.
4.2.2 Algorithm
The main idea of the approach here focuses on the iterative calculation
of the influence that multiple variables may have upon a single one. Indeed,
if it has been possible to use all the variables to explain one particular cat-
egorical outcome (such as a survival or a status in a disease), it should be
possible to use one of these variables as an outcome and all the remaining to
explain the level of expression of the first one, and then be able to find out
the influence everyone has on the expression level of this particular variable.
Once this process for the first variable is complete, the algorithm iteratively
repeats the procedure for each of the remaining variables. Briefly, it consists
of looking at how the level of expression of every single input can be pre-
dicted with all the others of the original dataset, and subsequently repeat
it iteratively for all of them. This algorithm is summarised in Figure 4.1,
and explained by the diagram in Figure 4.2.
92
Figure 4.1: Schematic representation of the simplified algorithm for interactions
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Figure 4.2: Diagram of the principle of the algorithm for interactions.
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At each step (i.e. for each variable tested), looking at the weights of the
trained ANN (with the lowest predictive error) that links each input to the
output gives an insight to establish a correlation between the input vector
and the predicted output, and it is then possible to extract the interaction
value, or score, with these weights. The variable considered as output
is firstly converted into a boolean value in order to apply a categorical
prediction of the value by the ANN. Therefore, the ANN is developed to
predict if the input vector can explain an over or under-expression of the
targeted variable.
An MCCV strategy is applied as well over 50 repeats with complete
random re-sampling of the cases independently for each variable studied.
For each of those repeats, a correlation analysis is conducted comparing
the series of the actual expected values of the targeted variable (output),
with its predicted values by the trained ANN, for all the cases of the test
subset. From this, the Pearson correlation coefficient r (Rodgers and Nice-
wander, 1988) is calculated and gives a level of confidence for each of the 50
models tested at predicting the output. If the Pearson coefficient is below
a threshold of 0.7 for more than 10 bootstraps out of 50, the model is no
longer considered as able to accurately predict the level of expression of the
variable tested, and the interaction scores targeting this particular variable
will be set at 0. This method allows us to apply a sort of pre-filter in order
to remove the most insignificant interactions.
To illustrate this, let’s consider 10 genes identified to be of interest re-
garding a particular question (e.g. cancer against control cases). The first
gene with its expression level is used as output, and all the 9 remaining
genes are used as input vector. The ANN is trained with the training sub-
set of the population, and subsequently tested against the test subset to
assess how the model with the 9 genes performed to predict the level of
expression of the first one. This is repeated over 50 folds, each time ran-
domly reshuﬄing the cases over the subsets. If the 50 models trained have
performed efficiently enough, the weights are derived according to a scoring
algorithm (see page 107) to link each gene of the input vector to the output
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gene with a particular score (either positive or negative). In contrast, if the
models did not perform satisfyingly enough, all the scores are set to 0. The
method then carries on, using the second gene as output and gene 1 and 3
to 10 as inputs, and recreates and trains 50 new ANN models. The same
process is repeated to obtain the scores linking the 9 genes to the second
one, and so on until the 10 genes have been used as the output of the ANN.
As a result, a Microsoft Excel spreadsheet is finally produced as output
containing the scores between every single input with all the others succes-
sively, with a direction of interaction given by the positivity or negativity
of the scores obtained since the weights within the trained ANN can either
be positive or negative. Moreover, there is an insight of bi-directivity infor-
mation since a variable is tested as output and input.
Once the information regarding all the interactions is available, it is then
possible to construct the network of interactions and display it in a visual
way, using in-house solutions or external software such as Cytoscape (Shan-
non et al., 2003).
4.3 Workflow of the method
4.3.1 Workflow
The standard workflow applied for the studies conducted using this
method is summarised in the Figure 4.3. It consisted of a preliminary
selection of the important variables by applying a Stepwise analysis. The
first step of this analysis provided a rank order of the most important vari-
ables contained in the dataset regarding a particular question (e.g. cancer
versus normal, or responder versus non-responder to therapy). The top 100
variables, once ranked by predictive error from the lowest to the highest,
are further selected. Indeed, despite the ability of the ANNs to cope with
highly dimensional datasets, we need to apply here a feature selection of
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the most important variables for two reasons. Firstly, the dimension of the
result is nearly quadratic from the initial number of variables, for n vari-
ables selected for interactions, each are tested against the remaining n− 1,
therefore the final number of interactions is n(n− 1) or n2 − n. Therefore,
reducing the number of investigated variables to the most relevant ones, will
help to reduce the time of processing. Secondly, since the main core of the
scoring system of the algorithm is based on the weights within the ANN,
having too many inputs would literally hide the importance of a particular
input amongst all the others.
4.3.2 Pre-processing step
An initial stage of the method consists in rescaling the whole array of
data in order to normalise the variables. They are independently rescaled
between 0 and 1 across all the cases. This allows application of a consistent
and normalised set of data to the algorithm.
4.3.3 Application of the algorithm
Subsequently, the actual interaction process is carried out using the al-
gorithm developed and discussed above as seen in Figure 4.1.
4.3.4 Filtering the interaction map
From this process an array of interaction scores between variables can
be extracted as a table in a Microsoft Excel spreadsheet format. Since ev-
ery single interaction between any pair of variables contained in the dataset
have been investigated, it appears that some (most) of the relationships are
not actual or of enough significance. Moreover, such an algorithm produces
a huge amount of data, as for n inputs, there are n(n−1), or n2−n, poten-
tial interactions. Therefore, it is necessary to filter out the non-significant
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Figure 4.3: Workflow of the interaction algorithm application
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interactions, and only keep the most interesting of them. Originally it has
been decided to consider as significant the interactions with the highest
absolute values of interaction score (either positive or negative). The sign
of the interaction score is preserved so that it is possible to determine the
direction for the mapped interaction indicating whether it is inhibitory or
stimulatory. Some other ways of filtering have been considered, such as
taking the average interaction values for 10 successive interaction models,
and keeping only the interactions with the lowest standard error across the
10 models, or only those interactions at the tails of the distribution. Some
of this filtering strategies are discussed in the following section discussing
the optimisation of the approach.
4.3.5 Visualisation of Interaction maps
The concept of the interaction mapping in the present case uses the
network theory as described by Barabási and Oltva (Barabási and Oltvai,
2004), where a single marker is symbolised by a node, and any relationship
between two markers is represented with a directed edge, and/or an arrow
setting one of the nodes as a source, and the other one as a target. In
order to build up and visualise such interaction networks, the open source
software Cytoscape (Shannon et al., 2003) has been used.
Although the whole concept relied on the basis of interaction map, al-
ternative displaying method could be considered. One to be mentioned is
the heatmap. Rather than presenting the results as a list of each possible
pair of interactions, the results are presented as a matrix with each variable
present in both column and rows. The interaction between each pair of
variables is represented by a spot where the variables cross in the matrix,
and the intensity of interaction score is coded by a gradual scale of blue
colours for negative scores and red colours for positive scores. Scores set at
0 by the algorithm are coded in white, and the spot at the cross between the
same variable is coded in black. An example of a heatmap for interaction
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scores is presented in Figure 4.4.
Figure 4.4: Example of a heatmap for interaction scores applied to a simulated dataset.
From this stage of development of the approach, the algorithm has been
applied to the van’t Veer dataset and results are described in the following
chapter.
4.4 Optimisation of algorithm and method
4.4.1 Application on simulated dataset
A simulated dataset has been created and used for the purpose of further
improving the algorithm. The dataset has been blindly generated using a
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custom R script1 and consisted of a population of 100 cases with 25,000
variables containing 32 highly correlating variables (c.f. Correlation matrix
in Table 4.2). The list of the 32 variables can be seen in Table 4.1. The
other 24,968 variables were randomly generated by the R script.
Position in ranking
Position in dataset at first step of Stepwise
1 12565 328
2 5209 79
3 16983 9679
4 12864 4996
5 14078 27
6 20634 25
7 97 30
8 15023 35
9 5604 22
10 11694 23
11 2631 24
12 24489 21
13 1644 11
14 4202 15
15 24857 9
16 2952 12
17 21230 13
18 13484 10
19 21422 16
20 8612 19
21 21803 18
22 6352 17
23 1122 20
24 23897 14
25 9866 3
26 9662 1
27 22109 4
28 13504 8
29 5702 6
30 22935 7
31 3368 5
32 10157 2
Table 4.1: List of the 32 highly-correlating variables of the simulated dataset. Positions in ranking
presented in bold show the variables not present in the top 100 in step 1 of the stepwise analysis.
Results of the stepwise analysis
Compliant to the workflow of the method, a preliminary step for fea-
ture selection involved the application of the stepwise algorithm. A single
1R is a programming language and a mathematical environment specialised in the
statistical analysis of data. It is popular amongst the bioinformatics community.
101
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 1 0.01 0.09 0.17 0.14 0.03 0.30 0.06 0.19 0.16 0.16 0.18 0.12 0.20 0.20 0.21
2 0.01 1 -0.02 -0.06 0.11 0.20 0.14 0.16 0.18 0.21 0.25 0.19 0.18 0.22 0.32 0.31
3 0.09 -0.02 1 -0.03 0.01 0.13 -0.06 0.01 0.15 0.09 0.13 0.05 0.13 0.09 0.14 0.11
4 0.17 -0.06 -0.03 1 0.22 -0.14 0.18 0.05 0.12 0.05 0.01 -0.02 0.17 0.14 0.19 0.19
5 0.14 0.11 0.01 0.22 1 0.14 0.32 0.23 0.29 0.24 0.29 0.24 0.38 0.31 0.41 0.41
6 0.03 0.20 0.13 -0.14 0.14 1 0.11 0.27 0.40 0.31 0.39 0.42 0.37 0.47 0.34 0.50
7 0.30 0.14 -0.06 0.18 0.32 0.11 1 -0.08 0.27 0.32 0.28 0.28 0.31 0.42 0.41 0.37
8 0.06 0.16 0.01 0.05 0.23 0.27 -0.08 1 0.28 0.24 0.22 0.19 0.28 0.32 0.39 0.31
9 0.19 0.18 0.15 0.12 0.29 0.40 0.27 0.28 1 0.52 0.51 0.59 0.54 0.56 0.57 0.67
10 0.16 0.21 0.09 0.05 0.24 0.31 0.32 0.24 0.52 1 0.47 0.55 0.58 0.62 0.56 0.57
11 0.16 0.25 0.13 0.01 0.29 0.39 0.28 0.22 0.51 0.47 1 0.44 0.56 0.63 0.60 0.50
12 0.18 0.19 0.05 -0.02 0.24 0.42 0.28 0.19 0.59 0.55 0.44 1 0.59 0.63 0.61 0.69
13 0.12 0.18 0.13 0.17 0.38 0.37 0.31 0.28 0.54 0.58 0.56 0.59 1 0.69 0.75 0.69
14 0.20 0.22 0.09 0.14 0.31 0.47 0.42 0.32 0.56 0.62 0.63 0.63 0.69 1 0.76 0.70
15 0.20 0.32 0.14 0.19 0.41 0.34 0.41 0.39 0.57 0.56 0.60 0.61 0.75 0.76 1 0.72
16 0.21 0.31 0.11 0.19 0.41 0.50 0.37 0.31 0.67 0.57 0.50 0.69 0.69 0.70 0.72 1
17 -0.20 -0.27 -0.15 -0.04 -0.38 -0.33 -0.38 -0.19 -0.60 -0.60 -0.60 -0.67 -0.76 -0.71 -0.76 -0.71
18 -0.33 -0.21 -0.20 -0.19 -0.38 -0.39 -0.38 -0.36 -0.64 -0.57 -0.47 -0.66 -0.67 -0.69 -0.72 -0.67
19 -0.27 -0.29 -0.10 -0.15 -0.30 -0.45 -0.33 -0.38 -0.61 -0.59 -0.59 -0.57 -0.68 -0.72 -0.73 -0.70
20 -0.22 -0.37 -0.07 -0.13 -0.33 -0.34 -0.29 -0.32 -0.59 -0.57 -0.49 -0.62 -0.64 -0.65 -0.70 -0.71
21 -0.21 -0.24 -0.01 -0.07 -0.36 -0.45 -0.38 -0.25 -0.61 -0.53 -0.61 -0.65 -0.66 -0.61 -0.70 -0.73
22 -0.23 -0.15 0.02 -0.12 -0.41 -0.37 -0.31 -0.29 -0.67 -0.57 -0.50 -0.64 -0.62 -0.65 -0.63 -0.71
23 -0.29 -0.17 -0.11 -0.20 -0.47 -0.35 -0.40 -0.28 -0.60 -0.55 -0.63 -0.55 -0.69 -0.67 -0.72 -0.70
24 -0.16 -0.22 -0.07 -0.13 -0.33 -0.36 -0.44 -0.23 -0.56 -0.60 -0.53 -0.67 -0.66 -0.70 -0.71 -0.69
25 -0.24 -0.29 -0.13 -0.08 -0.38 -0.42 -0.43 -0.29 -0.68 -0.56 -0.62 -0.69 -0.71 -0.71 -0.77 -0.77
26 -0.31 -0.31 -0.18 -0.12 -0.44 -0.47 -0.37 -0.34 -0.63 -0.55 -0.65 -0.69 -0.73 -0.78 -0.77 -0.80
27 -0.17 -0.27 -0.17 -0.09 -0.45 -0.45 -0.35 -0.33 -0.65 -0.59 -0.63 -0.67 -0.73 -0.76 -0.79 -0.77
28 -0.18 -0.26 -0.10 -0.10 -0.34 -0.46 -0.40 -0.34 -0.63 -0.67 -0.61 -0.67 -0.74 -0.81 -0.76 -0.79
29 -0.22 -0.31 -0.09 -0.16 -0.41 -0.48 -0.43 -0.36 -0.66 -0.60 -0.58 -0.68 -0.72 -0.80 -0.80 -0.82
30 -0.20 -0.34 -0.09 -0.16 -0.40 -0.46 -0.40 -0.33 -0.66 -0.63 -0.71 -0.70 -0.75 -0.79 -0.80 -0.79
31 -0.26 -0.23 -0.13 -0.16 -0.42 -0.43 -0.48 -0.31 -0.67 -0.62 -0.66 -0.70 -0.71 -0.79 -0.81 -0.78
32 -0.29 -0.33 -0.07 -0.15 -0.38 -0.47 -0.32 -0.40 -0.73 -0.64 -0.68 -0.67 -0.77 -0.77 -0.81 -0.79
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
1 -0.20 -0.33 -0.27 -0.22 -0.21 -0.23 -0.29 -0.16 -0.24 -0.31 -0.17 -0.18 -0.22 -0.20 -0.26 -0.29
2 -0.27 -0.21 -0.29 -0.37 -0.24 -0.15 -0.17 -0.22 -0.29 -0.31 -0.27 -0.26 -0.31 -0.34 -0.23 -0.33
3 -0.15 -0.20 -0.10 -0.07 -0.01 0.02 -0.11 -0.07 -0.13 -0.18 -0.17 -0.10 -0.09 -0.09 -0.13 -0.07
4 -0.04 -0.19 -0.15 -0.13 -0.07 -0.12 -0.20 -0.13 -0.08 -0.12 -0.09 -0.10 -0.16 -0.16 -0.16 -0.15
5 -0.38 -0.38 -0.30 -0.33 -0.36 -0.41 -0.47 -0.33 -0.38 -0.44 -0.45 -0.34 -0.41 -0.40 -0.42 -0.38
6 -0.33 -0.39 -0.45 -0.34 -0.45 -0.37 -0.35 -0.36 -0.42 -0.47 -0.45 -0.46 -0.48 -0.46 -0.43 -0.47
7 -0.38 -0.38 -0.33 -0.29 -0.38 -0.31 -0.40 -0.44 -0.43 -0.37 -0.35 -0.40 -0.43 -0.40 -0.48 -0.32
8 -0.19 -0.36 -0.38 -0.32 -0.25 -0.29 -0.28 -0.23 -0.29 -0.34 -0.33 -0.34 -0.36 -0.33 -0.31 -0.40
9 -0.60 -0.64 -0.61 -0.59 -0.61 -0.67 -0.60 -0.56 -0.68 -0.63 -0.65 -0.63 -0.66 -0.66 -0.67 -0.73
10 -0.60 -0.57 -0.59 -0.57 -0.53 -0.57 -0.55 -0.60 -0.56 -0.55 -0.59 -0.67 -0.60 -0.63 -0.62 -0.64
11 -0.60 -0.47 -0.59 -0.49 -0.61 -0.50 -0.63 -0.53 -0.62 -0.65 -0.63 -0.61 -0.58 -0.71 -0.66 -0.68
12 -0.67 -0.66 -0.57 -0.62 -0.65 -0.64 -0.55 -0.67 -0.69 -0.69 -0.67 -0.67 -0.68 -0.70 -0.70 -0.67
13 -0.76 -0.67 -0.68 -0.64 -0.66 -0.62 -0.69 -0.66 -0.71 -0.73 -0.73 -0.74 -0.72 -0.75 -0.71 -0.77
14 -0.71 -0.69 -0.72 -0.65 -0.61 -0.65 -0.67 -0.70 -0.71 -0.78 -0.76 -0.81 -0.80 -0.79 -0.79 -0.77
15 -0.76 -0.72 -0.73 -0.70 -0.70 -0.63 -0.72 -0.71 -0.77 -0.77 -0.79 -0.76 -0.80 -0.80 -0.81 -0.81
16 -0.71 -0.67 -0.70 -0.71 -0.73 -0.71 -0.70 -0.69 -0.77 -0.80 -0.77 -0.79 -0.82 -0.79 -0.78 -0.79
17 1 0.67 0.64 0.72 0.68 0.67 0.74 0.73 0.77 0.80 0.76 0.75 0.78 0.80 0.78 0.78
18 0.67 1 0.74 0.67 0.63 0.66 0.66 0.75 0.76 0.71 0.74 0.71 0.76 0.77 0.78 0.76
19 0.64 0.74 1 0.68 0.70 0.65 0.68 0.64 0.77 0.73 0.77 0.72 0.73 0.77 0.76 0.81
20 0.72 0.67 0.68 1 0.61 0.54 0.64 0.64 0.67 0.68 0.68 0.68 0.74 0.74 0.72 0.72
21 0.68 0.63 0.70 0.61 1 0.69 0.68 0.69 0.74 0.73 0.74 0.71 0.74 0.76 0.80 0.77
22 0.67 0.66 0.65 0.54 0.69 1 0.67 0.65 0.69 0.75 0.72 0.71 0.73 0.74 0.76 0.78
23 0.74 0.66 0.68 0.64 0.68 0.67 1 0.74 0.78 0.77 0.77 0.73 0.79 0.80 0.76 0.77
24 0.73 0.75 0.64 0.64 0.69 0.65 0.74 1 0.73 0.67 0.71 0.72 0.76 0.76 0.76 0.73
25 0.77 0.76 0.77 0.67 0.74 0.69 0.78 0.73 1 0.85 0.82 0.78 0.84 0.85 0.84 0.83
26 0.80 0.71 0.73 0.68 0.73 0.75 0.77 0.67 0.85 1 0.82 0.81 0.85 0.82 0.85 0.85
27 0.76 0.74 0.77 0.68 0.74 0.72 0.77 0.71 0.82 0.82 1 0.81 0.82 0.81 0.86 0.85
28 0.75 0.71 0.72 0.68 0.71 0.71 0.73 0.72 0.78 0.81 0.81 1 0.80 0.84 0.81 0.82
29 0.78 0.76 0.73 0.74 0.74 0.73 0.79 0.76 0.84 0.85 0.82 0.80 1 0.83 0.86 0.84
30 0.80 0.77 0.77 0.74 0.76 0.74 0.80 0.76 0.85 0.82 0.81 0.84 0.83 1 0.86 0.85
31 0.78 0.78 0.76 0.72 0.80 0.76 0.76 0.76 0.84 0.85 0.86 0.81 0.86 0.86 1 0.86
32 0.78 0.76 0.81 0.72 0.77 0.78 0.77 0.73 0.83 0.85 0.85 0.82 0.84 0.85 0.86 1
Table 4.2: Correlation matrix of the 32 correlating variables of the simulated dataset
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step has been carried out in order to extract the rank order for the 25,000
variables regarding their predictive ability to discriminate the 2 sub-groups
created in the simulated dataset. The selection of the top 100 variables from
this ranking gave the dataset to further submit to the interaction algorithm
(Table 4.3). The results showed that the Stepwise analysis successfully iden-
tified, among the top 100 variables, 29 out of the 32 correlating variables
(hence 90.6%).
Rank Input Median Test Average Correlating Rank Input Median Test Average Correlating
order name Performance Test Error variable order name Performance Test Error variable
1 9662 100.0% 0.052 Yes 51 19440 60.0% 0.237 No
2 10157 100.0% 0.062 Yes 52 13098 60.0% 0.237 No
3 9866 100.0% 0.065 Yes 53 9640 60.0% 0.237 No
4 22109 100.0% 0.066 Yes 54 14904 60.0% 0.237 No
5 3368 100.0% 0.071 Yes 55 20764 60.0% 0.237 No
6 5702 100.0% 0.072 Yes 56 18111 55.0% 0.238 No
7 22935 100.0% 0.073 Yes 57 6212 60.0% 0.238 No
8 13504 95.0% 0.087 Yes 58 14360 57.5% 0.238 No
9 24857 95.0% 0.090 Yes 59 14362 60.0% 0.238 No
10 13484 95.0% 0.091 Yes 60 10155 60.0% 0.238 No
11 1644 95.0% 0.095 Yes 61 16789 60.0% 0.238 No
12 2952 95.0% 0.095 Yes 62 9278 60.0% 0.238 No
13 21230 95.0% 0.100 Yes 63 16564 60.0% 0.238 No
14 23897 90.0% 0.103 Yes 64 20584 60.0% 0.238 No
15 4202 90.0% 0.104 Yes 65 13915 60.0% 0.238 No
16 21422 90.0% 0.107 Yes 66 22846 60.0% 0.238 No
17 6352 90.0% 0.115 Yes 67 21921 65.0% 0.238 No
18 21803 85.0% 0.119 Yes 68 22731 60.0% 0.238 No
19 8612 85.0% 0.127 Yes 69 10230 62.5% 0.239 No
20 1122 90.0% 0.130 Yes 70 12805 60.0% 0.239 No
21 24489 85.0% 0.139 Yes 71 20729 60.0% 0.239 No
22 5604 85.0% 0.142 Yes 72 17574 55.0% 0.239 No
23 11694 85.0% 0.146 Yes 73 23203 60.0% 0.239 No
24 2631 80.0% 0.158 Yes 74 16235 60.0% 0.239 No
25 20634 70.0% 0.208 Yes 75 13462 57.5% 0.239 No
26 17260 70.0% 0.210 No 76 506 60.0% 0.239 No
27 14078 70.0% 0.219 Yes 77 10319 60.0% 0.239 No
28 19253 65.0% 0.225 No 78 24778 60.0% 0.240 No
29 782 65.0% 0.228 No 79 5209 60.0% 0.240 Yes
30 97 65.0% 0.230 Yes 80 7854 55.0% 0.240 No
31 15931 65.0% 0.230 No 81 17223 60.0% 0.240 No
32 11172 60.0% 0.231 No 82 21231 60.0% 0.240 No
33 10009 60.0% 0.231 No 83 14961 60.0% 0.240 No
34 3375 60.0% 0.233 No 84 9306 55.0% 0.240 No
35 15023 60.0% 0.233 Yes 85 8220 55.0% 0.240 No
36 15230 55.0% 0.233 No 86 13184 60.0% 0.240 No
37 4123 60.0% 0.233 No 87 14629 60.0% 0.240 No
38 19024 65.0% 0.233 No 88 16162 60.0% 0.240 No
39 356 65.0% 0.234 No 89 15915 60.0% 0.240 No
40 3675 60.0% 0.235 No 90 18367 55.0% 0.240 No
41 22571 60.0% 0.235 No 91 22253 57.5% 0.241 No
42 11469 60.0% 0.236 No 92 6065 55.0% 0.241 No
43 23974 60.0% 0.236 No 93 15337 60.0% 0.241 No
44 12494 60.0% 0.236 No 94 9504 60.0% 0.241 No
45 9061 55.0% 0.236 No 95 11135 55.0% 0.241 No
46 9261 60.0% 0.236 No 96 18573 55.0% 0.241 No
47 2612 62.5% 0.236 No 97 5651 60.0% 0.241 No
48 3220 55.0% 0.236 No 98 24981 55.0% 0.241 No
49 22878 55.0% 0.237 No 99 15064 55.0% 0.242 No
50 18812 65.0% 0.237 No 100 10331 55.0% 0.242 No
Table 4.3: Results for the first step of the stepwise analysis
103
4.4.2 Optimisation of the algorithm
Using the artificial dataset and the selection of the top 100 best pre-
dictive variables; an experiment has been designed to further investigate
potential optimised algorithm for the scoring system (i.e. the core of the
algorithm).
Experimental design for the test of different algorithms
Figure 4.5: Representation of the MLP and its nomenclature used for the test of the 14 algorithms
Based on a classical MLP (c.f. Figure 4.5), 14 different algorithms (c.f.
Table 4.4) were implemented and tested. All the weights connecting a single
input (i) to the final output will be termed here as a "path". For a single
input i, the algorithms for the calculation of the score were defined as shown
in Table 4.4.
For each of the 14 algorithms tested, the behaviour of the number of
hidden nodes have been monitored too, applying each algorithm with al-
ternatively 2, 5 and 10 hidden nodes. In addition, the number of selected
variables from the stepwise analysis were tested: given the fact that 32
variables (see Tables 4.1 and 4.3) were supposed to be highly correlated
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Algorithm Description Expression
Algorithm 1 Multiplied weights for sparse network of first path (w11.wout1 )
Algorithm 2 Multiplied weights for sparse network of last path (wnm.woutm )
Algorithm 3 Multiplied weights for sparse network of one random path (wix.woutx ) with x = rand(i)
Algorithm 4 Multiplied weights for sparse network of the Max path Max(wij .woutj )
Algorithm 5 Sum of all the paths with multiplication of the weights
m∑
j=1
(
wij .woutj
)
Algorithm 6 Product of all the paths with multiplication of the weights
m∏
j=1
(
wij .woutj
)
Algorithm 7 Average value for all paths of multiplied weights
m∑
j=1
(
wij .woutj
)
m
Algorithm 8 Added weights for sparse network of first path (w11 + wout1 )
Algorithm 9 Added weights for sparse network of last path (wnm + woutm )
Algorithm 10 Added weights for sparse network of one random path (wix + woutx ) with x = rand(i)
Algorithm 11 Added weights for sparse network of the Max path Max(wij + woutj )
Algorithm 12 Sum of all the paths with addition of the weights
m∑
j=1
(
wij + woutj
)
Algorithm 13 Product of all the paths with addition of the weights
m∏
j=1
(
wij + woutj
)
Algorithm 14 Average value for all paths of added weights
m∑
j=1
(
wij+woutj
)
m
Table 4.4: Table of the 14 different algorithms tested
(see Table 4.2), the top 32 variables, as well as the top 100 (compliantly
to our standard approach) were applied for the tests. Finally, each of the
algorithms was tested over 10 independent runs to be able to monitor the
consistency of the results.
For the purpose of optimisation, several results were recorded and anal-
ysed subsequently to the tests for each of the algorithm considered. These
results mainly consisted of:
• The analysis of the Pearson correlation coefficient obtained by the
correlation analysis between the predicted scores for each pair of the 32
variables actually correlated with their actual correlation value from
the correlation matrix. This is justified as the two series compared
(predicted interaction scores against actual correlation for the pairs)
are linear. This coefficient was calculated for each of the algorithms
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and for each run, and averaged over the 10 runs.
• The signs obtained were compared in order to identify if any mismatch
of signs existed between the scores obtained from the algorithms and
the sign of the actual correlation value.
• A monitoring of the false positive rate has been carried out. It was
obtained by taking the list of the top 10, top 50 and top 100 for pos-
itive and negative pairs of variables in terms of interaction score, and
assessing out of each of these selections the number of pairs of vari-
ables where both of them were from the original pool of 32 variables
correlating.
• Finally, as all the algorithms have been tested successively with 2, 5
and 10 hidden nodes in the hidden layer, a comparison of the perfor-
mances for each parameterisation has been conducted.
Results
Assesment of performance with correlation coefficients
The results for the correlation values are summarised and reported in
Table 4.5. It has been easy to observe that the algorithms 8 to 14 worked
almost randomly to accurately predict interaction scores compared to the
actual correlation values; this is clearly shown in Figures 4.6 and 4.7. This
can be explained by the fact that these 7 algorithms consider only a part
of the problem by just adding the weights in the paths. In addition, no
significant result was obtained with the 6th algorithm after the first test
(not reported). The runs were consistently giving no scores as they were
always diverging quickly and giving too high values. Therefore the tests on
this algorithm were not further conducted.
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2 Hidden Nodes 5 Hidden Nodes 10 Hidden Nodes
top 32 top 100 top 32 top 100 top 32 top 100
Pearson’s Correct Pearson’s Correct Pearson’s Correct Pearson’s Correct Pearson’s Correct Pearson’s Correct
coefficient Signs coefficient Signs coefficient Signs coefficient Signs coefficient Signs coefficient Signs
Algorithm 1 0.788 88.16% 0.857 92.12% 0.653 80.31% 0.866 89.41% 0.617 78.17% 0.842 89.53%
Algorithm 2 0.787 88.73% 0.872 91.13% 0.619 81.31% 0.862 92.24% 0.599 77.46% 0.723 88.18%
Algorithm 3 0.797 89.59% 0.869 91.26% 0.648 81.03% 0.838 90.27% 0.590 77.75% 0.856 88.67%
Algorithm 4 0.808 91.44% 0.874 91.87% 0.675 82.31% 0.884 92.61% 0.638 80.46% 0.861 90.15%
Algorithm 5 0.805 89.16% 0.865 91.26% 0.653 80.31% 0.871 90.89% 0.607 79.32% 0.866 88.55%
Algorithm 6 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Algorithm 7 0.787 88.87% 0.865 91.50% 0.651 79.60% 0.868 89.78% 0.611 77.89% 0.823 88.67%
Algorithm 8 -0.569 33.10% -0.287 42.24% -0.011 53.07% -0.022 54.43% 0.000 51.93% -0.097 54.19%
Algorithm 9 -0.599 33.38% -0.325 40.02% 0.056 54.21% -0.174 53.45% -0.051 52.07% -0.083 52.22%
Algorithm 10 -0.534 33.38% -0.243 44.21% 0.056 54.21% -0.236 47.41% -0.125 51.21% -0.046 56.40%
Algorithm 11 -0.543 33.81% -0.243 41.50% -0.163 50.93% -0.175 48.52% -0.055 51.78% -0.126 51.60%
Algorithm 12 -0.612 32.10% -0.340 42.24% -0.041 53.21% -0.163 50.25% -0.090 52.21% -0.185 53.20%
Algorithm 13 -0.679 18.83% -0.379 40.27% 0.009 51.21% 0.045 49.14% -0.064 43.94% 0.033 51.35%
Algorithm 14 -0.623 31.95% -0.280 41.38% -0.094 52.07% -0.013 50.62% -0.066 53.07% -0.219 52.34%
Table 4.5: Results for the test of the 14 algorithms with the Pearson’s coefficient and percentage of correct signs.
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Figure 4.6: Results of Pearson correlation coefficient for each algorithm with 2, 5 and 10 hidden nodes
for the selection of the top 100 variables out from stepwise analysis
Figure 4.7: Results of Pearson correlation coefficient for each algorithm with 2, 5 and 10 hidden nodes
for the selection of the top 32 variables out from stepwise analysis
Assessment of the signs
Similarly, attention has been brought to the signs obtained for the pre-
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dicted interaction scores by the algorithm for each pair of variables, com-
pared to the sign for the actual correlation coefficient for same pair. It has
been carried out by taking out from the whole interaction results the pairs
of variables that are both from the 32 highly correlating set. With these
pairs, the number of the matching signs (between actual correlation value
and predicted interaction score) was recorded in order to give a percentage
of correct signs. The results are presented in Table 4.5.
Assessment of the true positive rate
The other major parameter on which it was crucial to focus on was the
true positive rate. In other words : How many actually highly correlating
pairs of variables can we pick within the pair of interactions predicted by
the algorithm?
The results, presented in Table 4.6, show some encouraging results for
the selection of 32 variables. However, this is not really relevant, there is no
surprise that about 90% of the actual correlations are picked since the top
32 selection contained 27 (84.38%) of the correlating variables. It is then
more relevant to focus on the top 100 variables selected. And the results for
the selection of 100 variables showed poor rate for true positives with about
35% to 50%. In addition, we can see that adding more hidden nodes to the
MLP doesn’t improve the interaction results in terms of true positive rate.
All these results suggest that the true positive rate is not really satisfactory.
However, this is not exactly due to the algorithm itself or scoring system,
but more a question of filtering. Therefore, improvements could be brought
by adapting the filtering method.
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Algo 1 Algo 2 Algo 3 Algo 4 Algo 5 Algo 6 Algo 7 Algo 8 Algo 9 Algo 10 Algo 11 Algo 12 Algo 13 Algo 14
2 Hidden Nodes
top 32
top10 + 90% 100% 100% 90% 100% n/a 100% 100% 100% 100% 100% 100% 100% 100%
top50 + 90% 88% 88% 86% 88% n/a 88% 100% 100% 100% 100% 100% 94% 100%
top100 + 87% 87% 86% 89% 88% n/a 88% 99% 100% 99% 100% 100% 91% 100%
top10 - 90% 90% 90% 100% 100% n/a 90% 90% 100% 100% 100% 100% 100% 100%
top50 - 96% 96% 98% 96% 96% n/a 96% 90% 94% 92% 94% 90% 90% 90%
top100 - 97% 96% 96% 95% 98% n/a 96% 89% 92% 87% 90% 89% 87% 87%
top 100
top10 + 20% 40% 20% 20% 10% n/a 30% 100% 80% 100% 90% 90% 30% 100%
top50 + 36% 38% 32% 34% 34% n/a 36% 94% 90% 90% 76% 94% 16% 94%
top100 + 33% 35% 29% 35% 33% n/a 40% 93% 86% 88% 72% 93% 12% 92%
top10 - 30% 10% 40% 60% 40% n/a 60% 60% 30% 30% 70% 80% 0% 70%
top50 - 46% 26% 40% 60% 42% n/a 50% 54% 46% 34% 48% 50% 16% 60%
top100 - 44% 29% 44% 56% 50% n/a 46% 42% 50% 39% 42% 44% 12% 51%
5 Hidden nodes
top 32
top10 + 70% 60% 50% 60% 40% n/a 70% 40% 90% 90% 60% 40% 80% 50%
top50 + 80% 86% 78% 70% 74% n/a 80% 74% 82% 82% 78% 74% 78% 78%
top100 + 83% 83% 83% 81% 79% n/a 83% 79% 78% 78% 83% 79% 85% 85%
top10 - 90% 90% 90% 80% 80% n/a 80% 60% 80% 80% 30% 80% 100% 40%
top50 - 94% 92% 88% 92% 88% n/a 94% 78% 74% 74% 60% 84% 88% 70%
top100 - 92% 95% 85% 89% 88% n/a 92% 81% 74% 74% 37% 83% 85% 80%
top 100
top10 + 0% 0% 0% 0% 0% n/a 0% 0% 0% 10% 0% 20% 0% 30%
top50 + 0% 0% 0% 0% 0% n/a 0% 0% 6% 6% 0% 16% 2% 30%
top100 + 0% 0% 0% 0% 0% n/a 0% 0% 10% 8% 0% 17% 7% 28%
top10 - 0% 0% 0% 0% 0% n/a 0% 0% 0% 0% 0% 30% 10% 0%
top50 - 0% 0% 0% 0% 0% n/a 0% 0% 2% 0% 0% 12% 20% 0%
top100 - 0% 0% 4% 2% 0% n/a 0% 1% 2% 0% 0% 9% 21% 0%
10 Hidden nodes
top 32
top10 + 40% 50% 50% 60% 60% n/a 60% 70% 70% 70% 70% 40% 90% 40%
top50 + 68% 76% 78% 82% 74% n/a 78% 80% 88% 78% 76% 74% 88% 76%
top100 + 75% 79% 77% 84% 72% n/a 81% 82% 90% 78% 83% 80% 86% 78%
top10 - 80% 80% 70% 90% 80% n/a 90% 60% 80% 80% 80% 70% 90% 80%
top50 - 90% 86% 86% 90% 92% n/a 92% 70% 60% 72% 62% 82% 88% 76%
top100 - 90% 83% 82% 90% 88% n/a 92% 72% 69% 72% 31% 56% 88% 50%
top 100
top10 + 0% 10% 0% 0% 0% n/a 0% 0% 0% 0% 0% 0% 0% 0%
top50 + 0% 4% 0% 0% 0% n/a 0% 0% 0% 0% 0% 0% 4% 0%
top100 + 0% 4% 0% 1% 0% n/a 2% 0% 0% 1% 0% 0% 6% 1%
top10 - 0% 0% 0% 0% 0% n/a 0% 0% 0% 0% 0% 0% 10% 0%
top50 - 0% 4% 0% 0% 0% n/a 0% 0% 0% 0% 0% 10% 2% 0%
top100 - 0% 2% 0% 1% 0% n/a 1% 0% 2% 1% 2% 7% 8% 0%
Table 4.6: Results for the true positive rate for the 14 algorithms.
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Number of hidden nodes
It was then interesting to assess as well if altering the number of hidden
nodes had any effect on the results. For that purpose, the tests were con-
ducted as described previously and iteratively and independently repeated
with 2, 5 and 10 hidden nodes in the single hidden layer of the MLP.
The results showed that the number of hidden nodes does not make
much of difference in terms of correlation results or in terms of signs (see
Table 4.5). Moreover, it appears that 2 hidden nodes are doing better for
the selection of the top 32 variables than for the top 100 from the stepwise
analysis. However, this can be easily explained by the inherent bias involved
in the top 100 variables. Indeed, the Tables 4.1 and 4.3 show that 27 out of
32 (84.38%) are from the actual pool of 32 variables correlating originally
in the dataset; whereas it automatically drops with the selection of the top
100 since 29 out of the 100 (29%) are from this pool of variables. Therefore,
it appears normal that the importance of the number of hidden nodes has
less influence for the selection of the top 100 variables.
In addition, the analysis of the results concerning the time of process
indicated that it is taking about 2 and then 3 times more time to run the
process on average for all the 14 algorithms, for 5 and 10 hidden nodes re-
spectively compared to running the algorithm with 2 hidden nodes (shown
in Figure 4.8). Since no actual improvement could be observed with 5 and
10 hidden nodes in terms of Pearson coefficient study and signs, and con-
sidering the processing time, it seems to be sufficient to use a two hidden
node-hidden layer for the interaction analysis purpose.
4.4.3 Optimisation of the filtering method
After completing the tests of the algorithms, the screening of the true
positive rate indicated that the filtering method, based on the absolute value
of the interaction scores (c.f. page 98), was inefficient (i.e. gave low true
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Figure 4.8: Average time spent by each algorithm for 10 runs, with 2, 5 and 10 hidden nodes (on Intel
Core2 duo E840 machines at 3.00 GHz with 2Gb memory running under Microsoft Windows XP SP3
system).
positive rate values for top 100+/- across all algorithms - c.f. results in
Table 4.6), and needed to be further optimised. Therefore, since 10 runs
of each test had been carried out, the consistency of the scores obtained
were used for filtering rather than using the only scores themselves. This
consisted of taking the Coefficient of Variation Cv, a relative measure of the
dispersion for a particular distribution (Hendricks and Robey, 1936), where
the Standard Deviation σ of the interaction scores found for each pair of
variables is divided by the mean value of the score µ for that particular pair,
in order to avoid its influence upon the deviation. Thus, the expression for
the new filtering value is :
Cv =
σ
µ
(4.1)
From the first results of the correlation coefficient, only the 5 first al-
gorithms were further tested with this new filter method (results shown in
Table 4.7), and only the selection of the top 100 variables from the stepwise
was applied. From these results, it clearly appears that the new filtering
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method brings a much more reliable strategy at deciphering the significant
interactions, especially shown by Figures 4.9 for positive scores and 4.10
for negative scores. This is particularly true when the number of hidden
nodes is increased: with the new filtering, the true positive rates with 5 or
10 hidden nodes can reach the rates obtained with 2 hidden nodes.
Algo 1 Algo 2 Algo 3 Algo 4 Algo 5
2 Hidden nodes
top 32
top10 + 90% (-) 90% (-10) 90% (-10) 90% (-) 90% (-10)
top50 + 92% (+2) 92% (+4) 88% (-) 92% (+6) 88% (-)
top100 + 92% (+5) 91% (+4) 88% (+2) 92% (+3) 89% (+1)
top10 - 70% (-20) 90% (-) 90% (-) 100% (-) 100% (-)
top50 - 88% (-8) 90% (-6) 90% (-8) 92% (-4) 96% (-)
top100 - 90% (-7) 91% (-5) 90% (-6) 92% (-3) 96% (-2)
top 100
top10 + 50% (+30) 60% (+20) 20% (-) 10% (-10) 90% (+80)
top50 + 56% (+20) 68% (+30) 56% (+24) 44% (+10) 74% (+40)
top100 + 58% (+25) 64% (+29) 52% (+23) 53% (+18) 69% (+36)
top10 - 90% (+60) 30% (+20) 70% (+30) 50% (-10) 60% (+20)
top50 - 64% (+18) 50% (+24) 64% (+24) 68% (+8) 66% (+24)
top100 - 59% (+15) 49% (+20) 59% (+15) 69% (+13) 63% (+13)
5 Hidden nodes
top 32
top10 + 90% (+20) 90% (+30) 100% (+50) 90% (+30) 70% (+30)
top50 + 86% (+6) 88% (+2) 90% (+12) 92% (+22) 86% (+12)
top100 + 87% (+4) 89% (+6) 86% (+3) 89% (+8) 86% (+7)
top10 - 80% (-10) 100% (+10) 80% (-10) 100% (+20) 100% (+20)
top50 - 92% (-2) 92% (-) 86% (-2) 96% (+4) 98% (+10)
top100 - 93% (+1) 87% (-8) 92% (+7) 92% (+3) 94% (+6)
top 100
top10 + 50% (+50) 70% (+70) 50% (+50) 80% (+80) 80% (+80)
top50 + 62% (+62) 60% (+60) 60% (+60) 56% (+56) 58% (+58)
top100 + 54% (+54) 54% (+54) 59% (+59) 52% (+52) 61% (+61)
top10 - 100% (+100) 70% (+70) 90% (+90) 80% (+80) 80% (+80)
top50 - 74% (+74) 68% (+68) 88% (+88) 62% (+62) 70% (+70)
top100 - 63% (+63) 61% (+61) 72% (+68) 60% (+58) 62% (+62)
10 Hidden nodes
top 32
top10 + 70% (+30) 90% (+40) 90% (+40) 90% (+30) 100% (+40)
top50 + 86% (+18) 84% (+8) 88% (+10) 92% (+10) 94% (+20)
top100 + 86% (+11) 84% (+5) 89% (+12) 89% (+5) 86% (+14)
top10 - 100% (+20) 90% (+10) 100% (+30) 100% (+10) 100% (+20)
top50 - 92% (+2) 90% (+4) 96% (+10) 96% (+6) 88% (-4)
top100 - 92% (+2) 89% (+6) 91% (+9) 93% (+3) 88% (-)
top 100
top10 + 60% (+60) 70% (+60) 60% (+60) 80% (+80) 100% (+100)
top50 + 56% (+56) 62% (+58) 62% (+62) 72% (+72) 76% (+76)
top100 + 56% (+56) 56% (+52) 56% (+56) 72% (+71) 70% (+70)
top10 - 90% (+90) 100% (+100) 100% (+100) 90% (+90) 90% (+90)
top50 - 78% (+78) 80% (+76) 82% (+82) 94% (+94) 94% (+94)
top100 - 76% (+76) 73% (+71) 70% (+70) 90% (+89) 87% (+87)
Table 4.7: Results for the test of the 5 first algorithms for true positive rate using the coefficient of
variation for filtering. In brackets are shown the positive or negative evolution compared to the previous
filtering method.
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Figure 4.9: Comparison of the improvements of true positive rate for the selection of the 100 pairs of
variables with the highest positive interaction score for algorithms 1 to 5.
Figure 4.10: Comparison of the improvements of true positive rate for the selection of the 100 pairs of
variables with the highest negative interaction score for algorithms 1 to 5.
4.5 Discussion
The increasing number of genomic array studies has allowed the po-
tential to assess the relative expression intensity of gene products in the
particular context of a disease system, hence allowing the evaluation of the
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potential regulatory relationships between genes. Since ANN techniques
have shown great abilities at predicting categorical outcomes in disease (c.f.
chapter 1 and 2), it was considered to develop a novel approach wrapping
an ANN core with a different shell.
This chapter described the development of an original algorithm seeking
to predict and infer interaction networks, or regulatory networks in the case
of genomic data. The chapter discussed the principles and hypothesis on
which the overall process of development was founded; and it discussed the
methodologies employed for the optimisation of the approach. The algo-
rithm of the approach itself and the workflow of its application has been as
well introduced. As a result, following the theoretical stage of the method
developed, it is possible to discuss its application for real-world data in
the following chapter. The first development of the approach was applied
to the van’t Veer dataset discussed in the following chapter (chapter 5).
Subsequently, it has been assessed and further improved using a simulated
dataset, and reapplied to the same dataset, presented in the next chapter
as well.
The optimisation consisted of testing 14 different algorithms (c.f. Table
4.4) in order to improve the scoring system. Another aspect tested and
improved was the filtering step. Therefore, this chapter described how the
simulated dataset was used to test the different algorithms. Each of these
14 algorithms were tested at trying to identify the most correlated pairs of
variables within the dataset. Several aspects were taken into account to de-
cide which of the algorithm was performing the best at predicting the actual
correlated pairs: the Pearson’s coefficient depicting the correlation obtained
between the scores predicted and the actual correlation values for the cor-
related pairs of variables; the percentage of signs of correlation predicted;
as well as the true positive rate (i.e. the percentage of actually correlated
pairs in the highest scores of predicted pairs by the algorithms).
The first observation showed that the 5 first algorithms were predicting
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accurately the correlation values of the pairs actually correlated, with a
range of very close Pearson values from 0.857 (for algorithm 1) to 0.874
(algorithm 4) for 2 hidden nodes and the top 100 selection of variables from
the stepwise analysis (used for feature selection). The other algorithms (6 to
14) were giving poor results and were not further tested. The tests showed
as well that the number of hidden nodes was not affecting the predictive
ability of the approach as similar range of Pearson values were observed
(0.838 to 0.884 for 5 hidden nodes; and 0.723 to 0.866 with 10 hidden
nodes). As a results, it was decided to focus the work with 2 hidden nodes
as the performance was not affected, whilst it was dramatically increasing
the time of computing (by a factor 2 and then 3 for respectively 5 and 10
hidden nodes - c.f. Figure 4.8).
Another great advantage of an ANN based algorithm is that the scoring
system can interpret the resulting weights in a positive or negative manner.
Therefore, not only it is possible to attribute a weighted score for each pair
of variables, but as well a sign; hence giving a clue of whether the interaction
is positive or negative. This particular aspect was assessed as well during
optimisation by comparing the sign of the predicted interaction score with
the sign of the actual correlation value in the original simulated dataset.
Here again the algorithms 1 to 5 provided accurate close results with a
range of correct signs from 91.13% (algorithm 2) to 92.12% (algorithm 1)
for top 100 feature selection and 2 hidden nodes. Similar observation was
made as previously regarding the number of hidden nodes.
Another point explored during the optimisation process was the true
positive rate. For that purpose a different approach toward filtering process
has been explored. Rather than filtering the relevant interacting pairs on
their absolute values of scores, as it was the case at the early stage of the
development, it has been decided to filter them on their consistency over
multiple runs. As a result, the filtering consisted of calculating the coeffi-
cient of variation for each interacting pair, and only keep the pairs with the
lowest absolute value (for both positive and negative scores). The coefficient
of variation gives an insight about the consistency of the scores (as it uses
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the standard deviation) but without the influence of the score. The results
shown in Table 4.7 and in Figures 4.9 and 4.10 show an improvement in
terms of true positive rate with this new filter value. Indeed, the results
show, with 2 hidden nodes and for the 100 features selected, an improve-
ment of 18 (algorithm 4 with 53% true positive rate) to 36 (algorithm 5
with 69% true positive rate) points in the 100 highest positive interaction
scores. Similarly, for the 100 highest negative interaction scores, algorithm
4 presented a 69% true positive rate (improving by 13 points the true pos-
itive rate of the previous filtering method) and algorithm 5 presented 63%
true positive rate (showing the same improvement).
The simulated dataset allowed to drastically improve the approach, in
terms of accuracy of prediction for the scores but as well to improve the
filtering step by employing a more relevant approach in order to maximise
the true positive rate. Nevertheless, the use of such an artificial dataset is
not free of pitfalls, as it has been pointed in (Rocke et al., 2009). Using a
simulated dataset reduces the complexity and does not take into account
the highly interconnected mechanisms taking place in genuine data from
gene expression arrays. It only simplified the problem in a pairwise fash-
ion. However, improving and assessing the performance of an approach on a
simplified example gives an insight about the abilities of the method on less
complex data, allowing to further build a robust approach once it is able to
accurately model such data. Once the best performing algorithm identified,
applying a real-world data will then allow a second level of validation with
the biological relevance of the findings.
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4.6 Conclusion
Considering all these results, the scoring algorithm number 5 has been
selected, as follows :
m∑
j=1
(
wij.woutj
)
(4.2)
This algorithm presented one of the best performances on the simulated
dataset for true positive rate (i.e. 63% and 69% respectively for top 100
negative and positive interactions), but also good results in the correlation
study of the predicted scores against the actual correlation value of similar
pairs (0.865 for Pearson’s correlation coefficient). Combined with a more
adapted filter of interaction scores, based on the coefficient of variation,
they were implemented in the software and the workflow of the method.
Subsequently, the dataset from van’t Veer has been re-applied in order to
get more accurate and up-to-date results, and can be seen in the following
chapter.
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Chapter 5
Application of the interaction
algorithm
Within this chapter will be discussed applications of the interaction al-
gorithm presented in chapter 4. These applications involved the use of the
dataset from the van’t Veer study (van’t Veer et al., 2002). The chapter will
report the applications of the approach before and after its optimisation, it
will review some of the validations carried out on the results. In particular,
section 5.1 will discuss the results from using the originally developed algo-
rithm; subsequently, section 5.2 will discuss the results obtained from using
the same dataset
5.1 Application of the original algorithm to
the van’t Veer dataset
The first application of the originally developed algorithm concerned the
dataset published by van’t Veer (van’t Veer et al., 2002). This particular
study from the Dutch group focused on the metastatic risk for patients with
breast cancer. This dataset contained 78 samples from breast cancer pa-
tients with different metastatic outcome for the prognostic prediction. Out
of these 78 patients, 34 of them developed distant metastases within 5 years
(which constituted the poor prognostic group) and 44 remained metastasis-
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free during at least 5 years (the good prognostic group). cRNA from tu-
mour samples were extracted and two hybridisation per sample had been
conducted on MA chips screening for 24,481 genes. This dataset had been
previously analysed for biomarkers related to metastatic risk, as shown in
chapter 2 of the present manuscript (Lancashire et al., 2009a). It was then
interesting to further investigate and try to understand how the identified
genes could be related to each other, in any sort of association or interaction.
5.1.1 Pre-processing step using the stepwise algorithm
The first step of the method consisted of screening of the rank order for
the genes found to be associated with metastatic risk in breast cancer in
terms of predictive ability for each of them. For this purpose, the stepwise
approach had been applied using a classical MLP with one hidden layer
containing 2 hidden nodes. An extensive cross validation strategy had been
used, randomly re-splitting the cases over 50 times in the 3 different subsets
for training, validation and independent test purpose with respectively 60%,
20% and 20% of the cases in each. Learning rate and momentum were re-
spectively set at 0.1 and 0.5. Training was performed with a BP algorithm
for 3,000 epochs, and an early stopping threshold was set at 1,000 epochs if
no improvement of the model was observed when applied on the validation
subset. The Stepwise approach was applied here for just the first step in
order to identify the most relevant genes for this particular set regarding
the question of distant metastasis outcome, and give a ranking of those
genes. The interaction algorithm could then provide with an insight of the
potential correlation and/or interaction that may exist between those genes.
Figure 5.1 shows the distribution of the genes ranked by their predictive
error for unseen data after the stepwise analysis. From the shape of the
graph, it is clear that the very first genes have a higher ability to predict
(with the lowest error) metastatic risks for the patients, and therefore are
most relevant for the system being investigated by interaction analysis.
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Figure 5.1: Distribution of the genes for their predictive error for unseen data. Red line indicates the
position of the 100th gene.
According to what is seen in Figure 5.1, and compliant to the workflow,
the first 100 genes were selected for further interaction analysis. To assess
the interactions within the genes associated with prognostic outcome we
selected the top 100 predictors from the screening and submitted them to
the interaction analysis. These genes had a range of predictive ability for
unseen data from 73.86% for the first gene to 60.79% for the 100th, and are
presented in Table 5.1.
Importantly, we can observe from the results that CA9, previously dis-
cussed in this manuscript, was found again as the best predicting gene for
metastatic risk. Although this is not so surprising since the very same
method was used for the same dataset, it is still a validation of the devel-
oped method showing a good reproducibility and consistency.
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Rank Input GenBank Test Test Gene Rank Input GenBank Test Test Gene
order number accession nb. Perf. Error name Reference order number accession nb. Perf. Error name Reference
1 2025 NM_001216 71.87% 0.438 CA9 (Span et al., 2003) 51 2207 AA425275 65.32% 0.471 COMMD6
2 118 AI742029 72.79% 0.444 TBC1D10A 52 2242 NM_002266 61.71% 0.471 KPNA2 (Dankof et al., 2007)
3 1514 NM_016598 67.58% 0.448 ZDHHC3 53 1228 NM_006763 65.71% 0.472 BTG2 (Boiko et al., 2006)
4 1336 AA830802 69.76% 0.448 AGTPBP1 54 677 H17914 65.46% 0.472 ZNF420 (Tian et al., 2009)
5 275 AI458063 71.08% 0.451 ZBTB45 55 674 AJ011306 65.12% 0.472 EIF2B4
6 1185 AI347425 73.86% 0.455 MOG 56 985 NM_005744 65.39% 0.472 ARIH1
7 692 NM_006117 71.37% 0.455 PECI 57 1819 AW162411 66.38% 0.472 TMEM218
8 1409 AA534406 71.59% 0.456 GALNT5 58 45 NM_001667 65.32% 0.473 ARL2 (Beghin et al., 2008)
9 642 NM_020678 69.93% 0.456 LRTM1 (Egland et al., 2006) 59 1066 D86957 64.39% 0.473 SEPT8
10 1113 NM_016017 63.93% 0.456 UCHL5 (Wicks et al., 2005) 60 974 NM_006461 62.37% 0.473 SPAG5
11 1443 NM_016448 68.37% 0.459 DTL (Ueki et al., 2008) 61 1827 AI183575 66.41% 0.473 DNAJC5G
12 1460 AA973313 67.81% 0.460 TSPYL5 (Kim et al., 2010) 62 1774 NM_018313 65.45% 0.473 PBRM1 (Horikawaa and Barrett, 2002)
13 170 AI885466 59.75% 0.461 C13orf37 63 450 AF052162 65.75% 0.474 LPCAT1
14 1053 NM_006544 66.28% 0.461 EXOC5 64 1143 NM_006625 62.23% 0.474 SFRS13A
15 909 AL080059 71.22% 0.461 TSPYL5 (Kim et al., 2010) 65 1640 NM_018131 63.36% 0.474 CEP55 (Inoda et al., 2009)
16 1081 NM_006581 67.00% 0.463 FUT9 (Bogoevska et al., 2006) 66 950 NM_006407 63.71% 0.474 ARL6IP5
17 505 NM_003766 67.15% 0.463 BECN1 (Won et al., 2010) 67 718 NM_004702 62.39% 0.474 CCNE2 (Payton et al., 2002)
18 1855 AA524093 68.96% 0.464 FBXO41 68 25 AL035297 62.24% 0.474 SFT2D2
19 497 NM_003748 70.22% 0.464 ALDH4A1 (Yoon et al., 2004) 69 1918 BE739817_RC 62.88% 0.474 IFNAR1
20 706 NM_013438 66.63% 0.465 UBQLN1 70 1474 AL137615 67.02% 0.475 MKNK2 (Chrestensen et al., 2007)
21 322 NM_003504 62.92% 0.465 CDC45L (Takahashi et al., 2008) 71 493 NM_005196 63.07% 0.475 CENPF (O’Brien et al., 2007)
22 1684 AF161451 70.23% 0.465 NSMCE1 72 1351 AI992158 66.61% 0.475 CDCA7
23 1283 AI14038 68.71% 0.465 FOXL2 73 1642 NM_018136 62.71% 0.475 ASPM
24 1724 NM_018265 66.16% 0.465 C1orf106 74 2034 NM_000507 62.77% 0.475 FBP1
25 283 NM_003450 68.85% 0.466 ZNF174 75 1510 AA759198 65.90% 0.476 -
26 936 NM_014400 67.08% 0.466 LYPD3 (Fletcher et al., 2003) 76 1912 AF073519 67.17% 0.476 SERF1A
27 143 NM_003258 63.88% 0.466 TK1 (O’Neill et al., 1992) 77 1446 NM_016458 67.19% 0.476 C8orf30A
28 86 NM_003163 65.96% 0.466 STX1B 78 1809 NM_018391 63.93% 0.476 FLJ11328
29 2075 NM_000599 69.04% 0.466 IGFBP5 (Ahn et al., 2010) 79 258 R73468 66.54% 0.476 SLC25A16
30 1078 AI918032 68.08% 0.466 RUNDC1 80 1812 NM_000286 66.77% 0.476 PEX12
31 736 AI479831 64.95% 0.466 MTHFR 81 188 AF016903 63.30% 0.477 AGRN
32 1153 NM_014675 66.35% 0.467 CROCC 82 2115 NM_002066 64.66% 0.477 GML
33 568 NM_004583 68.06% 0.467 RAB5C 83 248 AW137071 62.42% 0.477 SMARCE1 (García-Pedrero et al., 2006)
34 1167 NM_006681 69.19% 0.467 NMU 84 1384 NM_014968 66.17% 0.477 KIAA1104
35 1675 AI583960 68.92% 0.467 DHX58 85 1142 NM_006623 61.65% 0.477 PHGDH
36 663 NM_003977 69.55% 0.467 AIP 86 1082 NM_006582 64.84% 0.477 GMEB1
37 2152 AI738508 61.64% 0.467 ECT2 87 366 AL133447 65.93% 0.477 EDC3
38 278 NM_004163 66.46% 0.467 RAB27B (Hendrix et al., 2010) 88 1811 NM_000284 63.88% 0.477 PDHA1
39 1961 NM_000419 67.28% 0.468 ITGA2B 89 578 AF131828 66.46% 0.477 C9orf25
40 32 D42044 66.11% 0.468 KIAA0090 90 1226 AW162331 66.45% 0.477 ALKBH7
41 1236 AI554061 64.09% 0.468 QSOX2 91 98 AI393558 66.88% 0.478 CLSTN2
42 980 NM_014489 71.12% 0.468 PGAP2 92 1791 NM_018354 62.22% 0.478 C20orf46
43 138 NM_003239 66.63% 0.469 TGFB3 (Laverty et al., 2009) 93 307 AI912791 67.26% 0.478 FBXO16
44 1096 AI653719 64.77% 0.470 TTLL7 94 616 NM_013360 63.36% 0.478 ZNF222
45 738 AF257175 69.66% 0.470 PECI 95 1942 AI082587 66.92% 0.478 IL17RA
46 1442 NM_016444 64.37% 0.470 ZNF226 96 1465 AA834945 65.52% 0.478 LIN9 (Pandis et al., 1995)
47 572 NM_003862 63.12% 0.470 FGF18 97 1186 AI741080 67.14% 0.478 B3GALNT2
48 1832 AL122101 62.45% 0.470 TEF 98 428 NM_002916 60.79% 0.478 RFC4
49 102 NM_001756 68.45% 0.471 SERPINA6 99 742 AI828164 65.25% 0.478 FAM69B
50 1363 NM_016359 62.41% 0.471 NUSAP1 (Wadia et al., 2010) 100 1814 NM_000291 62.70% 0.478 PGK1 (Zhang et al., 2005)
Table 5.1: Rank order of the first 100 genes identified by the first step of the stepwise sorted by test error with gene names when available. The references indicate
previous evidence of involvement of the gene in breast cancer in the literature.
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5.1.2 Results
Global population
Following this initial selection step, the global population (i.e. both
poor and good prognostic groups combined) had been firstly applied and
ran through the interaction algorithm. The dataset was built using the
selected 100 genes for all the 78 cases. Once the format of the dataset
was appropriately defined, it had been applied to the interaction algorithm.
After running 10 runs of the original interaction algorithm, the resulting
matrix has been created in a Microsoft Excel format with each output as
target and each input for each output as source for the interaction pair,
hence with N = n(n − 1) (N=9900 with n=100) interaction pairs. For
each of these pairs, the interaction score was averaged over the 10 runs, and
its consistency monitored with standard deviation and confidence interval.
These gene-paired interactions, were displayed using Cytoscape (Figure 5.2).
From this interaction map, it clearly appears that no relevant information
can be elucidated due to its high dimensionality and complexity, and as a
consequence, stresses the need for a supplementary filtering step.
Figures 5.3 and 5.4 display the distribution of the ranked interaction
values. Clearly, it is possible to observe that the majority of the interaction
scores have very low absolute values, and only few scores have higher abso-
lute value, hence following a normal distribution with very small variance
(cf. Figure 5.3 and Figure 5.4). Overall the values range from -10.9 to
+17.2. These may be of biological significance upon further investigation.
During the process of the interaction analysis, the overall predictive
performance of the models used to define the interaction map had been
constantly monitored by determining the Pearson’s correlation coefficient
between actual and predicted level of expression of the targeted gene used
as output. Therefore, it was possible to constantly assess the degree of error
of the model, and get a level of confidence for the interactions identified. In
the present application, we have been able to get an averaged r2 value of
0.665.
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Figure 5.2: Complete display of the whole interactome obtained from the interaction algorithm for the
top 100 genes before any filter applied.
Figure 5.3: Distribution of the interactions sorted by interaction scores. The interactions in dark grey
at the extremities represent the strongest interactions at level 5 (i.e. with scores above 5 and below -5).
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Figure 5.4: Distribution of frequencies of interaction scores.
Considering the difficulty of interpretation of the results emerging from
the interaction analysis, mainly due to high dimension of the matrix, it was
decided to apply successive filters in order to remove the scores with the
lowest absolute value (Figures 5.5 and 5.6). This decision was based on the
hypothesis that low interaction scores might reveal less likely interactions
between the genes. When a filter removing links of absolute interaction
score between -5 and +5 was applied (level 5 filtering), the number of links
drastically decreased from 10,000 to 163 (1.63% of the original interactome).
This greatly simplified the interaction map, facilitating interpretation and
understanding of the key features within the global interaction map (ob-
tained with Cytoscape) as shown in Figure 5.7 where red edges indicate
a positive interaction (supposedly stimulation), and blue a negative one
(supposedly inhibition).
From this map, we could then identify the highest positive interaction
involving NM_016448 (Retinoic Acid-regulated nuclear Matrix-associated
Protein (RAMP) - also known as Denticleless homolog (Drosophila) (DTL))
which has already been described to have a role in cancer cell proliferation
(Crowe et al., 2003), and Contig42933_RC, which corresponds to the Gen-
bank accession number R73468, referring to an unknown gene sequence
which has already been strongly associated with metastasis in breast cancer
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Figure 5.5: Display of the interaction map reduced to level 2 (i.e. with scores above 2 and below -2).
Figure 5.6: Display of the interaction map reduced to level 4 (i.e. with scores above 4 and below -4).
(Takahashi et al., 2004). Conversely in the negative way, we identified the
strongest interaction between NM_016448 again with Contig55725_RC,
which corresponds to the Cell Division Cycle Associated 7 (CDCA7) which
has been shown to be over expressed in human tumours (Osthus et al.,
126
Figure 5.7: Display of the interaction map reduced to level 5 (i.e. with scores above 5 and below -5).
2005). Moreover, we can clearly identify some key nodes involved in dense
regions of interactions, here again NM_016448 (DTL) appears as a key fea-
ture within the whole pathway of interaction, interacting strongly (within
the interactions over 5) with 35 other genes, where most of these interac-
tions (33) have NM_016448 as the target.
According to these preliminary observations, it appears that DTL has a
key role in the whole interactome in this breast cancer study. Indeed, the
literature has demonstrated its implication in breast cancer (Crowe et al.,
2003) with the ability to decrease the expansion of cancer cells. Moreover,
the mRNA sequence for CA9, previously identified as the best predictor for
metastasis in that case, belongs to one of the features interacting with the
Retinoic acid-regulated nuclear matrix-associated protein (NM_016448).
In addition, the results show an interaction between CA9 and the mRNA
for Phosphoglycerate Kinase 1 (PGK1), interactions between both have al-
ready been described in literature in relation to cancer (Winter et al., 2007).
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However, all these results are only coming from a very early step of
the development process for this new method, and clearly needs to be val-
idated. As a first validation step, it was decided to analyse the literature
involving the 100 genes. This work was facilitated by the database from In-
genuity (Ingenuity R© Systems, www.ingenuity.com), which compiles all the
published work on identified interactions between any sort of molecule or
drug.
5.1.3 Validation using Ingenuity Pathway Analysis
The submission of the 100 selected input values in the Ingenuity Path-
way Analysis (IPA) (Ingenuity R© Systems, www.ingenuity.com) database
gave 62 matches (c.f. Table 5.2). Once these matching genes were isolated,
they were submitted to the pathway database of IPA R© and a map of in-
teractions had been designed (c.f. Figure 5.8) using the Path Explorer tool
with the whole set of 62 genes as Set A and Set B and exploring any direc-
tion.
This analysis tool employed in IPA R© in order to identify the poten-
tial relations existing between the 62 molecules introduced several others
as intermediates so that not only direct relations could be added to the
pathway, but indirect ones as well, with one degree of freedom (i.e. mean-
ing that only one intermediate candidate was added between 2 molecules).
Therefore the analysis introduced an extra set of 79 molecules (Table 5.3)
to the 62 originally identified as matching between the top 100 selected with
the Ingenuity databas entries (Table 5.2). As a consequence, the compari-
son of the maps obtained became a little less meaningful, since not all the
100 genes were present, but even more extra intermediate molecules were
added. However, it is still possible to discuss the indirect relations identified
by IPA R© between two of the 62 molecules with their intermediates. They
can still hold relevant information toward the validation of the findings from
the interaction algorithm.
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Nb. Accession nb. Symbol Name/Description
1 2025 NM_001216 CA9 Carbonic Anhydrase IX
2 1514 NM_016598 ZDHHC3 Zinc finger, DHHC-type containing 3
3 642 NM_020678 LRTM1 Leucine-rich repeats and transmembrane domains 1
4 1443 NM_016448 DTL Denticleless homolog (drosophilia)
5 1053 NM_006544 EXOC5 Exocyst complex component 5
6 909 AL080059 TSPYL5 TSPY-like 5
7 1081 NM_006581 FUT9 Fucosyltransferase 9 (α-(1,3)-fucosyltransferase)
8 505 NM_003766 BECN1 Beclin 1 (autophagy related)
9 497 NM_003748 ALDH4A1 Aldehyde dehydrogenase 4 family, member A1
10 706 NM_013438 UBQLN1 Ubiquilin 1
11 322 NM_003504 CDC45L CDC45 cell division cycle 45-like (S. cerevisiae)
12 1684 AF161451 NSMCE1 Non-SMC element 1 homolog (S. cerevisiae)
13 1724 NM_018265 C1orf106 Chromosome 1 open reading frame 106
14 283 NM_003450 ZNF174 Zinc finger protein 174
15 936 NM_014400 LYPD3 LY6/PLAUR domain containing 3
16 143 NM_003258 TK1 Thymidine kinase 1, soluble
17 2075 NM_000599 IGFBP5 Insulin-like growth factor binding protein 5
18 1153 NM_014675 CROCC Ciliary rootlet coiled-coil, rootletin
19 568 NM_004583 RAB5C RAB5C, member RAS oncogene family
20 1167 NM_006681 NMU Neuromedin U
21 663 NM_003977 AIP Aryl hydrocarbon receptor interacting protein
22 278 NM_004163 RAB27B RAB27B, member RAS oncogene family
23 1961 NM_000419 ITGA2B Integrin, alpha 2b
24 32 D42044 KIAA0090 KIAA0090 protein
25 980 NM_014489 PGAP2 Post-GPI attachment to proteins 2
26 138 NM_003239 TGFB3 Transforming growth factor, beta 3
27 738 AF257175 PECI Peroxisomal D3,D2-enoyl-CoA isomerase
28 572 NM_003862 FGF18 Fibroblast growth factor 18
29 1832 AL122101 TEF Thyrotrophic embryonic factor
30 102 NM_001756 SERPINA6 Serpin peptidase inhibitor, clade A(α-1 antiproteinase, antitrypsin), member 6
31 1363 NM_016359 NUSAP1 Nucleolar and spindle associated protein 1
32 2242 NM_002266 KPNA2 Karyopherin α 2 (RAG cohort 1, importin alpha 1)
33 1228 NM_006763 BTG2 BTG family, member 2
34 674 AJ011306 EIF2B4 Eukaryotic translation initiation factor 2B, subunit 4 δ
35 985 NM_005744 ARIH1 Ariadne (Drosophila) homolog, ubiquitin-conjugating enzyme E2-binding protein, 1
36 45 NM_001667 ARL2 ADP-ribosylation factor-like 2
37 1066 D86957 SEPT8 Septin 8
38 974 NM_006461 SPAG5 Sperm associated antigen 5
39 1774 NM_018313 PBRM1 Polybromo 1
40 450 AF052162 LPCAT1 Lysophosphatidylcholine acyltransferase 1
41 1143 NM_006625 SFRS13A Splicing factor, arginine/serine-rich 13A
42 1640 NM_018131 CEP55 Centrosomal protein, 55kDa
43 950 NM_006407 ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5
44 25 AL035297 SFT2D2 SFT2 domain containing 2
45 1918 BE739817_RC IFNAR1 Interferon (α, β and ω) receptor 1
46 1474 AL137615 MKNK2 MAP kinase interacting serine/threonine kinase 2
47 1642 NM_018136 ASPM asp (abnormal spindle) homolog (Drosophila), microcephaly associated
48 2034 NM_000507 FBP1 Fructose-1,6-bisphosphatase 1
49 1912 AF073519 SERF1A Small EDRK-rich factor 1A (telomeric)
50 1446 NM_016458 C8orf30A Chromosome 8 open reading frame 30A
51 1812 NM_000286 PEX12 Peroxisomal biogenesis factor 12
52 188 AF016903 AGRN Agrin
53 2115 NM_002066 GML Glycosylphosphatidylinositol (GPI) anchored molecule like protein
54 1142 NM_006623 PHGDH Phosphoglycerate dehydrogenase
55 1082 NM_006582 GMEB1 Glucocorticoid modulatory element binding protein 1
56 366 AL133447 EDC3 Enhancer of mRNA decapping 3 homolog (S. cerevisiae)
57 1811 NM_000284 PDHA1 Pyruvate dehydrogenase (lipoamide) α 1
58 578 AF131828 C9orf25 Chromosome 9 open reading frame 25
59 1791 NM_018354 C20orf46 chromosome 20 open reading frame 46
60 616 NM_013360 ZNF222 Zinc finger protein 222
61 428 NM_002916 RFC4 Replication factor C (activator 1) 4, 37kDa
62 1814 NM_000291 PGK1 Phosphoglycerate kinase 1
Table 5.2: 62 matching genes found by Ingenuity Pathway Analysis database entries ranked by predictive
ability in step 1 of stepwise analysis
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Symbol Name/Description Family
1 AHR aryl hydrocarbon receptor ligand-dependent nuclear receptor
2 ARF6 ADP-ribosylation factor 6 transporter
3 ARNT aryl hydrocarbon receptor nuclear translocator transcription regulator
4 ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) transcription regulator
5 ATN1 atrophin 1 transcription regulator
6 ATXN3 ataxin 3 other
7 BRCA1 breast cancer 1, early onset transcription regulator
8 Ca Calcium chemical drug
9 CD47 CD47 molecule other
10 CDC2 cell division cycle 2, G1 to S and G2 to M kinase
11 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) other
12 CDKN2A cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) transcription regulator
13 CDT1 chromatin licensing and DNA replication factor 1 other
14 CREB1 cAMP responsive element binding protein 1 transcription regulator
15 CREBBP CREB binding protein transcription regulator
16 CREM cAMP responsive element modulator transcription regulator
17 CSNK1A1 casein kinase 1, alpha 1 kinase
18 CTNNB1 catenin (cadherin-associated protein), β 1, 88kDa transcription regulator
19 DLG4 discs, large homolog 4 (Drosophila) kinase
20 E2F1 E2F transcription factor 1 transcription regulator
21 E2F4 E2F transcription factor 4, p107/p130-binding transcription regulator
22 EP300 E1A binding protein p300 transcription regulator
23 EPAS1 endothelial PAS domain protein 1 transcription regulator
24 EPB41 erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) other
25 EWSR1 Ewing sarcoma breakpoint region 1 other
26 FGFR3 fibroblast growth factor receptor 3 kinase
27 FN1 fibronectin 1 enzyme
28 FXR2 fragile X mental retardation, autosomal homolog 2 other
29 GATA1 GATA binding protein 1 (globin transcription factor 1) transcription regulator
30 GFI1B growth factor independent 1B transcription repressor transcription regulator
31 GRB2 growth factor receptor-bound protein 2 other
32 HGS hepatocyte growth factor-regulated tyrosine kinase substrate other
33 HIF1A hypoxia inducible factor 1, α subunit transcription regulator
34 Histone h3 group
35 HNF1A HNF1 homeobox A transcription regulator
36 HNF4A hepatocyte nuclear factor 4, alpha transcription regulator
37 HSP90AB1 heat shock protein 90kDa alpha (cytosolic), class B member 1 other
38 Importin α group
39 KCNMA1 potassium large conductance calcium-activated channel, subfamily M, α 1 ion channel
40 KPNB1 karyopherin (importin) beta 1 transporter
41 MAPK1 mitogen-activated protein kinase 1 kinase
42 MAPK13 mitogen-activated protein kinase 13 kinase
43 MAPK14 mitogen-activated protein kinase 14 kinase
44 MIR122 microRNA 122 microRNA
45 MIR17 microRNA 17 microRNA
46 MIRN324 microRNA
47 MYC v-myc myelocytomatosis viral oncogene homolog transcription regulator
48 NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 transcription regulator
49 PDE6D phosphodiesterase 6D, cGMP-specific, rod, delta enzyme
50 PI3K complex
51 PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1 enzyme
52 PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) other
53 POLA2 polymerase (DNA directed), alpha 2 (70kD subunit) enzyme
54 PPARA peroxisome proliferator-activated receptor alpha ligand-dependent nuclear receptor
55 PPARG peroxisome proliferator-activated receptor gamma ligand-dependent nuclear receptor
56 PRMT1 protein arginine methyltransferase 1 enzyme
57 RARB retinoic acid receptor, beta ligand-dependent nuclear receptor
58 RELA v-rel reticuloendotheliosis viral oncogene homolog A (avian) transcription regulator
59 SAP25 sin3A-binding protein, SAP25 other
60 SFN stratifin other
61 SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 transporter
62 SMAD1 SMAD family member 1 transcription regulator
63 SMARCA4 SWI/SNF related, actin dependent regulator of chromatin, subfamily a, member 4 transcription regulator
64 STAT2 signal transducer and activator of transcription 2, 113kDa transcription regulator
65 STAT4 signal transducer and activator of transcription 4 transcription regulator
66 TGFBR1 transforming growth factor, β receptor 1 kinase
67 THRB thyroid hormone receptor, β ligand-dependent nuclear receptor
68 TP53 tumor protein p53 transcription regulator
69 TSC22D1 TSC22 domain family, member 1 transcription regulator
70 UBC ubiquitin C other
71 UBQLN4 ubiquilin 4 other
72 UNC119 unc-119 homolog (C. elegans) other
73 VTN vitronectin other
74 YWHAB tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, β other
75 YWHAG tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, γ other
76 YWHAQ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, θ other
77 YWHAZ tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, ζ enzyme
78 ZFP36 zinc finger protein 36, C3H type, homolog (mouse) transcription regulator
79 ZNF143 zinc finger protein 143 transcription regulator
Table 5.3: 79 additional molecules added by the IPA R© Path Explorer analysis tool for direct and indirect
interactions.
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This can be seen as a valid method to confirm the results presented.
However, it suffered several important limitations, one of which is inherent
to the Ingenuity database. It compiles only published and established work
on interacting molecules. Therefore, it is only reliable to a certain point. It
can validate findings if an interaction identified by the method is present in
the database. However, if a strong interaction identified by the algorithm
is not present in the Ingenuity database, this does not necessary mean that
there is no actual interaction taking place there; but would just mean that
no group have previously demonstrated its existence in a laboratory.
Moreover, this database is subject to changes, and from one date to
another, additional interactions may have been added, and even more, some
others may have been removed.
In addition, only 62 out of 100 genes matched in the IPA R© database,
which dramatically reduced the possibility to identify matching interactions,
and 16 of the 62 matches could not find any interacting molecule according
to IPA R©. As well, since no direct connection could be observed, IPA R©
added extra molecules as intermediates to connect them, which added some
complexity to the interaction map, and limited the validation of the findings.
Although no clear overlapping could be observed between the results
from the interaction algorithm and the results from IPA R©, as for example,
there is no evidence in any sort of connection between CA9 and DTL in
IPA R© which was found by the algorithm; it was possible to identify with
IPA R© an indirect connection between CA9 and PGK1 (NM_000291) via
HIF1α where it was found by the interaction algorithm with an interaction
score of 6.54. Indeed, PGK1 has been reported to be one of the several
genes of the glycolytic pathway to be upregulated by HIF1α (Hu et al.,
2003; Wang et al., 2005; Winter et al., 2007).
A complete study of the interaction links will not be conducted, but it is
possible to describe some interactions detected that appeared as well in the
IPA R© analysis. Among some of the highest positive interaction scores iden-
tified by the algorithm is the link between DTL and CDC45L (NM_003504).
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Figure 5.8: Results obtained by querying Ingenuity Pathway with 62 matching genes using the Path
Explorer tool with the complete pool of 62 genes for Set A and Set B and any direction. In blue are
the 62 genes from the top 100 identified genes, and in orange are the additional molecules added by the
Path Explorer tool from Ingenuity.
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IPA R© found this link intermediated by CDKN1α, CDT1 or HNF-1α. HNF-
1α protein is involved in gene regulation of DTL (or RAMP) and CDC45L
(Odom et al., 2004). Therefore, it seems to make sense a strong associa-
tion between DTL and CDC45L (with a score of 15.49) has been identified,
as they would be following a similar coexpression pattern under the influ-
ence of HNF-1α. Other evidence showed that DTL, combined with other
molecules, is likely to promote the degradation of CDT1 (Higa et al., 2006);
and CDT1 enhances the expression of CDC45 (Ballabeni et al., 2009). Sim-
ilarly, the interaction algorithm identified a relation that exists between
DTL and KPNA2, confirmed by IPA R© via CDT1 here again. CDT1 has
just been described to have its degradation enhanced by a complex involv-
ing DTL (Higa et al., 2006), and according to the work of Sugimoto and
co-workers, CDT1 protein is involved in the formation of a protein-protein
complex with KPNA2 (Sugimoto et al., 2008).
Only one of the predicted negative interactions out of the 20 with highest
absolute value interaction score matched with the results in IPA R©. DTL
again was found to have a strong negative influence upon TEF with an in-
teraction score of -7.36. This was found to be the case by IPA R© via the
transcription factor HNF-1α.
Although several interactions matched with the database query, most of
them were not (5 out of top 20 for positive scores, and only one out of top
20 for negative scores). Therefore, this approach was not entirely conclusive
according to the validation of the algorithm. As a consequence, since no
clear overlapping result could be observed for validation purpose, the algo-
rithm has been optimised using an artificial dataset. Once optimised, the
same dataset has been re-applied. The results are presented in the following
section.
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5.2 Optimisation of the method: new applica-
tion of the van’t Veer dataset
Following the optimisation of the algorithm, the van’t Veer set has been
reapplied in order to further improve and refine the interactome previously
described. The whole set of data has been firstly analysed without consid-
eration of the population characteristics and disease subclasses (i.e. all the
cases where submitted to the analysis). Subsequently, the population was
split in two groups considering the metastatic risk status of the individu-
als, and thus analysing separately the interactions that may occur in the
good prognostic group and in the poor prognostic group. Finally, the result-
ing interactomes obtained from the algorithm are compared and analysed
to further identify potential alteration of interacting pairs that may occur
from one group to another.
5.2.1 Global population
As shown previously, the whole population of the dataset has been firstly
applied to infer the interaction patterns for the selection of top 100 genes.
The results are displayed as a map, here again using Cytoscape, in Figure
5.9.
Interestingly, we could firstly note that two of the probes belonging
to the top 100 selection (with the Genbank numbers : NM_006117 and
AF257175) are actually related to the same gene : Peroxisomal ∆3,∆2-
enoyl-CoA isomerase (PECI). Indeed, AF257175 refers to a cDNA sequence
of the PECI gene, and NM_006117 refers to an alternative mRNA tran-
script sequence of the same gene. As a result, the algorithm was able to
identify a very strong interaction score for the two pairs (see Table 5.4) :
47.389 between NM_006117 and AF257175 and 37.82 between AF257175
and NM_006117; which actually highlights a highly correlating expression
pattern, thus confirming in this case the fact that both probes referred
to the same gene product. And as a consequence, this artifact, resulting
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Figure 5.9: Display of resulting interaction map with algorithm 5, filter applied to all the interaction
pairs with Cv ≤ 0.25 and score > 10.
in those strong interaction scores, internally validates the robustness and
particularly the reproducibility of the approach.
In addition, similar phenomena can be observed with Testis-Specific Y-
encoded-like protein 5 (TSPYL5) and further validates the approach. This
particular gene was represented indeed by two probes with Genbank num-
bers AA973313 (Contig14882_RC) and AL080059. These two isoforms of
TSPYL5 were predicted interacting with scores of 59.36 for the interaction
between AA973313 toward AL080059 and 37.60 between AL080059 toward
AA973313.
In this application, it seems that DTL does not appear anymore to be so
highly relevant in the present network, although it was the case when anal-
ysed by the previous version of the algorithm. We can observe as well sev-
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Source Source Interaction Target Target Filter
GenBank Nb. Name Score Name GenBank Nb. value
1 AI912791 FBXO16 18.622 FBP1 NM_000507 0.094
2 AI738508 ECT2 11.174 CA9 NM_001216 0.122
3 NM_016359 NUSAP1 9.262 ECT2 AI738508 0.144
4 NM_000291 PGK 14.572 CA9 NM_001216 0.147
5 AF052162 LPCAT1 16.649 C1orf106 NM_018265 0.154
6 NM_006582 GMEB1 7.095 STX1B NM_003163 0.155
7 NM_018136 ASPM 10.182 ECT2 AI738508 0.156
8 NM_006117 PECI 47.389 PECI AF257175 0.157
9 NM_000284 PDHA1 7.935 ECT2 AI738508 0.157
10 NM_006763 BTG2 26.544 FBP1 NM_000507 0.157
11 AJ011306 EIF2B4 8.968 PECI AF257175 0.157
12 NM_016448 DTL 6.604 ECT2 AI738508 0.159
13 NM_004702 CCNE2 6.764 ECT2 AI738508 0.167
14 NM_006461 SPAG5 5.296 ECT2 AI738508 0.168
15 NM_005196 CENPF 9.157 ECT2 AI738508 0.174
16 NM_003163 STX1B 5.313 PGAP2 NM_014489 0.176
17 AI992158 CDCA7 13.370 ECT2 AI738508 0.176
18 NM_003239 TGFB3 9.224 PECI NM_006117 0.177
19 NM_000599 IGFBP5 9.992 CA9 NM_001216 0.177
20 AF257175 PECI 37.819 PECI NM_006117 0.178
21 AJ011306 EIF2B4 11.207 FBP1 NM_000507 0.178
22 NM_018136 ASPM 13.477 CDCA7 AI992158 0.181
23 NM_006625 SFRS13A 10.980 ECT2 AI738508 0.185
24 NM_013360 ZNF222 6.985 PECI NM_006117 0.187
25 NM_018313 PBRM1 6.760 STX1B NM_003163 0.187
26 AA759198 AA759198 6.125 STX1B NM_003163 0.189
27 NM_014489 PGAP2 12.276 C1orf106 NM_018265 0.189
28 NM_018131 CEP55 8.176 ECT2 AI738508 0.189
29 NM_006461 SPAG5 10.491 CDCA7 AI992158 0.190
30 NM_002916 RFC4 22.253 CDCA7 AI992158 0.190
31 NM_020678 LRTM1 5.720 AA759198 AA759198 0.191
32 AI741080 B3GALNT2 11.466 C1orf106 NM_018265 0.192
33 NM_006623 PHGDH 10.555 ECT2 AI738508 0.192
34 NM_000507 FBP1 18.265 RUNDC1 AI918032 0.194
35 NM_003163 STX1B 11.068 CA9 NM_001216 0.194
36 AL133447 EDC3 7.143 STX1B NM_003163 0.194
37 AI479831 MTHFR 5.264 AA759198 AA759198 0.195
38 NM_002916 RFC4 10.757 ECT2 AI738508 0.196
39 NM_016458 C8orf30A 5.005 AA759198 AA759198 0.196
40 NM_003504 CDC45L 18.138 CDCA7 AI992158 0.196
41 NM_020678 LRTM1 5.404 ZNF174 NM_003450 0.197
42 NM_003977 AIP 6.904 AA759198 AA759198 0.197
43 AL035297 SFT2D2 22.696 C1orf106 NM_018265 0.197
44 NM_014675 CROCC 17.745 SEPT8 D86957 0.197
45 NM_006625 SFRS13A 19.520 B3GALNT2 AI741080 0.197
46 AI992158 CDCA7 14.535 C1orf106 NM_018265 0.200
47 NM_016448 DTL 9.912 CDC45L NM_003504 0.200
48 AF016903 AGRN 22.772 B3GALNT2 AI741080 0.201
49 NM_016448 DTL 10.548 TK1 NM_003258 0.201
50 NM_018354 C20orf46 5.211 TSPYL5 AA973313 0.203
51 NM_000507 FBP1 11.523 PECI NM_006117 0.203
52 NM_000599 IGFBP5 9.104 PECI NM_006117 0.204
53 NM_003258 TK1 19.079 CDC45L NM_003504 0.204
54 AI992158 CDCA7 7.787 CA9 NM_001216 0.205
55 NM_018131 CEP55 10.652 CDC45L NM_003504 0.205
56 AI738508 ECT2 5.438 PECI AF257175 0.206
57 AI828164 FAM69B 5.020 ZNF174 NM_003450 0.206
58 AI554061 QSOX2 8.327 ECT2 AI738508 0.206
59 NM_006623 PHGDH 12.384 CDC45L NM_003504 0.206
60 NM_000419 ITGA2B 5.379 STX1B NM_003163 0.207
61 NM_000291 PGK 12.288 TK1 NM_003258 0.207
62 AW162411 TMEM218 7.385 RUNDC1 AI918032 0.207
63 NM_006117 PECI 11.011 TGFB3 NM_003239 0.207
64 AI918032 RUNDC1 50.522 FBP1 NM_000507 0.208
65 AF257175 PECI 8.123 TGFB3 NM_003239 0.208
66 NM_003977 AIP 6.520 STX1B NM_003163 0.210
67 NM_016359 NUSAP1 10.471 CDC45L NM_003504 0.212
68 AF257175 PECI 38.872 FBP1 NM_000507 0.215
69 NM_003504 CDC45L 7.694 ECT2 AI738508 0.216
70 AI183575 DNAJC5G 10.771 ARL6IP5 NM_006407 0.217
Table 5.4: Top 70 predicted positive interacting pairs by the algorithm filtered and sorted by Coefficient
of variation of score and with scores > 5. In bold are the interacting pairs of the isoforms of PECI.
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Source Source Interaction Target Target Filter
GenBank Nb. Name Score Name GenBank Nb. value
1 NM_005196 CENPF -8.712 PECI AF257175 0.118
2 NM_003504 CDC45L -21.411 FBP1 NM_000507 0.132
3 NM_013438 UBQLN1 -7.098 RUNDC1 AI918032 0.135
4 NM_018265 C1orf106 -5.061 ZNF226 NM_016444 0.138
5 NM_014400 LYPD3 -9.973 PECI AF257175 0.147
6 R73468 SLC25A16 -8.574 ECT2 AI738508 0.155
7 NM_006681 NMU -7.876 RUNDC1 AI918032 0.163
8 AI742029 TBC1D10A -9.479 ECT2 AI738508 0.164
9 AI885466 C13orf37 -7.641 PECI AF257175 0.166
10 NM_018131 CEP55 -13.571 FBP1 NM_000507 0.170
11 NM_003239 TGFB3 -10.991 ECT2 AI738508 0.173
12 LOC51630 UCHL5 -6.332 RUNDC1 AI918032 0.174
13 NM_002916 RFC4 -6.380 TSPYL5 AA973313 0.176
14 NM_000507 FBP1 -22.315 CDCA7 AI992158 0.177
15 AI918032 RUNDC1 -6.457 ECT2 AI738508 0.177
16 AL080059 TSPYL5 -12.444 PECI AF257175 0.178
17 AI082587 IL17RA -9.374 PECI NM_006117 0.179
18 AI082587 IL17RA -6.773 CA9 NM_001216 0.179
19 NM_000599 IGFBP5 -9.926 RUNDC1 AI918032 0.179
20 NM_016458 C8orf30A -10.899 C1orf106 NM_018265 0.180
21 NM_006681 NMU -32.387 FBP1 NM_000507 0.180
22 NM_014400 LYPD3 -10.005 PECI NM_006117 0.182
23 NM_018131 CEP55 -12.094 RUNDC1 AI918032 0.183
24 NM_014489 PGAP2 -5.629 ECT2 AI738508 0.184
25 NM_006763 BTG2 -6.047 CA9 NM_001216 0.184
26 NM_006763 BTG2 -12.659 ECT2 AI738508 0.184
27 NM_014675 CROCC -14.744 CA9 NM_001216 0.187
28 AL035297 SFT2D2 -9.395 PECI NM_006117 0.187
29 AI479831 MTHFR -6.546 PECI AF257175 0.187
30 AI082587 IL17RA -11.740 PECI AF257175 0.188
31 D86957 SEPT8 -12.825 ECT2 AI738508 0.190
32 AI828164 FAM69B -14.348 FBP1 NM_000507 0.190
33 AI918032 RUNDC1 -8.518 SFT2D2 AL035297 0.191
34 NM_005196 CENPF -8.927 PECI NM_006117 0.191
35 NM_006407 ARL6IP5 -7.200 CDC45L NM_003504 0.192
36 NM_001756 SERPINA6 -16.452 CDCA7 AI992158 0.193
37 NM_003239 TGFB3 -8.677 SFRS13A NM_006625 0.193
38 AF131828 C9orf25 -8.598 PECI AF257175 0.194
39 AI912791 FBXO16 -13.402 C1orf106 NM_018265 0.194
40 AL035297 SFT2D2 -10.963 PECI AF257175 0.195
41 R73468 SLC25A16 -12.790 SFT2D2 AL035297 0.195
42 AW137071 SMARCE1 -9.165 ECT2 AI738508 0.196
43 AI885466 C13orf37 -6.198 STX1B NM_003163 0.196
44 NM_018136 ASPM -6.246 PECI AF257175 0.197
45 AL035297 SFT2D2 -21.792 FBP1 NM_000507 0.199
46 AI479831 MTHFR -6.221 PECI NM_006117 0.200
47 NM_001216 CA9 -6.284 PECI NM_006117 0.200
48 AL137615 MKNK2 -6.335 ECT2 AI738508 0.202
49 NM_003239 TGFB3 -10.260 CDC45L NM_003504 0.204
50 AI741080 B3GALNT2 -45.063 FBP1 NM_000507 0.205
51 AI347425 MOG -11.578 CDCA7 AI992158 0.205
52 AI479831 MTHFR -23.630 FBP1 NM_000507 0.206
53 AW137071 SMARCE1 -8.157 CA9 NM_001216 0.207
54 NM_014675 CROCC -9.844 CDC45L NM_003504 0.207
55 NM_003766 BECN1 -5.444 CDC45L NM_003504 0.208
56 AI992158 CDCA7 -32.059 FBP1 NM_000507 0.208
57 AI082587 IL17RA -8.471 ECT2 AI738508 0.208
58 NM_018136 ASPM -7.071 RUNDC1 AI918032 0.208
59 FLJ11328 USP48 -5.541 SPAG5 NM_006461 0.209
60 AI741080 B3GALNT2 -12.538 RUNDC1 AI918032 0.211
61 AA534406 GALNT5 -5.786 TK1 NM_003258 0.213
62 AI992158 CDCA7 -7.135 FBXO16 AI912791 0.213
63 AA425275 COMMD6 -9.389 C1orf106 NM_018265 0.213
64 AL137615 MKNK2 -9.502 CENPF NM_005196 0.213
65 D86957 SEPT8 -12.783 SFRS13A NM_006625 0.214
66 AI885466 C13orf37 -8.309 PECI NM_006117 0.216
67 NM_003766 BECN1 -10.807 ECT2 AI738508 0.216
68 NM_006117 PECI -11.376 DTL NM_016448 0.216
69 R73468 SLC25A16 -17.114 DTL NM_016448 0.217
70 AW162411 TMEM218 -10.560 SFT2D2 AL035297 0.218
Table 5.5: Top 70 predicted negative interacting pairs by the algorithm filtered and sorted by Coefficient
of variation of score, and scores > 5.
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eral important hubs from the map (Figure 5.9), particularly around FBP1
(Fructose-1,6-bisphosphatase 1) that receives several very important con-
nections (21 links with interaction scores ranging from 11.21 up to 50.52 for
positive scores; and from -13.57 to -45.06). Furthermore, other hubs such
as CDC45L, ECT2, TK1, CDCA7 and Corf106 can be noticed.
Figure 5.10: CDC45L, DTL and TK1 interactions (shown in bold) predicted by the solution proposed
by Gevaert and coworkers (Gevaert et al., 2006)
It was possible to observe as well from the Table 5.4 that one of the
highest positive scores, with one of the best filter value (ranked number 1)
corresponded to the interaction between Contig42421_RC (for the F-box
protein 16) and FBP1 (Alexe et al., 2006). In addition, within the top
70 interactions predicted with positive scores presented in Table 5.4, CA9
presented two scores higher than 10 with ECT2 (rank 2, score=11.17) and
PGK (rank 4, score=14.57).
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The hub observed with CDC45L, DTL and TK1 (Figure 5.11) has al-
ready been inferred with an alternative in-silico method developed by Gevaert
and co-workers (Gevaert et al., 2006). The method proposed by Gevaert’s
group predicted interactions between CDC45L toward DTL and TK1 (see
Figure 5.10). These particular interactions have been inferred by the present
method too.
Comparison with IPA R© results
Figure 5.11: CDC45L, DTl and TK1 interactions predicted by the algorithm (a) and found by Ingenuity
Pathway Analysis (b).
From the results presented earlier in this chapter (c.f. Figure 5.8), a
rapid comparison of the interactions obtained with the refined algorithm
and method has been conducted, similarly to what has been done previ-
ously.
An interesting connection can be observed with BTG2 expression influ-
enced by FBP1. Although it is not shown by the map in Figure 5.9, because
of a slightly higher filter value (0.32), there is a strong positive score pre-
dicted of 9.72, suggesting this influence. According to IPA R© results, it
has been reported that BTG2 expression is promoted by the expression
of TP53 (a very well known gene involved in several cancers) (Amundson
et al., 2005), which have been reported to bind with HSPA8, itself binding
to FBP1 as well (Stelzl et al., 2005).
The network identified between CDC45L, DTL and TK1, which was
confirmed by another inferring method (Gevaert et al., 2006) as mentioned
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earlier, is confirmed as well by IPA R©, as seen in Figure 5.11. These 3 mark-
ers were found to be connected or related to CDKN1A. Their relationship
with CDKN1A are:
• TK1 binds to CDKN1A (Huang and Chang, 2001).
• CDC45L binds to CDKN1A (Ramachandran et al., 2004).
• DTL expression promoted by CDKN1A (Wu et al., 2002).
Nevertheless, IPA R© failed to show any direct relationship between the
3 markers. This can be explained by the fact that CDKN1A may be a key
molecule intermediating between those 3 markers; and since it doesn’t be-
long to the list of top 100 genes found by the preliminary analysis, it doesn’t
appear in the results for interaction. Consequently, the 3 genes are found
by the algorithm to be directly connected event though no direct connection
was found by IPA R©.
However, from the interaction map predicted by the algorithm, FBP1
seems to appear as a key hub concentrating important vectors of influence
towards it. The results with IPA R© failed to confirm this important hub as
it only identified a single indirect connection with PDHA1, intermediated
by FXR2.
Nevertheless, despite some interesting indirect matches with the results
obtained with IPA, it showed limited validation of the findings. The main
reasons for this lack of overlapping results have been already discussed, in
the previous section, and consists mainly of the fact that only very few
interaction or relationships between molecules have been described and val-
idated in vitro or in vivo.
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5.2.2 Good prognostic group and poor prognostic group
interaction analysis
The interest of the approach presented in this thesis does not only rely
on the analysis of interactions that might exist between genes in the global
population, but stands as well in the separate study of the interactions that
could exist in the subpopulations, and ultimately compare the results to
identify patterns of interactions significantly altered between the two sub-
populations.
With the van’t Veer study, the population could be separated regarding
their status to recurrence. The population has been split into two subgroups
with respect to the metastatic outcome of the individuals. The Good Prog-
nostic Group received the individuals who showed no relapse until five years
after treatment, and the Poor Prognostic group received the individuals who
presented recurrence before five years.
Figure 5.12 presents the interaction map for the analysis of the good
prognostic group. From this map, FBP1 does not seem to appear as a cen-
tral hub here anymore. However, it seems that BCEN1, CCNE2, ZNF226
as well as ECT2 concentrate a number of interactions around them. We
can see as well, that the group composed by DTL, CDC45L and TK1 is
showing a similar pattern of inter connection than seen earlier in the global
population analysis.
For the poor prognostic group, Figure 5.13 shows the resulting interac-
tion map. We can observe here that some other hubs stood out from other
markers, involving ARL2, FOXL2, Contig55725_RC (or CDCA7) or FBP1.
However, the filer for this subpopulation did not keep the interactions in-
volving DTL, TK1 and CDC45L, suggesting a lower consistency of these
connections in the model.
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Figure 5.12: Display of resulting interaction map for good prognostic group, ranked and filtered by
Coefficient of variation for values below 0.25. Red edges indicate positive interactions, and blue edges
indicate negatives ones.
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Figure 5.13: Display of resulting interaction map for poor prognostic group, ranked and filtered by
Coefficient of variation for values below 0.25. Red edges indicate positive interactions, and blue edges
indicate negatives ones.
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5.2.3 Differential patterns
With the separate analysis of the two sub-groups from the original
dataset, the most interesting aspect to investigate was to monitor the changes
that may have occurred between those two groups. In other words: is there a
possibility to identify strong patterns that constantly change from the good
prognostic group to the poor prognostic one. The hope here would then
be to identify new altered interactions or signalling paths that may have
changed for the poor prognostic group and then may explain the difference
of outcome for them, with the potential to lead to future new therapeutic
strategies.
This idea has been applied to the two sub-populations from the van’t
Veer set. The original tables with scores for both groups were compared.
The absolute value of interaction scores for each matching pair in both
analysis were substracted (good prognostic group score - poor prognostic
score), giving a new value for each interacting pair:
(|ScoreGPG| − |ScorePPG|) (5.1)
This value was therefore either positive (illustrating that higher interac-
tion is found for the good prognostic group) or negative (for the opposite).
Finally, displaying map for differential patterns with these new values using
Cytoscape gave the result seen in Figure 5.14, when a filter only kept values
of difference with an absolute value higher than 10. In this particular case,
the coloured edges don’t translate anymore an interaction, properly speak-
ing, but highlights a difference of interaction. Therefore, the blue edges
indicate a directed interaction that is significantly higher in the poor prog-
nostic group, and the red edges indicate significantly higher interaction in
the good prognostic group.
From the results, several significant alterations could be observed. It
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mainly involved TEF receiving a number of much higher influences in the
good prognostic than in the Poor Prognostic Group; among them is an inter-
action from CA9, these alterations are amongst the most important for the
interaction found higher in GPG. A similar pattern is observed for FLJ23033
(also known as TTL7 or Tubulin Tyrosine Ligase-like family, member 7).
We can hypothesise from this that as higher interactions seem to take place
toward TEF in good prognostic group, some alterations of these interac-
tions is taking place for poorer prognostic individuals and therefore this
could open a lead toward potential new therapeutic strategy. However, all
of this is highly hypothetical, and needs deeper investigation to validate if
the approach is correct.
As a consequence, because of the very nature of the method and its
results, it is particularly challenging and difficult to validate with existing
identifications of altered interactions in previous studies, and in the litera-
ture.
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Figure 5.14: Display of resulting differential patterns of interactions between the good prognostic group
and the poor prognostic group. Red edges represent interactions found to be higher in the good prognostic
group, and blue edges represent interactions higher in the poor prognostic group.
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5.3 Validation with the NKI295 cohort
Following the study of van’t Veer and co-workers (van’t Veer et al., 2002)
and their 70-gene signature predictive of breast cancer metastatic risk, van
de Vijver and co-workers provided one of the first major validation of this
signature using the same protocol (van de Vijver et al., 2002) on a larger
cohort of patients. The pool of samples consisted in 295 patients with breast
cancer, showing different phenotypes of ER positivity, or treatment. This
dataset has been chosen to validate the previous results obtained with the
van’t Veer set since they used the same microarray, and as a result, the
same gene expression were monitored, and similar normalisation techniques
were applied.
5.3.1 Methodology
A similar workflow (c.f. Figure 4.3) has been employed to proceed with
the NKI295 dataset. The 100 genes previously identified were selected with
their expression vector for each of the individuals. Prior interaction analysis,
the list of the patients redundant with the van’t Veer cohort were removed
in order to guarantee a non-questionable comparison as all the patients are
therefore completely unseen. The interaction study has been conducted
only on the overall population here, as it was primarily sought to assess
and validate the reproducibility of the method by comparing similar results
with the global population.
5.3.2 Results
The interaction scores resulting from the analysis for the overall popu-
lation in the NKI295 cohort are shown in Tables 5.6 and 5.7. These tables
summarise the 50 most important interactions for both positive and neg-
ative scores, and for both NKI295 and van’t Veer cohort. This allows the
comparison of the results obtained by the algorithm. When a similar pair
was found present in both cohort within the top50 interactions negative and
positive, the pair was highlighted in bold in the table. Therefore, it is pos-
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sible to observe that 12 of the top50 positive interactions and 8 out of the
top 50 negative interactions were found overlapping for both cohorts. These
results show that, although it is not perfect, this predictive interaction ap-
proach showed an encouraging reproducibility, and worth optimisation to
improve further this reproducibility.
NKI295 cohort van’t Veer cohort
Source Interaction Target Source Interaction Target
name scores name name scores name
TSPYL5 64.499 TSPYL5 TSPYL5 59.361 TSPYL5
PGK1 49.253 CA9 RUNDC1 50.522 FBP1
RAB5C 38.685 DHX58 B3GALNT2 48.759 AGRN
CA9 38.594 PGK1 PECI 47.389 PECI
TGFB3 36.274 01-sept ALKBH7 43.707 FBP1
ECT2 35.119 IFNAR1 ZDHHC3 41.56 SEPT8
KPNA2 34.530 DHX58 PECI 38.872 FBP1
PECI 32.729 PECI PECI 38.257 FBP1
ASPM 30.443 CENPF IFNAR1 37.919 AGRN
RUNDC1 29.526 FBP1 PECI 37.819 PECI
ZNF222 27.253 ZNF226 TSPYL5 37.604 TSPYL5
ZNF226 26.949 ZNF222 EDC3 37.163 FBP1
C9orf25 26.804 C20orf46 ZBTB45 36.447 AGRN
DHX58 26.326 RAB5C RUNDC1 34.979 BECN1
ALDH4A1 26.086 FBP1 STX1B 34.742 AGRN
TSPYL5 25.827 TSPYL5 C9orf25 33.898 C20orf46
PECI 25.325 ALKBH7 EXOC5 33.364 IFNAR1
BTG2 24.781 SEPT8 TGFB3 31.687 SEPT8
LRTM1 24.193 ALKBH7 TSPYL5 31.265 IFNAR1
RAB5C 23.970 FBP1 STX1B 31.053 SEPT8
SFRS13A 23.814 SERF1A TGFB3 30.297 CROCC
C13orf37 23.675 ZNF420 FLJ11354 29.538 AGRN
DHX58 23.657 FBP1 SFT2D2 29.492 C20orf46
PBRM1 23.522 C20orf46 NSMCE1 28.889 FBP1
EXOC5 23.372 IFNAR1 RAB5C 28.308 FLJ11354
PECI 23.254 PECI BECN1 28.236 SMARCE1
IFNAR1 22.968 ECT2 RAB5C 28.018 FBP1
CLSTN2 22.798 MTHFR CDC45L 27.992 DTL
SFRS13A 22.741 IFNAR1 FLJ23033 27.860 SEPT8
C9orf25 22.454 FBXO41 CDCA7 27.735 DTL
QSOX2 22.435 CDCA7 CENPF 27.690 DTL
CEP55 21.963 CDCA7 KPNA2 27.081 TK1
ZDHHC3 21.860 SEPT8 FLJ11354 27.049 BECN1
FBP1 21.817 DHX58 BTG2 26.544 FBP1
PECI 21.782 FBP1 CDC45L 26.429 TK1
FGF18 21.667 TGFB3 CENPF 26.166 AGRN
ZNF420 21.327 IFNAR1 AGRN 25.309 IFNAR1
EXOC5 21.129 ZNF420 FOXL2 24.989 40429
ZNF226 21.098 ZNF420 PHGDH 24.835 CDCA7
TSPYL5 20.972 IFNAR1 BECN1 24.735 FLJ11354
CROCC 20.910 GMEB1 NUSAP1 24.701 SMARCE1
RAB27B 20.871 FBP1 IFNAR1 24.488 EXOC5
TGFB3 20.870 TEF BTG2 24.305 SEPT8
PECI 20.729 FBP1 LIN9 24.301 DTL
BECN1 20.711 DHX58 FLJ11354 24.111 RAB5C
TEF 20.664 FBXO41 CROCC 23.967 TGFB3
CCNE2 20.538 DHX58 MKNK2 23.898 FBP1
SEPT8 20.501 TGFB3 FLJ11354 23.826 FBP1
SFRS13A 20.498 ECT2 C20orf46 23.756 FBP1
NSMCE1 20.486 FBP1 FLJ11328 23.458 IFNAR1
Table 5.6: Comparison of the 50 strongest positive scores obtained in both NKI295 and van’t Veer
interaction analysis. In bold are the interacting pair occurring in both lists.
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NKI295 cohort van’t Veer cohort
Source Interaction Target Source Interaction Target
name scores name name scores name
SLC25A16 -33.821 DHX58 B3GALNT2 -45.063 FBP1
PDHA1 -28.333 ALKBH7 ZNF222 -35.355 SERPINA6
CDCA7 -27.870 FBP1 PHGDH -34.984 FBP1
C13orf37 -27.355 GMEB1 CA9 -33.053 FBP1
C13orf37 -26.527 SEPT8 SERF1A -32.469 AGRN
ARL6IP5 -24.320 C9orf25 NMU -32.387 FBP1
PGK1 -24.173 GMEB1 CDCA7 -32.059 FBP1
SFT2D2 -23.238 FBP1 C9orf25 -29.522 AGRN
SLC25A16 -23.229 C20orf46 PDHA1 -28.772 IFNAR1
AIP -22.737 TSPYL5 CEP55 -26.596 AGRN
PEX12 -22.624 C20orf46 C1orf106 -26.507 FBP1
PECI -22.558 DHX58 GALNT5 -26.213 FBP1
TEF -21.943 C20orf46 C13orf37 -25.685 RAB5C
LYPD3 -21.816 FBXO41 PDHA1 -25.467 AGRN
QSOX2 -21.637 C13orf37 CDCA7 -24.693 SERPINA6
FBP1 -21.463 CDCA7 CDCA7 -24.360 IFNAR1
ZNF226 -21.408 PGK1 ARL2 -24.160 SERPINA6
ZNF420 -21.035 DHX58 SERPINA6 -24.041 SEPT8
ZNF226 -20.953 GMEB1 AA759198 -23.868 BECN1
C9orf25 -20.871 ALKBH7 MTHFR -23.630 FBP1
EIF2B4 -20.743 IFNAR1 ECT2 -23.548 SEPT8
MKNK2 -20.361 TSPYL5 PGK -23.305 CROCC
C1orf106 -20.226 SERPINA6 TSPYL5 -23.190 AGRN
ARL6IP5 -19.962 GMEB1 CA9 -23.120 NSMCE1
ALKBH7 -19.559 SEPT8 BTG2 -23.066 C20orf46
ARL2 -19.544 ZNF226 DTL -22.550 AGRN
RAB27B -19.203 GMEB1 CROCC -22.527 TK1
GMEB1 -19.202 C13orf37 C1orf106 -22.520 SERPINA6
RAB27B -19.046 C9orf25 FBP1 -22.315 CDCA7
SEPT8 -19.008 ALKBH7 EXOC5 -22.005 FBP1
CROCC -18.833 C20orf46 B3GALNT2 -21.865 SEPT8
PGK1 -18.727 ZNF226 SFT2D2 -21.792 FBP1
BTG2 -18.663 C20orf46 ARL6IP5 -21.789 FBP1
CA9 -18.496 FBP1 CDC45L -21.411 FBP1
SERF1A -18.301 GMEB1 SEPT8 -21.238 FBP1
SEPT8 -18.239 C13orf37 RFC4 -21.181 AGRN
TSPYL5 -18.016 DHX58 ASPM -20.898 AGRN
SFRS13A -18.004 FBP1 SERPINA6 -20.822 C1orf106
COMMD6 -17.990 DHX58 IFNAR1 -20.762 CDCA7
C1orf106 -17.907 DHX58 AGRN -20.670 DTL
PGK1 -17.865 SMARCE1 TGFB3 -20.617 SERPINA6
ZBTB45 -17.842 DHX58 CDCA7 -20.477 C20orf46
RAB27B -17.696 SERPINA6 CDCA7 -20.414 SEPT8
ARL6IP5 -17.691 FBXO41 ARIH1 -20.329 SMARCE1
ARL2 -17.531 SERPINA6 EDC3 -20.303 IFNAR1
PECI -17.422 C20orf46 ARL2 -20.121 SMARCE1
FBXO16 -17.413 GMEB1 ARL6IP5 -19.799 AGRN
QSOX2 -17.322 ALKBH7 NSMCE1 -19.703 CDCA7
SMARCE1 -17.258 DHX58 TK1 -19.493 CROCC
CDCA7 -17.218 SERPINA6 RAB5C -18.789 C13orf37
Table 5.7: Comparison of the 50 strongest negative scores obtained in both NKI295 and van’t Veer
interaction analysis. In bold are the interacting pair occurring in both lists.
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5.4 Discussion
The application of the first developed algorithm and then of its opti-
mised version have been discussed in the present chapter. The challenge
here was then to validate the approach at another level, with the results
obtained, after the optimisation and validation obtained with the simulated
dataset as discussed in chapter 4.
The first level of validation here tried to identify if any of the predicted
interactions from real world data had been previously reported. For this
reason, IPA R© appeared as an extremely useful tool from its very nature:
by compiling all the reported interactions in the literature from any study,
IPA R© allows to query the database and provides a direct insight into what
has been described until now about any molecule in the literature. As a re-
sult, the query of the selected 100 genes gave 62 matching results, for which
additional molecules were found to be intermediates in their interactions,
adding an extra pool of 79 molecules.
Despite the challenge of finding existing and previously described fea-
tures in literature that were predicted by the algorithm, it has been possi-
ble to identify some key components already described (CDC45L, TK1 and
DTL) by different solutions or with different platforms with the van’t Veer
dataset (van’t Veer et al., 2002).
The IPA R© study presented evidence of interactions of these 3 compo-
nents with CDKN1A, known to be inhibitor of DNA synthesis and to be
involved in DNA damage repair due to transcriptional expression increase
induced by the tumour suppressor p53 (Abbas et al., 2008), making sense in
the context of cancer. It helped to identify that TK1 was described to bind
with CDKN1A according to (Huang and Chang, 2001). This association
would then perturb the DNA synthesis inhibitory function of CDKN1A,
thus blocking its DNA repair activity. Similarly, in (Ramachandran et al.,
2004) have been described interactions occurring between CDC45L and
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CDKN1A (and with CDKN2A as well), found to be binding together. As
well, CDKN1A was found connected to DTL by IPA R© according to (Abbas
et al., 2008). They showed an involvement of both features in ubiquitylation
activity.
The results obtained with the global population showed as well an inter-
esting hub concentrating several important interactions towards FBP1: 21
links with some of the most important positive and negative scores (from
11.21 to 50.52, and from -13.57 to -45.06). Interestingly, FBP1 transcript
has been recently described as a regulator of c-myc, a well known proto-
oncogene, in renal cancer (Weber et al., 2008), they described as well its
frequent up-regulation in urothelial and prostate cancers, suggesting an im-
portant role in such tumour regulation. However, no evidence has been
found of its implication in breast cancer until now. Nevertheless, this gives
an important new confirmation of the relevance of what has been predicted
by the approach, thus validating the findings.
The chapter described as well that, by selecting two different isoforms of
two genes (PECI and TSPYL5) in the feature selection step, the approach
has been able to pick up this artifact by predicting as the most highly
interacting genes the 2 isoforms for both genes. Both isoforms of PECI
were predicted with a score of 37.82 and 47.39 ranking respectively 5th and
second in the global population with the van’t Veer dataset. For TSPYL5,
the two isoforms were found to be interacting with scores of 37.60 and
59.36. However, these two last interaction pairs, despite their very high
scores, showed lower consistency (coefficients of variation of 0.24 and 0.35)
and only ranked respectively 361st and 957th out of 9,900, explaining why
these pairs did not appear in Table 5.4.
It is interesting to note as well that, the isoforms of the two genes were
all predicted with positive scores, which one would expect considering they
have the same pattern of expression. This suggests that the scoring system
has reached an interesting level of accuracy in terms of signs of scores, at
least for positive scores, but still requires further improvements.
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To confirm the consistency of the findings, the comparison with the
NKI295 cohort showed as well that amongst the highest interaction scores
were found again the isoforms of both PECI and TSPYL5 (32.73 and 23.25
for PECI, and 64.5 and 25.83 for TSPYL5). These similar results between
the two cohorts suggest an encouraging reproducibility of the method and
the algorithm.
The comparison of the results for the population of the van’t Veer study
and the NKI295 study showed that amongst the 50 highest predicted in-
teraction scores, 13 pairs (26%) were common in the positive scores, and
8 pairs (16%) in the negative scores. Although not perfect, these results
proved an encouraging reproducibility of the algorithm and the method.
The analysis of the interactions occuring in the 2 subpopulations (good
and poor prognostic groups) offered an interesting perspective for the anal-
ysis of the results. Splitting the populations in subgroups offers the ability
to identify the potential changes occuring in the dynamic of the interactions
between the groups. Identifying these patterns could then stress important
dysregulation and provide new insight toward future therapeutic angles.
The study of the altered interaction in the van’t Veer cohort showed
some strong values as well, depicting really higher interactions taking place
in the GPG, and others really higher in the PPG. The most altered inter-
action, increased in the GPG (red edges in Figure 5.14) is the one from
PDHA1 toward TEF. As discussed, several important alterations could be
observed between the two groups. These alterations involved TEF, TTL7,
or ZNF222. No clear evidence of these altered interactions could be found in
the literature and therefore validating such results is really difficult. How-
ever they offer the potential of new interesting leads toward novel therapeu-
tic approaches or management in breast carcinomas.
The conjunction of all these aspects allowed to initiate the process of
validation of the method after the first level of validation with the simu-
lated dataset. These real world data showed interesting preliminary results
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by the method developed.
153
Chapter 6
Conclusion and discussion
6.1 Preamble
The recent advances achieved lately by important technological innova-
tions has pushed forward the ability of the scientific community to enhance
discovery, and, as a consequence, improve our knowledge of our environ-
ment. This is particularly true for the biomedical sciences. The latest
technological achievements have incredibly enhanced the possibility for re-
searchers to explore and discover the physiology or the physiopathology of
some particular disease. It is now almost possible to assess the expression of
the entire genome for an organism, even for a human individual (Ishkanian
et al., 2004).
However, technological achievements may not always be met by the ap-
propriate tools to properly analyse and interpret their output. The delay in
time between new technologies and the emergence of the most appropriate
tools to interpret their output can lead to misinterpretation, or even worse
to wrong conclusions and false discovery. It is crucial that, besides the pro-
duction of new technologies, a careful interpretation of the results is carried
out.
Furthermore, although satisfactory analysis tools may see the day for the
appropriate analysis of the output for a particular technology, they might
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offer a robust but yet superficial interpretation of the amount of data pro-
vided by such high-throughput technologies.
This motivated the reason why one of the aims of this study was to
develop a new approach for deeper exploration of the potential information
being held within an expression MA dataset.
It was sought, within this study, to develop, optimise and apply robust
computational solutions to accurately identify potential markers specific to
a question within a disease system, and subsequently identify the potential
patterns of relationship between the markers of interest with an innovative
ANN-based approach. The original contribution stood in the optimisation
implemented in the existing approaches, and more importantly in the de-
velopment of an original ANN based algorithm with the scope of interaction
network inference.
6.2 Stepwise analysis and biomarker discovery
There has been a decade now since the appearance and rise of genomic
MAs, which allowed an increasing screening over the years for gene ex-
pression level, assessed against particular phenotypes to identify key genes
involved in different disease systems, or cell conditions. However, we have
seen that despite this decade of research, relatively few biomarkers have
emerged from this technology despite the great potential they carry for this
purpose (Rifai et al., 2006).
This manuscript demonstrates that these technologies, and in particu-
lar their output, need to be appropriately addressed by robust and reliable
methods in order to get the most accurate results; and we have shown the
development and optimisation of one particular algorithm involving ANNs
with the scope to investigate for potential biomarkers related to a question
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within a particular system like a disease (e.g. breast cancer). These meth-
ods have provided with interesting results, and have provided already with
new potential biomarkers with the possibility to develop assays from them
for future clinical routine application.
Among these newly identified biomarkers, this thesis reviewed the iden-
tification of CA9 as a marker of prediction for metastatic risk for breast can-
cer patients. The study involved the van’t Veer breast cancer cohort (van’t
Veer et al., 2002) for which the originally developed Stepwise algorithm
identified a smaller and more accurate fingerprint than the 70 gene model
presented by van’t Veer and coworkers and applied in the Mammaprint R©
test. The identification of CA9 was further validated by immunohistochemi-
cal staining from pathologists confirming the validity of CA9 as a biomarker
for breast tumours, but confirming as well the robustness of the approach.
More details can be found in the published paper (Lancashire et al., 2009b).
The further optimisation of the method has carried great improvements,
mainly standing in a more reliable and accurate solution, but more impor-
tantly a faster one. The redevelopment using the C programming language
allowed great efficiency to increase the speed of execution. It has been
demonstrated that the number of 50 MCCV repeats show a good balance
between time of execution with the modelling performance obtained.
It has been demonstrated as well that this solution has already given
insight in some important applications, particularly in breast cancer; and
some results were even validated by in vitro experimentation. This was illus-
trated by the example of applications presented previously where miRNAs
could be related to be important in subclasses of breast cancer. The opti-
mised Stepwise approach successfully identified sets of miRNAs predictive
of ER, PR and HER2/neu status in breast cancer. Subsequent RQ-PCR
investigations confirmed the presence of the miRNAs identified for each sig-
nature, confirming the validity of the model developed and the rosbustness
of the approach.
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As a result, the two studies discussed in these first chapters demon-
strated the strength of the approaches developed, and the reliability of the
models, signatures and markers identified.
6.3 Interaction algorithm
Within this study it was mainly sought to develop an algorithm for the
exploration of interactions between genes within gene MA data. This al-
gorithm uses a multifactorial ANN based approach to model the potential
interactions. This approach, incorporating an ANN based interaction map-
ping, offers the potential to identify key components and interactions in a
multifactorial fashion overcoming the limitations from previous studies with
simple pairwise interaction inference methods, or based upon biomolecu-
lar functions; and facilitating the identification of unidirectional influences.
Moreover, the reliability of ANNs will offer the benefit to incorporate mul-
tiplatform data for exploration, and therefore not only focus on a particular
system, but investigate on a wider scale for cross-platform interactions (e.g.
gene expression level in DNA with mRNA transcripts). However, for such
cross-platform application, extreme care need to be taken as mentioned
by Bitton et al. (Bitton et al., 2008). The inherent variability from one
experiment to another would introduce a bias that would not allow valid
conclusion to be drawn.
6.3.1 Optimisation
Chapter 3 demonstrated the development, and moreover the optimisa-
tion of the interaction algorithm and the method for its application. It
showed great improvements after optimisation, in terms of predictive abil-
ity of correlated and interacting pairs of markers. In addition, it allowed
identification of the most accurate scoring algorithm and optimal number
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of hidden nodes for the optimal balance between accuracy and time con-
sumption. This led to an important leap towards a more effective algorithm
that enabled more advanced validation step as shown by the results with
the simulated dataset.
6.3.2 Validation
Previously, as discussed in the second chapter, Lancashire and cowork-
ers (Lancashire et al., 2009a) identified a rank order of genes of biological
relevance to metastasis from the van’t Veer cohort (van’t Veer et al., 2002).
CA9, appeared as the strongest feature from the screening step. The inter-
action algorithm presented here showed CA9 to have a strong interaction
with PCK1, both already described to interact and to be involved in breast
cancer (Winter et al., 2007). Moreover, DTL, known to have a role in cancer
cell proliferation (Crowe et al., 2003), has been found to be strongly influ-
enced within the whole interactome. We have shown other features with
biological significance, which helped to start building the validation for the
method developed.
We have seen that, despite the difficulty to confirm the results with
IPA, it was possible to identify potential relations between genes or gene
products predicted by the algorithm with IPA via intermediate molecules.
In addition it has been possible to overlap with some results of previous
groups (Gevaert et al., 2006), particularly for the relation between CDC45L,
TK1 and DTL again. Finally, we have shown, using a larger cohort of
patients, that the algorithm was able to show encouraging results regarding
reproducibility, with results and particularly interaction scores for gene pairs
matching between the two cohorts.
The possible reasons why definite validation of the results could not be
obtained are:
• There might be biases introduced by the technical experimentation
for the MA, resulting in artifacts of the expression monitored from
one gene to another.
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• IPA only provides a database compiling what has been reported in the
literature. Therefore, there is a chance that the interactions requested
have not been published yet.
• Interactions could be identified only with intermediate molecules with
IPA due to the low number of genes interrogated (100).
• Actual interactions might not be identified by the algorithm if they
only take place under some particular conditions, or might be hidden
among the others due to the heterogeneity of the population.
6.3.3 Advantages
The method described here brings some novelties to existing approaches
discussed in the introduction. The ANN technology coupled with a robust
cross-validation technique constitute an efficient solution and allow the com-
plexity and bias induced by expression array technologies to be overcome
(Hart et al., 2006). One of the main advantages compared to other pro-
posed techniques stands in the consideration of the overall panel of genes
rather than just single ones in a pairwise fashion or subgroup. However, the
scoring system based on a weight analysis of the ANN does not yet permit
a comprehensive analysis of a broad panel of genes, and this will require
further work.
Additionally, the optimisation process coupled with the artificial dataset,
allowed to assess and even to significantly improve one of the most important
aspect of network inference modeling tools: true positive rate (Goldberg
and Roth, 2003). It is important to clearly understand and be aware of
the level of confidence it is possible to have in the results of the inferred
network, and the optimisation work carried out and presented in this thesis
gives the opportunity to have an idea of how genuine is the interaction map
deciphered.
Furthermore this novel approach, contrary to most alternatives, has the
potential to be applied to several types of data from different technologies
like MS for exploring interactions between peptides or proteins.
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6.3.4 Limitations
Nonetheless, despite encouraging primary validation, the approach may
have few limitations. Firstly, one of the main limitations may come from
the origin of the data itself. Indeed, we are well aware that the collection of
experimental data involves a certain level of bias. However, as we can only
investigate and explore for relative interactions, none of the interactions are
absolute, but relative to all the others within the dataset. Such a limitation
is not a constraint as far as the same procedure was employed for the whole
dataset, but would have an increased influence once the approach is applied
to a cross-platform dataset, investigating transcriptomics data for instance,
and such an application will require extreme care in normalisation (Bitton
et al., 2008).
Another important limitation has been highlighted by the validation
with Ingenuity. Although the algorithm described here considers the mark-
ers in a multifactorial approach, it still suffers from the limited amount of
genes that can be explored. Only very few connections could be confirmed
using IPA, in an indirect way in addition. Since not all the gene products
are questioned, there might be important features of connection missed by
the algorithm. The restriction of taking 100 markers to investigate their po-
tential relationships reaches the limit of validation, and it is highly unlikely
that out of the 100 markers, they have been directly described to be inter-
acting. However, we have been able to find, with the help of the literature
and IPA that, even if some markers have not yet been described directly,
indirect pathways may have been described, and show that there is a likeli-
hood that what was predicted could actually be what is really taking place
in vivo. Nevertheless, this highlights a major limitation, maybe not for the
algorithm, but more for the method, and particularly the feature selection
step. Reducing the system to only 100 markers can give a biased insight.
The awareness of this limitation, is crucial, and it needs to be addressed.
Another limitation could be identified as well, coming from the com-
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plexity of the overall interactome obtained which appeared to be important
too, and the relevance of the filtering strategy employed has been shown to
be critical (c.f. chapter 3). It will be challenging to propose and address
alternative filtering strategies and be able to only keep the most accurately
predicted and significant interactions, meanwhile not to remove any inter-
action that can have relevance in the actual interactome. In chapter 3, it
has been demonstrated that a relevant filtering method could increase the
true positive rate (i.e. the number of interactions actually taking place out
of the total number of interactions predicted by the algorithm) up to 70%
in average (for 2 hidden nodes and top 100 selection).
But the most important limitation here stands in the modelling process.
The expression level of the gene considered as output in the ANN is mod-
elled in a categorical fashion. The other genes are then used to predict, by
training the ANN, if the targeted gene is over or under expressed compared
to its median value accross the overall population. Therefore a lot of infor-
mation is missed as it is simplifying an analogic problem in a numeric way,
reducing the precision that could be acquired by using the continuous data
of the actual expression values.
Therefore, this tool, although not entirely validated, provides an insight
to what can happen in interactions and offers trails to follow for future
interaction studies on the bench.
6.3.5 Future work
Re-development of the method
One of the main limitations so far within this algorithm stood in the
prediction of a categorical (binary) output, as discussed previously. This
is one of the first and most critical improvements to carry out, by using a
continuous output for the ANN. It will then be interesting to reassess the
complete study with the artificial dataset, and compare the improvement of
performance with the previous results.
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Another interesting challenge to tackle will be the display strategy, we
have seen that another consideration can be a heatmap, and it would be an
interesting development of the program.
A crucial final point to work on will be the number of inputs integrated
in the interaction analysis. Unless studying simple organisms, it is unlikely
that a system can be reduced to a pool of 100 genes. Therefore, for accu-
rate and meaningful results, the program needs improvements in terms of
feature selection and coping with higher inputs for the scoring algorithm.
Further validation
Further validation is required in order to confirm the findings of the al-
gorithm and subsequently validate the method itself. The next objective
would be to validate it against existing concurrent methods such as bayesian
network-based methods (Hartemink et al., 2002; Jansen et al., 2003; Need-
ham et al., 2009), as it as been carried out with IPA and the Gevaert method
(Gevaert et al., 2006) in this work. Although, since no gold standard method
has been described and fully validated to date, due to the youth of this do-
main, developing a validation protocol would be challenging, and require
a certain amount of time. Nevertheless, beside using alternative in silico
based techniques, the ultimate validation of the findings would be in vitro
or in vivo techniques, using for instance gene silencing techniques. The
observation of the interaction between 2 molecules could be validated by si-
lencing the expressing gene of one of them, and monitor the effect it might
have on the other one. Although conducting such a project would become
really time consuming and require a multidisciplinary project and team.
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Range of applications
Cross platform applications (miRNAs and cDNA for miRNA targets), or
even transcriptomics (mRNA, cDNA) can be considered as potential future
applications. However, as discussed previously, multi-experiment datasets
would hold biased informations, and in addition extreme care needs to be
taken when considering post-transcriptional alterations (e.g. alternative
splicing) that take place in a living organism.
We have seen that, despite the fact it may suffer from some disadvantages
and limitations and needs to be further improved, it is clear, according to our
preliminary results, that a novel powerful ANN-based tool for interaction
discovery has been developed in its early stages. This has the potential to
investigate biological systems further, and possibly discover new potential
targets for therapies.
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Abstract Gene expression microarrays allow for the high
throughput analysis of huge numbers of gene transcripts
and this technology has been widely applied to the
molecular and biological classification of cancer patients
and in predicting clinical outcome. A potential handicap of
such data intensive molecular technologies is the transla-
tion to clinical application in routine practice. In using an
artificial neural network bioinformatic approach, we have
reduced a 70 gene signature to just 9 genes capable of
accurately predicting distant metastases in the original
dataset. Upon validation in a follow-up cohort, this signa-
ture was an independent predictor of metastases free and
overall survival in the presence of the 70 gene signature
and other factors. Interestingly, the ANN signature and
CA9 expression also split the groups defined by the 70
gene signature into prognostically distinct groups. Sub-
sequently, the presence of protein for the principal
prognosticator gene was categorically assessed in breast
cancer tissue of an experimental and independent valida-
tion patient cohort, using immunohistochemistry. Impor-
tantly our principal prognosticator, CA9, showed that it is
capable of selecting an aggressive subgroup of patients
who are known to have poor prognosis.
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Introduction
Breast cancer is a heterogeneous disease where the outcome
and response to therapy is often uncertain due to the com-
plex network of overlapping and interacting molecular
pathways. New strategies are needed to maximise thera-
peutic outcomes while limiting unnecessary over-treatment,
achievable through customised treatment regimens. Previ-
ous studies have shown the ability of microarrays [1] to
successfully predict clinical outcome in a variety of
malignancies [2–6]. In particular, the molecular classifica-
tion of malignant breast tumours using high throughput
technologies including expression arrays and immunohis-
tochemistry screening on tissue microarrays (TMAs), has
successfully identified a number of biologically relevant
subgroups [5, 7–10], showing good association between
group membership and prediction of clinical outcome, tar-
geted treatment and sensitivity to therapeutics [11–13].
Although there has been little overlap between different
studies, more recent meta-analyses have demonstrated
that different signatures identify similar groups of patients
who have tumours with high proliferation rates [14, 15].
However, these meta-analyses have also demonstrated that
most signatures reported to date have a relatively poor
discriminatory power in oestrogen receptor negative disease
[15]. Determining an optimal subset of predictive markers
from microarray data is daunting due to the number of
potential biomarker combinations present in these complex
datasets. As an example, the seminal gene expression array
data of van’t Veer et al. [13] comprised in excess of 24,000
variables (gene transcripts) per sample. More recent gen-
erations of gene chip now contain in excess of one million
variables, further highlighting the requirements for robust
computational analysis methods and emphasising the dif-
ficulties in translating these results to routine clinical
practice.
Given the obvious advantages of analysing high density
microarrays offering large (or even complete) genome
coverage, powerful approaches are required for determin-
ing prognostic gene subsets in breast cancer. One such
approach utilises Artificial Neural Networks (ANNs) to
assess the prognostic potential of each gene transcript
individually in a univariate procedure, and then adding
further genes in a sequential, multivariate manner to
improve upon the classification accuracy [16]. ANNs are a
form of artificial intelligence inspired by learning in human
neuronal systems and have been shown to be capable of
modelling complex systems with high predictive accura-
cies on blind data [3, 17–19]. ANN models are developed
by iteratively changing a network of weights, in response to
predictive error. Predictions are made by mathematically
modifying weights generated from input values (e.g. gene
transcript intensity), in turn producing a predicted output
value (for example, predicted survival). Moreover, the
importance of the individual inputs in generating these
predictions may be determined to define optimal subsets of
biomarkers within the system being analysed. In a previous
study [16], we developed a novel iterative stepwise
approach to ANN modelling. In this study, we have applied
ANN to van’t Veer’s dataset [13] to determine a minimal
set of biomarkers required for the prediction of metastasis
in patients with breast cancer. We identified a panel com-
prising just nine genes predicting tumour metastasis with
98% accuracy. The principal prognostic indicator had a
prediction accuracy of 70% when used independently in
the model and was found to be the hypoxia-associated
enzyme carbonic anhydrase IX (CA9). The prognostic gene
panel was validated on a second gene expression dataset
consisting of 295 cases [20], with CA9 expression dis-
playing an accuracy of 63% in predicting the development
of metastasis in a categorical yes/no fashion. This increased
to 66% when the remaining genes in the signature were
included and was shown to be an independent predictor of
both overall survival and metastasis free survival in this
second cohort. Consequently, we investigated the immu-
nohistochemical protein expression of CA9 as a prognostic
and predictive indicator in an independent patient TMA
containing 552 unselected breast cancers, and in 390 full-
face breast excision tumour blocks comprising an experi-
mental and validation cohort of 160 and 230 patients,
respectively.
Materials and methods
ANN model development to identify a prognostic gene
signature for metastasis
The ANN modelling used a supervised learning approach,
multi-layer perceptron architecture with a sigmoidal
transfer function, where weights were updated by a back
propagation algorithm [21]. Learning rate and momentum
were set at 0.1 and 0.5 respectively. The ANN architecture
utilised five hidden nodes in the hidden layer and ran-
domised initial weights. The output node was coded as 0 if
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the patient showed no evidence of metastasis within
5 years, and 1 if metastasis was evident. Data were
downloaded in Microsoft Excel format from http://www.
rii.com/publications/2002/vantveer.html. This initial set
consisted of 78 samples each with 24,481 corresponding
variables specifying the Log10 expression ratio of each
gene. Prior to ANN training, the data was randomly divi-
ded into three subsets; 60% for training, 20% for validation
(to assess model performance during the training process)
and 20% for testing (to independently test the model on
data completely blind to the model). This Monte–Carlo
cross validation procedure [22] avoids over-fitting of the
data, and has been shown to outperform and to be more
consistent than the commonly used leave-one-out cross
validation [23, 24], which may be a poor candidate for
estimating the prediction error [25].
The forward stepwise approach to biomarker identifi-
cation using ANNs has been previously described in detail
(for specific details the reader is referred to [16]). This
method develops a predictive model containing a parsi-
monious gene expression signature accurately classifying
the cases according to the development of metastasis.
Receiver Operating Characteristic (ROC) curves were
generated to provide statistics regarding the sensitivity,
specificity and area under the curve (AUC) of the model.
Patient selection and TMA preparation
Six paraffin processed TMA blocks containing 555 con-
secutive primary operable invasive breast carcinomas from
patients involved in the Nottingham Tenovus Primary
Breast Carcinoma Series between 1986 and 1993, were
used as detailed previously [10]. The TMA construction
involved sampling donor tissue cores from the tumour
periphery and avoiding regions of obvious necrosis. In
addition, 160 full face paraffin blocks of breast cancer were
selected for comparison because of observed heterogeneity
of CA9 distribution using immunohistochemistry. All cases
used in this study are well characterised and have data on
tissue protein expression for tumour-relevant biomarkers,
comprehensive pathology and long term clinical follow-up
data [10] including information on local, regional and
distant tumour recurrence, and survival outcome. Patients
with ER positive tumours were treated with adjuvant
endocrine therapy whereas patients with a moderate and
poor Nottingham Prognostic Index received chemotherapy.
CA9 protein expression was further validated on a cohort
of 245 patients diagnosed and managed at the Royal Marsden
Hospital (RMH) between 1994 and 2000. Patients were
selected on the basis of being eligible for therapeutic surgery,
being followed up at the RMH, having representative his-
tological blocks in the RMH pathology files, and receiving
standard anthracycline-based adjuvant chemotherapy. All
patients were primarily treated with therapeutic surgery
followed by anthracycline-based chemotherapy. Adjuvant
endocrine therapy was prescribed for patients with ER
positive tumours (tamoxifen alone in 96.4% of the patients
for the available follow-up period). Complete follow-up was
available for 244 patients, ranging from 0.5 to 125 months
(median = 67 months, mean = 67 months). Tumours were
graded according to a modified Bloom–Richardson scoring
system [26] and size was categorised according to the TNM
staging criteria. The project was approved by the Ethics and
R&D committees at NUH and RMH.
CA9 immunohistochemistry and morphometry
Four micron thick paraffin-processed TMA and full face
sections were subjected to microwave antigen retrieval in
citrate buffer (pH 6.0), and then immunohistochemically
stained with an antibody against CA9 on a TechMate im-
munostainer (DakoCytomation, Cambridge, UK). The CA9
rabbit polyclonal antibody (Abcam 15086, Cambridge,
UK) was used at an optimised working dilution of 1:2,500
with a labelled streptavidin biotin (LSAB) technique.
Sections were counterstained in haematoxylin and mounted
using DPX mounting medium. Negative control sections
had non-immune serum substituted for the primary anti-
body and positive control sections comprising high-grade
ovarian cancer with necrotic foci were included in each
immunohistochemistry run.
The immunohistochemically stained TMA and full face
sections were scored with observers blinded to the clini-
copathological features of tumours and patients’ outcome.
Staining was assessed in the cell membrane of morpho-
logically unequivocal neoplastic cells of tumours and in
stromal fibroblasts. The presence of CA9 staining in stro-
mal fibroblasts was recorded because it has previously been
suggested to be of prognostic significance [27]. Presence of
tumour membrane and fibroblast CA9 staining was recor-
ded ‘1’ for affirmative and ‘0’ for negative. Damaged tissue
cores and those that did not contain invasive carcinoma
were excluded from scoring.
Univariate and multivariate statistics
The Chi square test was used for testing the association
between CA9 protein expression and other biomarkers
scored as categorical variables, to produce contingency
tables (Version 15, SPSS Inc., IL, USA). Similarly, the
presence or absence of tumour-associated membranous and
normal stromal cell cytoplasmic CA9 staining was cate-
gorically scored as positive or negative, regardless of
its extent or staining intensity. Kaplan–Meier survival
plots were produced to estimate disease-free interval
(DFI), breast cancer specific survival (BCSS) and the
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development time for metastasis formation. DFI was
expressed as the number of months from diagnosis to the
occurrence of invasive local recurrence, local LN relapse
or distant relapse. Survival rates were compared using the
log rank (Mantel–Cox) test. A P-value of less than 0.05
was deemed significant with 95% confidence intervals.
Results
Development of a signature to predict development
of distant metastasis using ANNs
ANN analysis identified a gene expression signature con-
sisting of nine genes which predicted patient prognosis
with 98% sensitivity and 94% specificity, with an AUC of
0.971 when assessed by ROC curve analysis. The overall
screening process assessed over eleven million individual
models. A summary of performance for the models at each
step is shown in Table 1 and Supplementary Fig. 1. To
further validate the model, an additional set of 19 samples
were downloaded from the same location as the first series
and used as a second order validation set, as in the original
manuscript [13]. This set consisted of 7 patients who
remained metastasis free, and 12 who developed metasta-
ses within 5 years. The novel nine gene expression
signature correctly diagnosed all 19 samples, further
emphasising the models predictive power. The response
curves for these genes were also analysed, with seven of
the nine having strong discriminatory responses (Supple-
mentary Fig. 2 shows the response curve for CA9. The
association between increased expression and development
of metastases is clearly seen).
As seen in Table 1, four of the nine genes showed a
positive association between increased expression and the
probability of developing distant metastases, as output by the
model. Of those four genes, CA9 gave the highest accuracy
(70%) for predicting metastases. On the contrary, three genes
showed an inverse association between increased expression
and the predicted likelihood of metastases. In addition, two
genes showed a weak response in the predicted probability of
developing metastases, possibly modulating the responses of
other genes in an additive fashion.
Validation of ANN findings
Since the ANN gene signature was capable of predicting
the development of metastases to a high degree, the
expression of these genes were further explored and vali-
dated using the NKI295 dataset [20] which includes gene
expression data for a 295 patient cohort. Using the ANN 9
gene signature to classify this series of cases into two
groups showed a significantly reduced overall survival
(P \ 0.001) and metastasis free survival (P \ 0.001)
between groups in univariate Kaplan–Meier analysis
(Supplementary Fig. 3). Interestingly, the ANN signature
was also able to split the groups defined by the original 70
gene signature into prognostically distinct groups
(P \ 0.001). In a multivariate Cox regression model
adjusted for age, nodal status, tumour size, ER status,
therapy type (chemotherapy or hormonal) and van’t Veer’s
70 gene signature, the ANN signature was shown to be an
independent predictor of metastasis free survival (P =
0.003, Hazard ratio = 1.92) and overall survival (P =
0.012, Hazard ratio = 1.89) in this larger cohort (Supple-
mentary Table 1a, b). Furthermore, analysis of CA9 gene
expression in the NKI295 dataset showed a significant
positive association with tumours of a basal-like phenotype
(P \ 0.001) and an inverse association with luminal type
cancers (P \ 0.001). These findings led us to investigate if
Table 1 Summary of the nine genes used in the gene expression signature at each step of model development
Step Input added Gene name Description Cumulative
accuracy (%)
Error Response
1 NM_001216 CA9 Carbonic anhydrase IX 70 0.44 Positive
2 Contig52778_RC EST 80 0.38 Weak
3 Contig35076_RC EST 83 0.38 Negative
4 Contig40557_RC FLJ13409 EST 87 0.35 Positive
5 AB032973 LCHN LCHN protein 80 0.40 Positive
6 AB004064 TMEFF2 Transmembrane protein with EGF-like
and two follistatin-like domains 2
95 0.23 Positive
7 NM_006101 HEC/KNTC2 Kinetochore associated 2 95 0.22 Weak
8 AF161451 HSPC333 HSPC337 96 0.17 Negative
9 Contig33475 EST’s 98 0.15 Weak
Table details the identity of the input added at each step, the gene name (where known) and description. The model accuracy and error when
applied to the independent validation data splits are also shown, together with the direction of response of the gene as it correlated with
metastases
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our gene expression findings could be translated into a
routine immunohistochemistry practice for the principal
prognosticator CA9.
CA9 protein distribution in breast tumours
within the Nottingham patient cohort
CA9 staining was heterogeneously distributed in the cell
membrane of tumour tissue and in the cytoplasm of stromal
fibroblast. CA9 staining of tumours was predominantly
associated with necrotic glandular foci (Fig. 1a, b) but in
contrast, positively stained fibroblasts did not always show
close association with necrotic malignant tissue. In TMAs,
552 cores were readable but comparison with the full face
sections showed lack of concordance (Supplementary
Table 1). Membranous CA9 expression was under-repre-
sented in TMAs due to heterogeneity in CA9 localisation
and because of avoidance of necrotic regions during TMA
construction. Membranous CA9 expression was identified
in 26/552 (4.7%) TMA cores compared with 29/160
(18.1%) full face cases. For these reasons, only data from
the full face sections was used.
Associations between CA9 expression
and other clinicopathological variables
Membranous CA9 staining was significantly increased in
younger patients with high histological grade cancers
(P \ 0.001; Table 2). However, membranous CA9 expres-
sion showed no significant association with menopausal
Fig. 1 CA IX immunostaining (arrow) was detected in breast tumour
cell membrane (a), cytoplasm (b) and stroma (c) in TMA sections but
its frequency was reduced due to its heterogeneous localisation. The
latter is demonstrated in full face sections of ductal cancer (d),
especially in cases showing glandular necrosis (N) (e) associated with
hypoxia. Original magnification a–d 209; e 49
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status, tumour size, lymphovascular invasion (P = 0.056)
or lymph node metastases (P = 0.051; Table 3a, b).
Membrane expressing tumours showed a strong negative
association with the steroid hormonal receptors (HR) [ER,
PgR and androgen receptor (P \ 0.001 each)], and the
luminal cytokeratin CK19 (P = 0.015). Importantly, tum-
ours expressing membranous CA9 showed a triple negative
phenotype (ER-, PgR-, HER2-) [28] and expressed basal-
like markers [CK5/6 (P = 0.001), CK14 (P = 0.02),
BRCA1 nuclear positivity (P = 0.002), p53 (P = 0.001)
and P-cadherin (P = 0.01). No association with E-cadherin
expression was seen (Table 3a, b).
Fibroblast expression
Stromal fibroblast CA9 staining was seen in 26 (16%)
cases; 5 of them showed coexisting membranous and
stromal cell CA9 expression (Table 2). Stromal expression
showed no significant association with tumour size or
menopausal status (Table 3c, d). CA9 expression showed a
trend towards association with p53 (P = 0.06) and lymph
node involvement (P = 0.051), but showed no signifi-
cant associations with the other clinicopathological vari-
ables including HR, E-cadherin, HER2, CK56 or CK14
(Table 3c, d).
Survival analysis
No significant association between membranous CA9
immunohistochemical expression in cancer cells or stromal
cells was observed with BCSS, DFI or local/regional
recurrence.
CA9 protein expression in the validation patient cohort
CA9 protein expression was validated in a cohort of 245
patients, of which 230 could be evaluated for CA9
immunohistochemical expression. Membranous CA9 pro-
tein expression was present in 29 cases. Similar to the
experimental patient group, the validation cohort showed a
significant negative association with ER and PgR expres-
sion (Table 3a, b), and was significantly associated with
triple negative basal-like tumours (P \ 0.001). Similar to
the Nottingham patient group, the validation group showed
no significant association between CA9 expression in
cancer cells or fibroblasts and other clinicopathological
variables including tumour size, vascular invasion, or
patients’ outcome in terms of BCSS and DFI. However,
CA9 staining in the validation group differed in showing a
negative significant association with ER (P = 0.033),
CK5/6 (P = 0.01), and CK14 (P = 0.001), and an absence
of borderline association with lymph node involvement
(P = 0.268; Table 3c, d).
Discussion
The aim of our study was to derive a minimal gene
expression signature predictive of the outcome of breast
cancer patients by applying an ANN approach to analyse a
previously published dataset of breast cancer [13]. We
hypothesised that this signature would be capable of pre-
dicting survival to at least the degree of accuracy obtained
in the original study. Using an ANN approach developed
specifically for the identification of optimal biomarker
subsets in complex data, we found just nine genes were
necessary to predict metastatic spread with sensitivity of
98%. This compares favourably with the computational
approach used in the original manuscript [13] that resulted
in the identification of a prognostic panel comprising 70
genes with a prediction accuracy of 83%. The principal
prognostic indicator in our signature was identified as CA9,
and this gene correctly predicted metastasis in 70% in the
original cohort (van’t Veer’s) and in 63% of the validation
Table 2 Distribution of patients according to localisation of CA9 immunostaining by age, tumour grade and lymph node involvement
Cytoplasmic staining Membrane staining Fibroblast staining
Age distribution
Grade 1 51 (39–59) 44 (44) 55.6 (54–57)
Grade 2 54.5 (28–69) 53.5 (51–56) 49 (41–69)
Grade 3 47 (25–66) 48.8 (25–66) 51.1 (28–67)
CA9 distribution (%) CAIX (?) CAIX (-) CAIX (?) CAIX (-) CAIX (?) CAIX (-)
Grade 1 8/89 (95.5) 20/71 (71.8) 1/29 (3.4) 26/131 (19.8) 3/26 (11.5) 24/134 (17.9)
Grade 2 26/89 (30.8) 31/71 (50) 3/29 (10.3) 54/131 (41.2) 7/26 (26.9) 49/134 (36.5)
Grade 3 55/89 (57.5) 20/71 (15) 25/29 (86.2) 49/131 (37.4) 16/26 (61.5) 55/134 (41)
Node involvement (%)
Lymph node negative 85/89 (95.5) 51/71 (71.8) 28/29 (96.5) 106/131 (80.9) 25/26 (82) 105/134 (78.3)
Lymph node positive 4/89 (4.5) 20/71 (28.2) 1/29 (3.4) 23/131 (17.5) 1/26 (3.8) 23/134 (17.1)
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Table 3 Association between CA9 IHC protein expression with biological markers and clinical parameters assessed in full face sections of
breast tumours, according to the cytoplasmic, membranous, or stromal staining pattern of localisation
Parameter Experimental cohort Validation cohort
Number of samples (%) v2 P value Number of samples (%) v2 P value
CA9(-) CA9(?) CA9(-) CA9(?)
a
Tumour size
Small 59 (88.1) 8 (11.9) 3.194 0.074 180 (86.5) 28 (13.5) 3.117 0.210
Large 70 (76.9) 21 (23.1) 12 (85.7) 2 (14.3)
Menopausal status
Premenopausal 41 (74.5) 14 (25.5) 4.567 0.102 – – – –
Postmenopausal 72 (85.7) 12 (14.3) – – – –
ER
Negative 24 (53.3) 21 (46.7) 27.196 \0.001 28 (66.6) 14 (33.3) 16.946 \0.001
Positive 87 (91.6) 8 (8.4) 161 (90.9) 16 (9.1)
PgR
Negative 38 (64.4) 21 (35.6) 13.746 \0.001 41 (74.5) 14 (25.5) 8.586 .003
Positive 73 (90.1) 8 (9.9) 148 (85) 16 (15)
AR
Negative 23 (56.1) 18 (43.9) 16.401 \0.001 – – – –
Positive 79 (87.8) 11 (12.2) – – – –
P-cadherin
Negative 53 (86.9) 8 (13.1) 4.110 0.043 – – – –
Positive 56 (72.7) 21 (27.3) – – – –
E-cadherin
Negative 47 (87.0) 7 (13.0) 2.984 0.084 60 (85.7) 10 (14.3) 0.055 0.973
Positive 66 (75.0) 22 (25.0) 111 (86.7) 17 (13.3)
b
c-erbb2
Negative 96 (79.3) 25 (20.7) 0.283 0.413 161 (87.5) 23 (12.5) 2.003 0.157
Positive 21 (84.0) 4 (16.0) 25 (78.1) 7 (21.9)
CK5/6
Negative 111 (87.4) 16 (12.6) 27.806 \0.001 172 (89.5) 20 (10.5) 11.685 0.001
Positive 8 (38.1) 13 (61.9) 14 (63.6) 8 (36.4)
CK14
Negative 103 (83.1) 21 (16.9) 6.456 0.011 179 (89) 22 (11) 13.089 \0.001
Positive 11 (57.9) 8 (42.1) 12 (60) 8 (40)
P53
Negative 91 (87.5) 13 (12.5) 14.276 \0.001 130 (86.6) 20 (13.4) 0.207 0.649
Positive 23 (59.0) 16 (41.0) 48 (84.2) 9 (15.8)
Vascular invasion
Absent 87 (79.8) 22 (20.2) 1.353 0.508 61 (83.5) 12 (16.4) 0.762 0.408
Present 42 (87.5) 6 (12.5) 130 (87.8) 18 (12.2)
Lymph node involvement
Absent 106 (79.1) 28 (20.9) 3.801 0.051 68 (85) 12 (15) 0.481 0.531
Present 23 (95.8) 1 (4.2) 121 (88.3) 16 (11.7)
Tumour recurrence
Absent 112 (83.6) 22 (16.4) 2.208 0.137 – – – –
Present 17 (70.8) 7 (29.2) – – – –
Overall survival – – 2.976 0.085 – – 1.310 0.253
DFI – – 2.756 0.097 – – 2.870 0.093
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Table 3 continued
Parameter Experimental cohort Validation cohort
Number of samples (%) v2 P value Number of samples (%) v2 P value
CA9(-) CA9(?) CA9(-) CA9(?)
c
Tumour size
Small 58 (86.6) 9 (13.4) 0.827 0.363 170 (81.7) 38 (18.3) 3.703 0.157
Large 73 (81.1) 17 (18.9) 14 (100) 0 (0)
Menopausal status
Premenopausal 42 (76.4) 13 (23.6) 4.567 0.102 – – – –
Postmenopausal 71 (85.5) 12 (14.5) – – – –
ER
Negative 36 (80.0) 9 (20.0) 0.183 0.669 30 (71.4) 12 (28.6) 4.562 0.033
Positive 78 (114) 16 (17.0) 151 (85.3) 26 (14.7)
PgR
Negative 51 (86.4) 8 (13.6) 0.986 0.321 42 (23.2) 139 (76.8) 2.023 0.155
Positive 64 (80.0) 16 (20.0) 13 (34.2) 25 (65.8)
AR
Negative 34 (85.0) 6 (15.0) 0.288 0.592 – – – –
Positive 73 (81.1) 17 (18.9) – – – –
P-cadherin
Negative 54 (88.5) 7 (11.5) 1.258 0.262 – – – –
Positive 62 (81.6) 14 (18.4) – – – –
E-cadherin
Negative 23 (82.1) 5 (17.9) 0.029 0.865 163 (92.6) 13 (7.4) 1.692 0.429
Positive 96 (83.5) 19 (16.5) 106 (82.8) 22 (17.2)
d
c-erbb2
Negative 9,100 (83.3) 20 (16.7) 0.161 0.688 151 (82) 33 (18) 0.100 0.751
Positive 20 (80.0) 5 (20.0) 27 (84.4) 5 (15.6)
CK5/6
Negative 104 (82.5) 22 (17.5) 0.129 0.72 164 (85.4) 28 (14.6) 6.692 0.010
Positive 18 (85.7) 3 (14.3) 14 (63.6) 8 (36.4)
CK14
Negative 101 (82.1) 22 (17.9) 1.932 0.165 173 (86) 28 (14) 16.621 \0.001
Positive 18 (94.7) 1 (5.3) 10 (50) 10 (50)
P53
Negative 90 (87.4) 13 (12.6) 3.533 0.060 129 (86) 21 (14) 5.570 0.025
Positive 29 (74.4) 10 (25.6) 41 (71.9) 16 (28.1)
Vascular invasion
Present 91 (83.5) 18 (16.5) 1.482 0.477 123 (83.1) 25 (16.9) 0.029 0.865
Absent 39 (83) 8 (17) 60 (82.2) 13 (17.8)
Lymph node involvement
Absent 106 (79.1) 28 (20.9) 3.801 0.051 63 (78.8) 17 (21.2) 1.226 0.268
Present 23 (95.8) 1 (4.2) 116 (88.5) 21 (11.5)
Tumour recurrence
Absent 113 (85.0) 20 (15.0) 1.460 0.227 – – – –
Present 18 (75.0) 6 (25.0) – – – –
Overall survival – – 1.989 0.158 – – 0.120 0.7280
DFI – – 1.431 0.232 – – 0.700 0.4034
P values refer to v2 or log rank test for overall survival. Significance level = \0.05
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cohort [20]. In this validation cohort, the ANN 9 gene
signature was showed to be an independent predictor of
both metastasis free and overall survival, and interestingly,
was able to split the groups defined by the original 70 gene
signature into prognostically distinct groups.
A further aim of our study was to investigate if our
ANN-derived minimal gene panel for predicting poor
prognosis in breast cancer could be successfully translated
into routine practice. To test this, we studied the immu-
nohistochemical localisation of the principle prognosticator
CA9 in unselected breast cancer. Carbonic anhydrases are
induced by hypoxia induced factor 1 alpha (HIF-1a) and
assist cancer cells in avoiding death by neutralising acid pH
conditions associated with hypoxia-induced glycolysis.
Furthermore, it has been proposed that CA9 promotes
tumour migration and invasion via its role in extracellular
matrix degradation and through the induction of growth
factors [29]. These important roles suggest that not only is
CA9 a key candidate prognostic biomarker for determining
clinical outcome, but because of its resistance to degrada-
tion, it could be a more robust marker of hypoxia than HIF-
1a protein [30]. Previously, a number of studies have
shown that over-expression of CA9 is functionally impor-
tant in several tumour types including colorectal [31],
cervical [32] and uterine [33] cancers, and sarcomas [34].
Although the contribution of CA9 as a prognostic marker
in breast cancer has been obscured by conflicting reports,
some authors [35] demonstrated that its expression is
associated with tumours characterised by a basal-like
phenotype and showing reduced patients’ survival,
emphasising the relationship between CA9 expression and
poor prognosis.
In this study, we found membranous expression of CA9
is associated with tumours showing aggressive features
including younger patients’ age, high grade ductal cancers,
basal-like phenotype (CK5/6?, CK14?; ER-, PgR-,
HER2-) and BRCA1 positivity. Such patients showed a
tendency towards reduced breast cancer specific survival
and disease free interval even in the absence of lymph node
involvement. It should be noted, however, that immuno-
histochemical expression of CA9 was not significantly
associated with outcome of breast cancer patients.
Immunohistochemical assessment of CA9 was shown to
be heterogeneously distributed and was frequently associ-
ated with regions showing necrotic foci. Donor tissue used
in TMA construction specifically avoided necrotic regions
resulting in under-representation of CA9 expression. For
this reason, results of full face sections were considered in
our study. Supporting our concern about the unsuitability
of TMAs for studying CA9 expression, Brennan et al. [35]
also identified a reduced frequency (11%) of membranous
expression in TMAs when compared with larger samples of
tumours.
In agreement with others [27, 36, 37], CA9 expression
was identified in the cell membrane of tumour cells and in
the cytoplasm of stromal fibroblast cells. The experimental
and validation patient cohorts were concordant for mem-
brane staining. In agreement with other studies [35, 38] our
data provide further evidence that CA9 occurs in tumours
with features of aggressive clinical behaviour, including
loss of hormonal receptors, showing poor response to
adjuvant endocrine therapy [38].Previously, it was reported
that hypoxia can down-regulate ER expression via tran-
scriptional nuclear factors and this might explain the
observation seen in the current study [39]. In addition,
hypoxia is reported to promote basal tumour-like features
(ER-/HER2-negative, CK5-positive) due to up-regulation
of SLUG gene expression [40]. Here, our data showed that
62% membrane CA9-expressing tumours significantly
associate with the basal markers CK5/6 [41], and have a
triple negative phenotype (TNP) [28], supporting the recent
findings of Van den Eynden et al. [42]. More recently, it
has been proposed that the use of five immunohistochem-
ical markers (ER-, PgR-, HER2-, CK5/6?, EGFR?)
can identify a basal subgroup with a worse prognosis
(10 year BCSS, 62%) than that seen in TNP (10 year
BCSS, 67%) [43]. We showed that 12/29 (41.3%) cases of
membranous CA9 fall in the five marker subgroup and,
similar to Nielsen et al. [43], we found no lymph node
involvement despite their poor prognosis. In addition,
16/26 (61.5%) of the membrane CA9 group were positive
for BRCA1 nuclear IHC positivity [44].
The biological significance of CA9 localization in
fibroblasts is not readily understood but it has been pro-
posed that it might be caused by the effect of HIF-1a
induction factors in these cells due to reasons other than
hypoxia [45]. Further work is required to explore the sig-
nificance of fibroblast CA9 staining.
Other genes identified in our expression signature were
more compatible with a tumour suppressor function,
including TMEFF2 and HEC. TMEFF2 encodes for a
transmembrane protein containing an epidermal growth
factor (EGF)-like motif and two follistatin domains. Our
data showed a negative correlation between TMEFF2
expression and the development of distant metastases,
supporting the study of Gery et al. [46] who showed that
TMEFF2 could suppress the growth of prostate cancer
cells. More recently [47], it was proposed that TMEFF2
suppression may contribute to the oncogenic properties of
c-Myc, thereby promoting cell proliferation, differentia-
tion, and apoptosis. HEC (also known as kinetochore-
associated 2), was shown here to be associated with
metastases with increased expression. Similar findings
have been reported [48] where HEC was identified as part
of an 11 gene signature predictive of disease recurrence
and distant metastasis in prostate and breast cancer.
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Furthermore, elevated HEC expression has been shown to
be associated with poorer prognosis in non-small cell lung
carcinomas [49], and therefore a potential target for treat-
ment of cancers, highlighted further still by Gurzov and
Izquierdo [50]. Four of the nine genes identified in our
panel represent expressed sequence tags (EST’s) and the
associated gene is therefore of unknown function. How-
ever, given their predictive capability with regard to
survival, further analysis is justified.
To conclude, using powerful ANN methodologies, we
have identified a minimal gene signature that is predictive of
outcome at least with a similar degree of accuracy to that
obtained in van’t Veer’s study [13]. Interestingly, this gene
signature was shown to have a similar accuracy in predicting
the development of metastasis and to be an independent
predictor of outcome (metastasis free and overall survival)
in a larger validation series from the same group [21].
Moreover, using immunohistochemistry we confirmed its
practical and translational application. In agreement with
van’t Veer et al. [13] we have shown that whilst single genes
are capable of discriminating between different disease
states, multiple genes in combination enhance the predictive
power of these models. Our signature predicted the hypoxic
marker CA9 as the principal indicator of poor clinical out-
come and although assessment of CA9 protein expression
showed no significant association with patients’ outcome
when compared with our prediction gene panelta, CA9
expression showed association with variables of poor
prognosis and aggressive behaviour. In particular, CA9 is
associated with basal-like and triple negative cancers. Fur-
ther studies of all nine genes in combination using
immunohistochemistry are warranted to assess the prog-
nostic value of this signature in routine practice.
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Abstract
Introduction Breast cancer is a heterogeneous disease
encompassing a number of phenotypically diverse tumours.
Expression levels of the oestrogen, progesterone and HER2/
neu receptors which characterize clinically distinct breast
tumours have been shown to change during disease
progression and in response to systemic therapies.
Mi(cro)RNAs play critical roles in diverse biological processes
and are aberrantly expressed in several human neoplasms
including breast cancer, where they function as regulators of
tumour behaviour and progression. The aims of this study were
to identify miRNA signatures that accurately predict the
oestrogen receptor (ER), progesterone receptor (PR) and
HER2/neu receptor status of breast cancer patients to provide
insight into the regulation of breast cancer phenotypes and
progression.
Methods Expression profiling of 453 miRNAs was performed in
29 early-stage breast cancer specimens. miRNA signatures
associated with ER, PR and HER2/neu status were generated
using artificial neural networks (ANN), and expression of specific
miRNAs was validated using RQ-PCR.
Results Stepwise ANN analysis identified predictive miRNA
signatures corresponding with oestrogen (miR-342, miR-299,
miR-217, miR-190, miR-135b, miR-218), progesterone (miR-
520g, miR-377, miR-527-518a, miR-520f-520c) and HER2/
neu (miR-520d, miR-181c, miR-302c, miR-376b, miR-30e)
receptor status. MiR-342 and miR-520g expression was further
analysed in 95 breast tumours. MiR-342 expression was highest
in ER and HER2/neu-positive luminal B tumours and lowest in
triple-negative tumours. MiR-520g expression was elevated in
ER and PR-negative tumours.
Conclusions This study demonstrates that ANN analysis
reliably identifies biologically relevant miRNAs associated with
specific breast cancer phenotypes. The association of specific
miRNAs with ER, PR and HER2/neu status indicates a role for
these miRNAs in disease classification of breast cancer.
Decreased expression of miR-342 in the therapeutically
challenging triple-negative breast tumours, increased miR-342
expression in the luminal B tumours, and downregulated miR-
520g in ER and PR-positive tumours indicates that not only is
dysregulated miRNA expression a marker for poorer prognosis
breast cancer, but that it could also present an attractive target
for therapeutic intervention.
Introduction
Breast cancer is a heterogeneous disease that encompasses
a range of phenotypically distinct tumour types. Underlying this
heterogeneity is a spectrum of molecular alterations and initi-
ating events that manifest clinically through a diversity of dis-
ease presentations and outcomes. Novel therapeutic
strategies are increasingly being investigated and imple-
mented, but unpredictable response and the development of
ABCG2: ATP-binding cassette sub-family G member 2; ANN: artificial neural network; BCRP: breast cancer resistance protein; bp: base pairs; ΔΔCt: 
comparative cycle threshold; E: PCR amplification efficiencies; ER: oestrogen receptor; HER2/neu: v-erb-b2 erythroblastic leukaemia viral oncogene 
homolog 2 receptors; miRNA: microRNA; PR: progesterone receptor; RQ-PCR: real-time quantitative polymerase chain reaction; RT: reverse tran-
scriptase; UTR: untranslated region.
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resistance to adjuvant therapy remain major challenges in the
clinical management of breast cancer patients.
The key to optimizing and targeting therapy lies in a more com-
plete understanding of the complex molecular interactions that
underlie breast cancer and contribute to its heterogeneous
nature. Breast-cancer-related genes have been extensively
investigated, largely through the development of high-through-
put array-based gene expression profiling platforms. The sub-
stantial datasets that have ensued have enabled us to
decipher in depth some of the molecular intricacies associated
with breast cancer, and have expanded our knowledge of the
genetic pathways associated with breast carcinogenesis,
resulting in classification systems predictive of outcome [1,2].
Breast tumours can now be classified into major subtypes on
the basis of gene expression – luminal, v-erb-b2 erythroblastic
leukaemia viral oncogene homolog 2 receptors (HER2/neu)
overexpressing and basal like – and further analysis has iden-
tified additional subtypes within the original subgroups [3].
The expression of specific genes such as the oestrogen
receptors (ERs) and HER2/neu are indicative of outcome in
breast cancer patients, and the clinically relevant subgroup-
ings are based broadly on ER/progesterone receptor (PR)/
HER2/neu status. The ability to classify breast cancers in this
manner has obvious beneficial implications for the develop-
ment of targeted therapies; multigene prognostic and predic-
tive tests have been developed, have been commercialized
and have become established as tools in breast cancer diag-
nostics [4], although as yet there is little knowledge regarding
the precise regulation of these genes and receptors.
MicroRNAs (miRNAs) are short (~22 bp), single-stranded,
noncoding RNAs that have recently been recognized as a
highly abundant class of regulatory molecules. They are
thought to regulate up to one-third of the human genome via
sequence-specific regulation of post-transcriptional gene
expression by targeting mRNAs for cleavage or translational
repression [5]. miRNAs have recently been identified as key
players in cellular processes including self-renewal, differenti-
ation, growth and death [6], all of which are dysregulated in
carcinogenesis. There is increasing evidence to suggest that
miRNAs may be responsible for a large proportion of breast
cancer heterogeneity. A number of miRNAs have been shown
to be dysregulated in breast cancer [7-10], and specific miR-
NAs functioning as regulators of tumorigenicity, invasion and
metastasis have been identified [11-14]. Furthermore, miRNA
regulation of ER and HER2/neu, known to be of prognostic
significance in breast cancer, has been demonstrated [15,16].
As each miRNA can target up to 200 mRNA sequences, and
mRNAs can have multiple miRNA target sites [5], it is probable
that further miRNA regulators of these genes remain to be
determined.
Expression profiling of miRNA to classify breast tumours
according to clinicopathological variables currently used to
predict disease progression is of particular interest. Firstly,
profiling highlights the potential to identify novel prognostic
indicators, which may contribute to improved selection of
patients for adjuvant therapy. This approach has already
shown promise with genomic signatures [2], and miRNA pro-
files appear to have superior accuracy to mRNA profiling [17].
Furthermore, the identification of miRNAs with regulatory roles
in clinically distinct breast tumour samples could identify novel
targets for therapeutic manipulation.
Despite its apparent clinical application, microarray technol-
ogy remains deficient with regard to its translation into routine
clinical practice. There has been little overlap between the
breast cancer gene sets, leading to questions regarding their
biological significance and reproducibility [18]. Array technol-
ogy is highly dependent on bioinformatics, mathematics and
statistics to produce biologically relevant results. The genera-
tion of high-complexity microarray data has necessitated the
development of novel data analysis methodologies that can
cope with data of this nonlinear and highly dimensional nature.
Current conventional methods such as hierarchical clustering
have shown limitations for the modelling and analysis of high-
dimensionality data [19].
Artificial neural networks (ANNs) are a form of artificial intelli-
gence that can learn to predict, through modelling, answers to
particular questions in complex data. The models produced by
ANNs have been shown to have the ability to predict well for
unseen data and have the ability to cope with complexity and
nonlinearity within the dataset [20,21]; these features of ANNs
means they have the potential to identify and model patterns in
this type of data to address a particular question. ANNs are
therefore able to determine patterns or features (for example,
in genes or proteins) within a dataset that can discriminate
between subgroups of a clinical population (for example, dis-
ease and control), or disease grades [22]. Indeed, this discrim-
ination has been previously demonstrated in different tumour
types [22,23]. These patterns can combine into a fingerprint
that can accurately predict the subgroups.
Our aims in the present study were to identify miRNA signa-
tures using ANNs that accurately predict the ER, PR and
HER2/neu status of breast cancer patients, thus identifying
potential biologically relevant miRNAs and providing further
insight into breast cancer aetiology and regulation.
Materials and methods
Patients and samples
Breast tumour specimens were obtained from patients during
primary curative resection at Galway University Hospital, Gal-
way, Ireland. Matched tumour-associated normal breast tissue
was also obtained from a subset of these patients where pos-
sible. Following excision, tissue samples were immediately
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snap-frozen in liquid nitrogen and stored at -80°C until RNA
extraction. Prior written and informed consent was obtained
from each patient and the study was approved by the ethics
review board of Galway University Hospital. The initial cohort
for microarray analysis consisted of 29 early-stage, invasive
ductal carcinoma breast tumour specimens. A larger cohort of
fresh-frozen breast tumour (n = 95) and tumour-associated
normal breast tissue (n = 17) specimens was used for valida-
tion and further analysis of selected miRNAs. Clinical and
pathological data relating to the clinical samples are presented
in Tables 1 and 2.
The ER, PR and HER2/neu status of the patients was deter-
mined by immunohistochemistry on formalin-fixed, paraffin-
embedded sections of clinical specimens as part of routine
pathology to guide clinical decision-making regarding adjuvant
therapy. Immunohistochemistry was performed using a rabbit
monoclonal antihuman ER antibody (clone SP1; Dako, Cam-
Table 1
Clinical and pathological data for breast tumours analysed by microarray
Number ID Age (years) Tsize (mm) Lymph node status Grade UICC stage ER PR HER2/neu Subtype
1 52 49 23 Negative 1 2A P P N Luminal A
2 53 52 30 Negative 3 2A N N P Her2 overexpressing
3 54 57 45 Negative 3 2A N N P Her2 overexpressing
4 56 51 21 Negative 3 2A P P N Luminal A
5 58 68 15 Negative 3 1 P N N Luminal A
6 59 42 22 Negative 3 2A N N N Triple negative
7 60 54 26 Negative 3 2A N P N Luminal A
8 61 35 22 Negative 3 2A P P N Luminal A
9 62 50 16 Negative 3 1 N N N Triple negative
10 63 49 25 Negative 2 2A N N N Triple negative
11 64 59 20 Negative 3 1 N P N Luminal A
12 65 58 22 Negative 3 2A P P N Luminal A
13 66 58 18 Negative 1 1 N P P Her2 overexpressing
14 67 66 22 Negative 3 2A P P N Luminal A
15 94 56 17 Negative 1 1 N N N Triple negative
16 95 48 30 Negative 3 2A N N P Her2 overexpressing
17 96 60 26 Negative 3 2A P P N Luminal A
18 97 56 29 Negative 2 2A P P N Luminal A
19 98 50 3 Negative 2 1 P P N Luminal A
20 99 40 7 Negative 1 1 P P N Luminal A
21 100 40 6 Negative 2 1 P P N Luminal A
22 101 58 35 Negative 2 2A P P N Luminal A
23 102 64 34 Negative 3 2A P P N Luminal A
24 103 66 26 Negative 1 2A P P N Luminal A
25 104 84 16 Negative 2 1 N P N Luminal A
26 105 57 7 Negative 3 1 N P N Luminal A
27 106 68 35 Negative 3 2A P P N Luminal A
28 107 40 20 Negative 2 1 P P P Luminal B
29 108 49 35 Negative 3 2A N N N Triple negative
ER, oestrogen receptor; HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors; ID, identification; N, negative 
confirmed; PR, progesterone receptor; P, positive confirmed; Tsize, Tumour size in mm; UICC, stage of breast tumour according to the 
international union against cancer staging criteria.
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Table 2
Clinical and pathological data for breast tumours in the independent validation cohort
Breast cancer clinicopathological characteristic Number of patients (n = 95)
Median (interquartile range) tumour size (mm) 23.5 (17.75 to 35.0)
Histologic subtype
Invasive ductal 80
Invasive lobular 13
Colloid/mucinous 1
Tubular 1
Tumour-associated normal 17
Intrinsic subtype
Luminal A (ER/PR+, HER2/neu-) 47
Luminal B (ER/PR+, HER2/neu+) 21
Her2 overexpressing (ER-, PR-, HER2/neu+) 11
Triple-negative (ER-, PR-, HER2/neu-) 11
Missing data 5
Grade
1 14
2 26
3 53
Missing data 2
Nodal status
Node-negative 50
N1 17
N2 17
N3 11
Oestrogen receptor status
Positive 62
Negative 32
Missing data 1
Progesterone receptor status
Positive 58
Negative 33
Missing data 4
Her2/neu status
Positive 32
Negative 59
Missing data 4
UICC stage
Stage 1 23
Stage 2a 29
Stage 2b 8
Stage 3a 14
Stage 3b 4
Stage 3c 8
Stage 4 9
ER, oestrogen receptor; HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors; PR, progesterone receptor; UICC, 
stage of breast tumour according to the international union against cancer staging criteria.
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bridgeshire, UK) and a polyclonal rabbit antihuman PR anti-
body (Dako). The Allred scoring method was used for
expression scoring of ER and PR based on proportion and
intensity. In brief, the proportion score represented the esti-
mated percentage of tumour cells staining positive (0 = 0%; 1
= 1%; 2 = 1 to 10%; 3 = 10 to 33%; 4 = 33 to 66%; 5 = >
67%), and the intensity of staining was scored as follows: 1 =
weakly positive; 2 = moderately positive; 3 = strongly positive.
The total score was derived from the following equation, a
score of 0 being negative and a score of 2 to 8 being positive:
Membranous staining was scored for HER2/neu according to
the HercepTest (Dako) as follows: 0 = negative; 1 = weak
incomplete membranous staining of > 10% cells (negative); 2
= weak – moderate complete membranous staining of > 10%
of cells (equivocal-fluorescence in situ hybridization was used
to assess amplification in these cases); 3 = strong complete
membranous staining of > 30% of cells (positive).
miRNA microarray
RNA extraction
Depending on whether samples were destined for microarray
or RQ-PCR analysis, slightly modified RNA extraction meth-
ods were employed. For the microarray experiment, total RNA
was required. Breast tumour tissue (50 to 100 mg) was
homogenized using a bench-top homogenizer (Polytron®
PT1600E; Kinematica AG, Littau-Luzem, Switzerland) in 1 ml
QIAzol lysis reagent (Qiagen, Crawley, UK). Total RNA was
isolated from homogenized breast tissue using the RNeasy®
Tissue Mini Kit (Qiagen) according to the manufacturer's
instructions. For RQ-PCR, miRNA was selectively isolated
from approximately 100 mg tissue.
Large RNA fractions (> 200 nucleotides) and small RNA frac-
tions (< 200 nucleotides) were isolated separately using the
RNeasy Plus Mini Kit and RNeasy MinElute® Cleanup Kit (Qia-
gen) according to the supplementary protocol: purification of
miRNA from animal cells. The concentration and purity of total
RNA were assessed using a NanoDrop™ 1000 spectropho-
tometer (Nanodrop Technologies, Wilmington, DE, USA).
RNA integrity was assessed using the RNA 6000 Nano
LabChip Series II Assay with the 2100 Bioanalyzer System
(Agilent Technologies, Palo Alto, CA, USA). Electrophero-
grams and gel-like images were evaluated using the Agilent
2100 Expert software (version B.02.03; Agilent Technologies,
Palo Alto, CA, USA), which generated the RNA integrity
number to ensure that only RNA of good integrity was used in
these experiments (RNA integrity number range, 7.6 to 9.5).
The miRNA concentration and purity were also assessed by
NanoDrop™ 1000 spectrophotometry. Small miRNA-enriched
fractions were analysed using the Small RNA Assay on the
Agilent 2100 Bioanalyzer.
RNA labelling and microarray hybridization
Total RNA was Cy-dye labelled and hybridized on miRNA
microarray chips as previously described [24]. Briefly, 5.5 μg
total RNA was 3' ligated to Cy dye-linked 2'-deoxyuridine-5'-
triphosphate using T4 RNA ligase (catalogue number 2141;
Ambion, Woodward, Austin, TX, USA), in the presence of
RNase inhibitor (catalogue number 2682; Ambion, Wood-
ward, Austin, TX, USA), ATP (Grade I, catalogue number
A2383-1G; Sigma-Aldrich Corp. St. Louis, MO, USA), and
polyethylene glycol 50% aqueous solution (PEG 6000, cata-
logue number 81304; Fluka, Sigma-Aldrich Corp, St. Louis,
MO, USA). Following a 12-hour to 16-hour incubation,
labelled RNA was washed in ethanol, and precipitated in
sodium acetate (3 M) using linear acrylamide. Labelled RNA
was hybridized to LNA™ miChip array platforms (Exiqon ver-
sion 7, containing 453 miRNA sequences) over 16 hours at
54°C using a rotational hybridization chamber. Arrays were
subsequently washed in varying stringency washes, rinsed,
drained and scanned using a GenePix 4000AL laser scanner
(Axon Instruments, Foster City, CA, USA).
Data processing
Images generated by the GenePix 4200AL scanner were
imported to GenePix 6 microarray analysis software (Axon
Instruments, Foster City, CA, USA). Artefact-associated spots
were removed by both software-guided and visual-guided
flags. Empty and control data were filtered out. Signal intensi-
ties were measured according to the local background sub-
traction method as a function of the median of foreground
pixels minus the median of background pixels. The median
spot intensities were then normalized to the median intensity
per chip using custom R scripts. All microarray data were sub-
mitted to the Gene Expression Omnibus [GEO:GSE15885].
Artificial neural network algorithms and architecture
Within the present study, a three-layer multilayer perceptron
modified with a feedforward back-propagation algorithm and a
sigmoidal transfer function [25] was employed (Figure 1). The
learning rate and momentum were respectively set at 0.1 and
0.5. Automatic pre-processing normalized the data between 0
and 1 for each variable. The intensity values for the miRNA for
each individual were represented in the input layer, the hidden
layer contained two hidden nodes, and the class (related to
ER, PR or HER2/neu) was represented in the output layer
coded as 0 for negative and 1 for positive.
A randomly selected subset of the cases devolved for training
purpose is presented to the network to train it (training data)
while it is constantly monitored with a randomly select subset
of unseen cases (test data). These test data are used to stop
the training process once the model has reached predeter-
mined conditions such as an optimal error value preventing
overtraining. Once training is stopped, the efficiency of the
model is further assessed by presenting a third, randomly
selected, blind subset to the model to determine performance
Percentage of positive cells intensity of staining total s+ = core
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for unseen cases not involved in the training process. This sub-
set selection process was repeated up to 50 times for ran-
domly selected subsets, a process known as Monte – Carlo
cross-validation. The suite of 50 models produced was ana-
lysed and screened for model optimization purposes.
Model optimization
An additive stepwise approach was employed (as described
previously [21]) to identify an optimal set of markers explaining
variation in the population of each of the questions explored:
ER, PR and HER2/neu status, for miRNA microarrays. In brief,
the stepwise approach consists of taking each single variable
as an input to the ANN, and training 50 submodels with
Monte–Carlo cross-validation. Each single input model subset
is then analysed and the median classification performance
(based on the predictive error for the blind test set) is deter-
mined. The median performance for all single inputs is then
analysed and the inputs ranked accordingly. The best predic-
tor input (with the lowest error) is then selected and a second
single variable added, creating a two-input model. This was
repeated for all of the variables in the dataset, and the best pair
was determined again based on the classification error. Fur-
ther inputs are then added in stepwise fashion (generating
three-input models, four-input models, and so on) until no fur-
ther improvement is obtained and an optimal model with the
best predictive performance is generated.
cDNA synthesis and RQ-PCR
RQ-PCR quantification of miRNA expression was performed
using TaqMan MicroRNA® Assays (Applied Biosystems, Fos-
ter City, CA, USA) according to the manufacturer's protocol.
Small RNA (5 ng) was reverse-transcribed using the Multi-
Scribe™-based High-Capacity cDNA Archive kit (Applied Bio-
systems). RT-negative controls were included in each batch of
reactions. PCR reactions were carried out in final volumes of
20 μl using an ABI Prism 7000 Sequence Detection System
(Applied Biosystems). Briefly, reactions consisted of 1.33 μl
cDNA, 1× TaqMan® Universal PCR Master Mix, 0.2 μM Taq-
Man® primer–probe mix (Applied Biosystems). Reactions
were initiated with a 10-minute incubation at 95°C followed by
40 cycles of 95°C for 15 seconds and 60°C for 60 seconds.
miRNA-16 and let-7a were used as endogenous controls to
standardize miRNA expression [26]. An interassay control
derived from a breast cancer cell line (ZR-75-1) was included
on each plate. All reactions were performed in triplicate. The
threshold standard deviation for intra-assay and inter-assay
replicates was 0.3. The percentage PCR amplification efficien-
cies (E) for each assay were calculated, using the slope of the
semi-log regression plot of cycle threshold versus log input of
cDNA (10-fold dilution series of five points), with the following
equation:
A threshold of 10% above or below 100% efficiency was
applied.
Relative quantification
The relative quantity of miRNA expression was calculated
using the comparative cycle threshold (ΔΔCt) method [27].
The geometric mean of the cycle threshold value of the endog-
enous control genes was used to normalize the data, and the
lowest expressed sample was used as a calibrator.
Statistical analysis of RQ-PCR miRNA expression data
The Kolmogorov–Smirnov normality test was applied; as the
values of miRNA expression displayed a non-normal distribu-
tion, data were standardized by log10 transformation. Associa-
tions between miRNA expression and standard prognostic
factors (patient age, tumour size, tumour grade, axillary nodal
status, hormonal status and HER2/neu status) were examined
using t tests, analysis of variance and Pearson correlations.
The above tests were performed in SPSS® (version 14.0;
SPSS Inc., Chicago, IL, USA). P < 0.05 was considered sta-
tistically significant.
Results
miRNA signatures predictive of ER, PR and HER2/neu 
status
Using the ANN to analyse miRNA array expression data, we
identified distinct miRNA expression signatures predictive of
ER, PR, and HER2/neu status in breast tumour samples. The
ER signature consisted of six miRNA transcripts (miR-342,
miR-299, miR-217, miR-190, miR-135b, miR-218), and dis-
criminated cases correctly with a median accuracy of 100%
when classifying between ER-positive and ER-negative phe-
notypes. Similarly, four miRNA transcripts (miR-520g, miR-
377, miR-527-518a, miR-520f-520c) were identified that pre-
E = − −( ) ×10 1 1 100/slope
Figure 1
Multilayer perceptron with sigmoidal activation function. Weights are 
adjusted at the end of each epoch by the back-propagation algorithm.
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dicted tumour PR status with 100% accuracy, and HER2/neu
status was predicted with 100% accuracy by a signature of
five miRNAs (miR-520d, miR-181c, miR-302c, miR-376b,
miR-30e) (Table 3).
These reported accuracies are from separate validation data
splits where the samples were treated as blind data over 50
models with extensive Monte–Carlo cross-validation. At each
step of the model, additional miRNA transcripts were
selected; the addition of key miRNA transcripts improved the
predictive capabilities of the signature. When there was no fur-
ther improvement in performance with regards to predictive
error, no additional miRNA transcripts were added as the sig-
natures were now considered to contain the optimum miRNAs
to most accurately model the data. Figure 2 shows the per-
formance of the models at each step of the analyses, and it is
evident that the selection and addition of key transcripts led to
an overall improvement in the error associated with predictive
capabilities of the model for blind data. After step 6, step 4 and
step 5 for the ER, PR and HER2/neu data, respectively, no fur-
ther steps were conducted as no significant improvement in
performance with regards to predictive error could be
achieved. At this point the models were considered to contain
the miRNAs that most accurately predicted receptor status.
A detailed examination of the ranked model performance for
the most predictive individual miRNA transcripts in step 1 of
the analysis is presented in Table 4. There are a number of
miRNA transcripts capable of classifying samples effectively,
independently of the miRNA ranked highest in terms of predic-
tive ability. All of these miRNAs are considered important in
step 1 of the analysis; however, they are not independent of
each other and may all explain the same variation in the data.
These miRNAs are not subsequently identified as important in
the following steps of the analysis, and as a result are not all
present in the final signatures. The miRNA signatures that are
included in the final model each explain additional variation in
the patient data, and the combination of these transcripts con-
tributes to the final predictive power of the model. Table 3
summarizes the performances of the network models at each
step of the analysis; the transcripts in this table composed the
final miRNA signatures for ER, PR and HER2/neu status,
respectively.
Table 3
Summary microRNAs used in the expression signature at each step of model development
Rank miRNA Chromosomal location Validated mRNA targets Mean squared error Median accuracy (%) Responsea
ER status
1 miR-342 14q32.2, intronic - 0.132 83.3 (+)
2 miR-299-3p 14q32.31, intergenic - 0.087 100 (-)
3 miR-217 2p16.1, intergenic - 0.07 100 (+)
4 miR-190 15q22.2, intronic - 0.06 100 (-)
5 miR-135b 1q32.1, intronic - 0.057 100 (-)
6 miR-218 4p15.31, intronic LAMB3 0.047 100 (+)
PR status
1 miR-520g 19q13.42, intergenic - 0.186 83.3 (-)
2 miR-377 14q32.31, intergenic - 0.129 83.3 (+)
3 miR-527-518a 19q13.42, intergenic - 0.086 100 (-)
4 miR-520f-520c 19q13.42, intergenic - 0.07 100 (+)
HER2/neu status
1 miR-520d 19q13.42, intergenic - 0.109 100 (+)
2 miR-181c 19q13.12, intergenic Tcl1 0.086 100 (-)
3 miR-302c 4q25, intronic Cyclin D1 0.062 100 (*)
4 miR-376b 14q32.31, intergenic - 0.050 100 (+)
5 miR-30e-3p 1p34.2, intronic Ubc9 0.047 100 (*)
Summary microRNAs (miRNAs) used in the expression signature at each step of model development for oestrogen receptor (ER) status, 
progesterone receptor (PR) status and v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors (HER2/neu) status. a(+), increased 
miRNA expression leads to increased probability of receptor positive status; (-), increased miRNA expression leads to increased probability of 
receptor negative status; (*), weak response, possibly interacting to modify the response of other miRNAs.
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Figure 2
Performance of the models at each step of the analyses. Model performance with each input addition over the course of the analysis for (a) oestro-
gen receptor (ER) status – 6 optimal transcripts. After the addition of the six optimal microRNA transcripts, the accuracy of the model has reached 
100% and there is no further improvement in the error. At this point the model is considered to contain the transcripts that most accurately model 
the data. Columns represent median model accuracy; lines represent mean squared error for the predictions at each step. (b) progesterone receptor 
(PR) status – four optimal transcripts, and (c) v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptor (HER2/neu) status – five optimal 
transcripts.
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Sample population analysis
Figure 3 shows population structures for ER, PR and HER2/
neu status. The transcript signature determined from the ANN
model was used to position patients into population structures
based upon the ANN predicted probability of the individual
falling into a given receptor status class. By ranking the prob-
abilities for individuals, the population structure is determined.
The developed ANN model may be used to predict probability
of receptor status and thus position new individuals within the
population structure.
miRNA response curve analysis
To determine the effect of each individual miRNA on class pre-
diction, the ANN model was presented with controlled input
values representing discreet intervals across the range of the
miRNA of interest (keeping all others at their mean value). The
predicted probability in the output class of interest (that is, ER,
PR and HER2/neu status) was determined under these input
conditions and response curves were plotted. This enabled an
understanding of how the miRNAs govern the tumour sample
classification by assessing the strength of response. The
response can be discriminatory (crosses the 0.5 class thresh-
old) or co-factorial (does not cross the 0.5 class threshold).
Such analysis identifies whether specific miRNA expression is
Table 4
Summary of step 1 of the stepwise analysis of the ER, PR, and HER2/neu signatures
Rank MicroRNA Chromosomal location Validated mRNA targets Mean squared error Median accuracy (%)
ER status
1 miR-342 14q32.2, intronic - 0.132 84
2 miR-520g 19q13.42, intergenic - 0.198 73
3 miR-107 10q23.31, intronic - 0.200 73
4 miR-149 2q37.3, intronic - 0.201 69
5 miR-520g-h 19q13.42, intergenic - 0.203 73
6 miR-155 21q21.3, exon AGTR1, AID, TP53INPI 0.208 70
7 miR-30c 1p34.2, intronic - 0.210 67
8 miR-382 14q32.31, intergenic - 0.211 67
PR status
1 miR-520g 19q13.42, intergenic - 0.180 83.3
2 miR-520d 19q13.42, intergenic - 0.181 83.3
3 let-7d 9q22.32, intronic SMC1A 0.185 67
4 miR-328 16q22.1, intronic CD44, BCRP 0.189 83.3
5 miR-373 19q13.41intergenic E-Cadherin, lats2 CSDC2, CD44, RAD23B 0.189 83.3
6 miR-217 2p16.1, intergenic 0.196 67
7 miR-504 Xq26.3, intronic 0.198 67
8 miR-485-3p 14q32.31, intergenic 0.201 83.3
HER2/neu status
1 miR-520d 19q13.42, intergenic 0.109 87.5
2 miR-30b 8q24.22intergenic 0.111 83.3
3 miR-217 2p16.1, intergenic 0.114 83.3
4 miR-363 Xq26.2, intergenic 0.115 83.3
5 miR-383 8p22, intronic 0.115 83.3
6 miR-377 14q32.31, intergenic 0.120 87.5
7 miR-130a 11q12.1, intergenic GAX, HOXA5 0.121 83.3
8 miR-422a 15q22.31, intergenic 0.122 83.3
ER, oestrogen receptor; PR, progesterone receptor; HER2/neu, v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 receptors.
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increased or decreased with respect to the receptor status,
providing an indication of their possible biological role.
The analysis is performed using the trained ANN model and
adjusting an input variable of interest to monitor the affect of
this adjustment on the output variable. The output, with
respect to the changing input value, is plotted to produce a
response graph. The response graphs for miR-342, miR-520g
and miR-520d* in relation to ER, PR and HER2/neu status,
respectively, are shown in Figure 4. Some miRNAs showed
that with increased expression, the probability of receptor pos-
itivity increased; conversely, other miRNAs showed that with
increased expression, the likelihood of the sample being
classed as receptor-positive decreased. This highlights poten-
tial regulatory roles for these miRNAs through inhibition of the
receptors themselves or of their co-regulators. Table 3
includes information on how the level of expression of each
miRNA correlates with the receptor status.
Coordinated expression of miRNA clusters
The expression of miRNAs from the same chromosomal loca-
tion was shown to be coordinated in our dataset. Figure 5
shows pairwise scatterplots for miRNAs transcribed from
adjacent chromosomal regions. This highly correlated expres-
sion of adjacent miRNAs is in keeping with their processing
from primary polycistronic transcripts.
Figure 3
Population analysis for receptor status. Population analysis for (a) oestrogen receptor (ER) status. Using the transcript signature from the ANN 
model, it is possible to be able to place a patient with unknown ER status within this population structure, with 100% accuracy from an ANN predic-
tion, (b) progesterone receptor (PR) status, and (c) HER2/neu status. White, receptor-negative patients; grey, receptor-positive patients. y axis, arti-
ficial neural network (ANN) prediction with 0 being a receptor-negative prediction and 1 a receptor-positive prediction. Error bars indicate a 95% 
confidence interval.
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PCR validation
To confirm expression results obtained from the microarray
analysis we carried out RQ-PCR on a subset of miRNAs.
There was good correlation in sample-to-sample expression
patterns between the two techniques (Figure 6).
Validation/interrogation of identified miRNAs
The first miRNA identified by the ANN model in relation to ER
status was miR-342. The expression of miR-342 was further
analysed in a cohort of 95 breast tumours, 17 of which had
matched tumour-associated normal tissue. RQ-PCR of mature
miR-342 in these samples showed no significant difference in
expression between tumour and tumour-associated normal tis-
sue (P = 0.6, paired t test). Within the tumour samples, the
expression of miR-342 was significantly higher in ER-positive
tumours (n = 62) compared with ER-negative tumours (n =
32) (P = 0.04, independent t test), confirming the association
with ER positivity identified in the ANN response curve analy-
sis. miR-342 expression was also higher in the HER2/neu-
positive tumours (n = 59) versus the HER2/neu-negative
tumours (n = 32) (P = 0.001, independent t test). The expres-
sion of miR-342 was highest in the luminal B subtype of breast
cancers and was lowest in the triple-negative/basal subtype (P
= 0.001, analysis of variance; Figure 7). There was no associ-
ation of miR-342 with other clinicopathological parameters,
including PR status, grade, stage or nodal status.
Figure 4
Response curves for miR-342, miR-520g and miR-520d. Response curves for (a) miR-342, (b) miR-520g and (c) miR-520d*. Figures show the 
intensity of each transcript plotted against the artificial neural network (ANN) prediction with respect to the sample being classified as either (a) oes-
trogen receptor (ER)-positive or ER-negative, (b) progesterone receptor (PR)-positive or PR-negative and (c) v-erb-b2 erythroblastic leukaemia viral 
oncogene homolog 2 receptor (HER2/neu)-positive or HER2/neu-negative. Error bars indicate 95% confidence intervals.
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miR-520g was the top-ranked miRNA in the PR status signa-
ture (Table 3) and the second-ranked miRNA predictive of ER
in step 1 of the analysis (Table 4). The expression of miR-520g
was also analysed using RQ-PCR. There was a significant
positive correlation between miR-520g microarray expression
and RQ-PCR (R = 0.4, P = 0.029, Pearson). In the cohort of
95 breast tumours with 17 matched tumour-associated nor-
mal breast tissue tissues there was no significant difference in
miR-520g expression between tumour and tumour-associated
normal breast tissue (P = 0.228, paired t test). Within the
tumour samples, miR-520g expression was significantly
higher in PR-negative breast tumours (n = 33) compared with
PR-positive tumours (n = 58) (P = 0.032, independent t test).
The miR-520g expression was also significantly higher in ER-
negative tumours (n = 32) compared with ER-positive tumours
(n = 62) (P = 0.005, independent t test). There was no signif-
icant association of miR-520g with other tumour characteris-
tics, including HER2/neu status, tumour size, grade, stage or
nodal status.
Discussion
In the wake of molecular profiling and the identification of
intrinsic subtypes, breast cancer is now considered a hetero-
geneous group of disease entities with distinct clinical, patho-
logical and molecular features. This biologic heterogeneity has
implications for treatment; response to therapy can be pre-
dicted by subtyping tumours based on their expression pro-
files [2]. The molecular subclasses of breast cancer that are
predictive of prognosis are based on their expression of spe-
cific genes including ER and HER2/neu: luminal-A subtype,
ER+/HER2/neu-; luminal-B subtype, ER+/HER2/neu+; basal-
like subtype, ER-/PR-/HER2/neu-; HER2/neu-overexpressing
subtype, ER-/HER2/neu+ [1]. The expression of these recep-
tors alone has also been shown to have an effect on chemo-
Figure 5
Coordinate expression of co-located microRNAsi . Scatterplots of expression values for microRNAs located adjacently on the same chromosome. (a) 
miR-16 and miR-15a; Ch13q14.3. (b) miR-16 and miR-15b; Ch3q26.1. (c) miR-143 and miR-145; Ch5q14. (d) miR-99a and let-7c; Ch21q16. 
(e) miR-195 and miR-497; Ch17p13.1. (f) miR-520g and miR-520h; Ch19q13.42. (g) miR-17-5p, miR-18a, miR-19a, miR-19b, miR-20a, miR-92; 
Ch13q31.3.
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therapy sensitivity [28]. Furthermore, the only targeted
therapies currently used in the management of breast cancer
are directed at these receptors; ER-positive tumours are
treated with endocrine therapy in the form of selective ER
modulators, pure anti-oestrogens such as fulvestrant that com-
pletely inhibits ER signalling, or aromatase inhibitors that
deplete extragonadal oestrogen synthesis. The monoclonal
antibody trastuzumab has been developed to target the
HER2/neu, while lapatinib inhibits HER2/neu-associated tyro-
sine kinase activity.
The specific combination of receptor status has a significant
impact on the outcome of these targeted therapies; HER2/
neu-positive breast cancer is less responsive to any type of
endocrine treatment [29]; approximately one-half of HER2/
neu-positive breast cancers are also ER-positive, and this
breast cancer subgroup (luminal B) is thus more refractory to
endocrine therapy – despite the ER-positive status. In addi-
tion, many patients with HER2/neu-positive breast cancers do
not respond or eventually evade trastuzumab by both de novo
and acquired mechanisms of therapeutic resistance. The sub-
set of patients who are HER2/neu-negative and ER-negative
(basal like/triple negative) are a particular therapeutic chal-
lenge as they typically exhibit aggressive clinical behaviour and
poorer prognosis. Focused research has revealed promising
strategies for treating this subtype of breast cancer, including
platinum agents, epidermal growth factor receptor (EGFR)-tar-
geted agents and poly(ADP-Ribose) polymerase (PARP)
inhibitors; however, there is as yet no specific target for effec-
tive tailored therapy in this subgroup.
Clearly the hormone (ER and PR) and HER2/neu receptors
are vitally important to the current classification and manage-
ment of breast cancer; however, there is little knowledge
regarding the precise regulation of these receptors. For this
reason we sought to identify miRNAs associated with these
receptors.
Figure 6
Correlation between microRNA expression on microarray and RQ-PCR. For a subset of microRNAs (miRNAs) and samples we performed RQ-PCR 
to independently assess miRNA expression. RQ-PCR data are normalized using let-7a and miR-16. There is generally good correlation between 
miRNA expression using the two techniques. probe-specific differences were observed, however. R value using Pearson correlation, P < 0.05 signif-
icant.
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Microarray profiling is a useful strategy for examining global
gene and miRNA expression [17]. Messenger RNA profiling
has been central to breast cancer subtyping. Adaptation of
microarray-devised gene sets into routine clinical practice,
however, has been hindered by the apparent lack of consen-
sus between gene sets. One reason for this hindrance is that
the classical computational analysis of such highly dimen-
sional microarray data has proved problematic as it is not
robust enough. The inherent noise (for example, experimental
error, sample and chip variability) can significantly interfere
with the development of accurate predictive models, and their
performance is compromised by their modelling of extraneous
portions of the dataspace. Michiels and colleagues ques-
tioned the robustness of the analysis of several microarray
studies, and found that the molecular signatures were largely
dependent on the selection of patients in training sets and that
several of the largest studies addressing cancer prognosis
failed to classify patients better than randomly [30].
ANNs were chosen as the bioinformatics tool for microarray
data analysis for the present study due to their ability to cope
with complex data and the potential for modelling data of high
nonlinearity. For this reason, they have been widely applied to
a range of domains including character/face recognition [31],
stockmarket predictions [32], or survival prognosis for trauma
victims [33]. ANN model development is achieved by a training
process involving the adjustment of the weighted interconnec-
tions between nodes within the neural network over a defined
number of epochs. This adjustment occurs by the iterative
propagation of the predictive error back through the entire net-
work with a learning algorithm (for example, the back-propaga-
tion algorithm used in the present study). ANNs have already
been successfully applied in a number of contexts where mark-
ers of biological relevance have been identified, including poly-
cystic ovarian syndrome [34], melanoma [22], prostate cancer
[35] and breast cancer [36].
The miRNA expression profiles have shown superior accuracy
to mRNA signatures at classifying tumours [17]. The novel
application of ANNs to the analysis of miRNA array data
should serve to enable breast tumours to be classified accord-
ing to their miRNA expression profile, and should also focus
Figure 7
Expression of miR-342 and miR-520g in breast tumours. RQ-PCR detection analysis shows that expression levels of miR-342 are increased in: (a) 
oestrogen receptor (ER)-positive tumours compared with ER-negative tumours (P = 0.04), (b) v-erb-b2 erythroblastic leukaemia viral oncogene 
homolog 2 receptor (HER2/neu)-positive compared with HER2/neu-negative tumours (P = 0.001), and (c) luminal-B subtype of breast tumours (P 
= 0.001). (d) miR-520g expression is increased in ER-negative tumours compared with ER-positive tumours (P = 0.005) and in progesterone 
receptor (PR)-negative tumours compared with PR-positive tumours (P = 0.032). MicroRNA expression presented as log10 of the relative quantity. 
*P < 0.05, **P < 0.005.
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attention upon a relatively small number of molecules that
might warrant further biochemical/molecular characterization
to assess their suitability as potential therapeutic targets.
In the present study, miRNA transcript signatures predictive of
ER, PR and HER2/neu status were generated from microarray
data using an ANN model (Tables 3 and 4). The breast
tumours selected for the array experiment were relatively
homogeneous in terms of other clinicopathological parame-
ters, all being early stage (stages 1 and 2a) and free of nodal
disease. In the first step of the analysis, miRNAs capable of
classifying tumour samples according to receptor status with
an accuracy of 67 to 87% were identified. Sequential selec-
tion and addition of miRNAs to the ANN successfully identified
an optimum miRNA set based on predictive performance.
While the model shows high confidence for the dataset ana-
lysed (100% predictive accuracies), further validation is
required on larger datasets and validation of the miRNA sets
identified using alternative methods such as PCR.
Confirmation of the expression data from the microarray by
RQ-PCR was used for validation in this dataset; the expres-
sion patterns of a subset of eight miRNAs was validated in the
same sample set by stem-loop RQ-PCR, and there was signif-
icant positive correlation in sample-to-sample expression pat-
terns between the two techniques (Figure 6, P < 0.05).
Furthermore, the expression patterns and phenotypic associa-
tions of the top-ranking miRNAs miR-342 and miR-520g were
validated in an independent sample set of 95 tumours (Figure
7).
The miRNA signatures generated for ER status (miR-342,
miR-299, miR-217, miR-190, miR-135b, miR-218), for PR
status (miR-520g, miR-377, miR-527-518a, miR-520f-520c)
and for HER2/neu status (miR-520d, miR-181c, miR-302c,
miR-376b, miR-30e) include miRNAs that have previously
been identified as dysregulated in breast cancer and other
cancers [7,9,37-43] and involved in the regulation of cell func-
tions such as growth, apoptosis, migration and invasion
[38,42,43]. This finding suggests that the miRNAs thus iden-
tified are biologically relevant and their selection is not arbitrary
or a result of the highly dimensional nature of the data.
Notably, two chromosomal locations account for a number of
the dysregulated miRNAs in these predictive sets: Ch19q13
(miR-520g, miR-520d, miR-527-528a, miR-520f-520c, miR-
181c) and Ch14q32 (miR-342, miR-299, miR-377, miR-
376b). Allelic deletions on chromosome 14q32 are frequently
observed in various tumours, including renal cell carcinoma
[44], neuroblastoma [45], colorectal carcinoma [46], bladder
cancer [47], ovarian carcinoma [48], meningioma [49] and
breast carcinoma [50].
Approximately one-third of human miRNAs are organized in
clusters, which may represent a single transcriptional unit and
coordinated regulation – possibly leading to synergistic bio-
logical effects, as suggested by the inclusion of miRNAs from
adjacent chromosomal locations in our signatures. This may
contribute to our finding that while single miRNAs are capable
of distinguishing between different breast tumours (step 1;
Table 4), multiple miRNAs in combination significantly
enhance the predictive power of these models (step 2; Table
3). Our finding of co-expression of other neighbouring miRNAs
not included in the predictive signatures (Figure 5) is in con-
cordance with previous studies [7,51] and is probably due to
shared regulatory elements.
A primate-specific conserved miRNA family is located at
Ch19q13.42 [52]. Two miRNAs from this location, miR-373
and miR-520c, have previously been shown to stimulate can-
cer cell migration and invasion in both in vitro and in vivo mod-
els and to be expressed at increased levels in metastatic
breast cancer [43]. The miRNAs from this family were associ-
ated with ER, PR and HER2/neu status in our analysis. Similar
seedpairing in miRNA families indicates that they may function
through the same pathways and share mRNA targets – such
as CD44, identified as a target of miR-373 and known to cor-
relate with survival in breast cancer patients [53]. It is likely that
this particular miRNA family has a significant regulatory role in
breast cancer.
miR-520g was ranked as the top miRNA in the PR signature
and also was identified in step 1 of the analysis as an ER-pre-
dictive miRNA. Both of these findings were validated using
RQ-PCR in a larger, more heterogeneous cohort of 95 breast
tumours (Figure 7d). To our knowledge this is the first report
of miR-520g dysregulation in association with ER and PR sta-
tus in breast cancer. Importantly, miR-520g is computationally
predicted to target a number of breast-cancer-related genes
including ABCG2 (BCRP) [54]. ABCG2/BCRP is an ATP-
binding cassette transporter that is often associated with
multidrug resistance due to its ability to remove substrates
from a cell against a concentration gradient [55]. ABCG2
expression in cancer cells has been shown to confer a drug-
resistant phenotype and correlates with response to anthracy-
clines in breast cancer [56]. The regulation of ABCG2/BCRP
is controlled via oestrogen and progesterone response ele-
ments [57,58], and the steroid hormones have been shown to
impact on ABCG2 expression [57,59,60].
Recent studies have shown that ABCG2 expression is also
regulated by miRNAs including miR-328 [61], leading to
increased mitoxantrone sensitivity, and by miRNAs from the
Ch19q13.42 cluster. Specifically, ABCG2 is downregulated
by miR-519c in drug-sensitive cells via a binding site in the 3'
UTR that is not present in their drug-resistant counterparts
[62], and miR-520h targets ABCG2 in hematopoietic stem
cells during their differentiation into progenitor cells [63]. miR-
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520g shares sequence homology with miR-520h, and these
miRNAs were coordinately expressed in our dataset (Figure
5); it is therefore probable that miR-520g may also be a regu-
lator of ABCG2. This hypothesis warrants further investiga-
tion; identification of miRNA binding sites in the 3' UTR of
genes such as ABCG2 that promote multidrug resistance
could enable the delivery of specific miRNAs from this cluster
to tumours in an attempt to repress ABCG2 and to increase
sensitivity to existing therapeutic agents.
The ER-status predictor miR-342, identified as having the
strongest response curve, was also chosen for further charac-
terization. Expression of miR-342 in the larger cohort of breast
tumours (n = 95) using RQ-PCR confirmed the microarray
findings of an association between miR-342 and ER positivity.
Furthermore, we report the first findings of an association
between miR-342 and HER2/neu positivity. Increasing evi-
dence suggests that miR-342 plays an important role in the
carcinogenic process, particularly in the hormonally regulated
breast cancer. miR-342 is dysregulated in multiple myeloma
[64] and has been shown to be epigenetically silenced by
methylation in colorectal carcinoma [42]. In vitro studies have
demonstrated that introduction of a hsa-miR-342 mimic to
colorectal cancer cells induces apoptosis, suggesting a
potential tumour suppressor role for this miRNA [42].
Previous miRNA profiling studies in breast cancer have identi-
fied associations between miR-342 and ER, intrinsic breast
cancer subtype and tumour grade [7,9]. A recent study has
shown downregulation of miR-342 in tamoxifen-resistant
breast cancer cells compared with tamoxifen-sensitive breast
cancer cells, suggesting a potential role as a biomarker of drug
sensitivity [65]. To our knowledge this is the largest number of
primary breast tumours in which miR-342 has been quanti-
tated using RQ-PCR. Our findings of increased miR-342
expression in both ER-positive and HER2/neu-positive
tumours is of particular interest as the luminal B (ER+/HER2/
neu+) and triple-negative tumours present particular therapeu-
tic challenges. In the present study, miR-342 has emerged as
a potential candidate for regulation of ER/HER2/neu expres-
sion that warrants further functional investigation to elucidate
its mRNA targets and its precise role in breast carcinogenesis.
Conclusions
Our novel use of ANN to analyse miRNA expression profiles
has identified biologically relevant miRNAs capable of discrim-
inating between tumours with differing hormone receptor sta-
tus in breast cancer. This approach contributes to the
understanding of miRNA expression profiling in breast cancer,
and the selection of the most predictive signatures has identi-
fied specific individual miRNAs and families of miRNAs that
are promising candidates for future functional studies. These
miRNAs have a potential influence on the behaviour of breast
cancer subtypes in addition to their role as potential biomark-
ers. Uncovering the miRNA layer of genetic regulation will be
part of the optimal approach to targeted therapy in breast can-
cer; this involves improving our understanding of molecular tar-
gets such as ER, PR and HER2/neu in addition to identifying
novel molecular pathways and targets in order to predict
response and to identify pathways of primary and acquired
resistance to therapy.
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Abstract. With the advent of new genomic platforms there is the potential for data 
mining of genomic profiles associated with specific subclasses of disease.  Many 
groups have focused on the identification of genes associated with these subclasses.  
Fewer groups have taken this analysis a stage further to identify potential associations 
between biomolecules to determine hypothetical inferred biological interaction 
networks (e.g. gene regulatory networks) associated with a given condition (termed 
the interactome). Here we present an artificial neural network based approach using 
the back propagation algorithm to explore associations between genes in hypothetical 
inferred pathways, by iteratively predicting the level of expression of each gene with 
the others, with respect to the genes associated with metastatic risk in breast cancer 
based on the publicly available van’t Veer data set [1].  We demonstrate that we can 
identify a subset of genes that is strongly associated with others within the metastatic 
system.  Many of these interactions are strongly representative of likely biological 
interactions and the interacting genes are known to be associated with metastatic 
disease. 
Keywords: artificial neural networks; breast cancer; metastasis; interactions; 
interactome. 
1   Introduction 
1.1   The interactome problem and its potential 
Recently, with the advent of gene expression array platform technologies, a large 
number of groups have focused on the profiling of a range of diseases and conditions.  
While huge efforts have focused on the generation of data, fewer groups have 
addressed issues of appropriate analysis.  The data generated by microarray platform 
technologies is non-linear and highly dimensional with significant redundancy.  This 
necessitates analysis strategies that appropriately identify components of functional 
relevance.  To date, many groups have analysed microarray data for the identification 
of gene signatures that associate with specific clinical questions. For example van’t 
Veer et al. [1] and West et al. [2] focused on genes associated with metastases in 
breast cancer. However, not all of the potential information contained within these 
datasets has been deeply investigated and by limiting our efforts to single biomarkers 
we are attempting to model a real-world system that is dynamic, highly complex and 
correlated. 
More recently groups have considered the use of microarray data for the 
investigation of gene regulations in terms of a more systems level view of the 
processes associated with disease. Barabási & Oltva stated that “it is increasingly 
clear that a discrete biological function can only rarely be attributed to an individual 
molecule.” [3], but on a highly and complex interaction of biomolecules.   While the 
identification of gene signatures remains important, investigating an extension of this 
in describing how these gene sets change in expression, and subsequently change the 
expression of other genes of functional relevance with a given clinical question has 
the potential to elucidate  novel disease specific pathways that may be used to identify 
potential therapeutic targets. 
1.2   Interaction studies 
Several techniques for the exploration of interaction networks in both proteins and 
genes have already been described. Examples include likelihood approaches [4] and 
Bayesian methods [5]. A number of groups focused their studies on the use of 
functionality to define interactions [6-8]. Schlitt & Brazma present a review of 
methodologies for gene regulatory networks [9]. However, the main disadvantage of 
many of these methodologies is that they provide only limited information regarding 
the nature of the interactions.  In many cases only the presence of an interaction is 
considered.  Furthermore, interactions are often only considered in the context of the 
target, and not within the whole gene marker pool. 
To overcome current limitations we propose a novel approach based on back-
propagation (BP) artificial neural networks (ANNs) that simultaneously considers all 
genes in a dataset. This will be introduced using genes associated with distant 
metastasis in breast cancer explored previously by the van’t Veer study [1]. This is 
achieved by the development and comparison of a series of ANN models, each of 
which uses all available inputs (genes) to predict the expression of a single omitted 
input.  This is repeated for all single inputs within the set.  By examination of the 
weights and predictive performance of each model a matrix of interactions can be 
determined.  The advantage of this approach over others is that the multi-factorial 
consideration of each input allows the magnitude of interaction to be determined for a 
given pair of parameters,   whether it be inhibitory, stimulatory, bi or unidirectional. 
Once the initial screening is complete, non-significant interactions are removed using 
a decision threshold based upon the absolute values of the association between each 
input determined by the matrix of interactions. This study adopts an approach based 
on iterative prediction of each single input expression from all the others in a defined 
set.  The results from each of these models are subsequently integrated into an 
interaction map based on the weights of each sub model.  All sub models used to 
define the interaction map are extensively validated by Monte Carlo Cross Validation 
(MCCV).  Previously, other groups have only investigated inferences by an analysis 
of large complicated ANN models associated with particular classes of expression 
[10-11]. This study advances upon these methods by allowing the direct prediction of 
associations between expressions of genes.  The problems analysed are broken into 
small components that are unlikely to suffer from dimensionality issues associate with 
model complexity. Further, through a process of MCCV, early stopping and 
optimisation on a validation dataset, the findings are more likely to reflect a real-
world solution and not an overfitting of the dataset of interest. 
1.3   Artificial Neural Networks 
ANNs are from the field of artificial intelligence and can “learn” from patterns by 
example [12-13], by adapting the connectivity between the nodes of the network. 
ANNs have been widely used in biology and Lisboa et al. [14] reviews their use in 
cancer applications. A major advantage of ANNs is their ability to cope with noisy 
and non-linear data, such as that found in microarray studies. Learning in ANNs 
occurs by adapting the weights of the connections between nodes of subsequent 
layers. 
1.4   The dataset 
The dataset we used here consisted of the gene profiling with microarray from the 
seminal van’t Veer breast cancer study  [1]. This was, downloaded in excel format 
from http://www.rii.com/publications/2002/vantveer.html, and contained 78 samples, 
each with 24,481 inputs representing the expression ratio of each gene. 
2   Materials and Methods 
2.1   Data-preprocessing  
The dataset was utilized as presented by the van’t Veer data set [2].  All the data were 
normalized to get a coherent dataset. The level of expression of every single gene was 
rescaled between 0 and 1 through all the cases. 
2.2   Pre-screening of the data to determine genes associated with metastatic risk 
The ANN algorithm described in [13] and [15] was successfully applied to the dataset 
to screen microarray data for genes of relevance to a given biological question.  Here, 
we have utilised this approach to select the most important genes that can accurately 
predict the metastatic risk class described in the van’t Veer study [1]. Gene 
microarray intensities from the arrays were used as single inputs to the ANN model.  
The output node represented two classes; 0 represented no distant metastases within 5 
years, 1 represented cases who developed distant metastases within 5 years. The 
performance for each single gene model was determined based on prediction accuracy 
on a test dataset using cross validation. This produced a rank order of genes based on 
their predictive performance for the metastatic risk class.  The top 100 genes defined 
in this analysis were further used in our interaction algorithm.  
2.3   The interaction algorithm 
The main idea of the approach lies on the iterative calculation of the influence that 
multiple variables may have on a single one. Indeed, if we have been able to use all 
the variables to explain one particular outcome, we can now use one of these variables 
as an outcome and all the remaining to explain the level of expression of the first one, 
and therefore be able to find out the influence everyone has on this particular gene 
expression level. Once the first input is complete, we repeat the procedure for all the 
other variables. 
The interaction algorithm presented in this study is based on a three-layer feed 
forward Perceptron with a BP algorithm and a sigmoid transfer function [16]. The 
hidden and output layers consisted of 2 and 1 nodes respectively. Training was 
performed through 3000 epochs, terminated by either a window of 1000 epochs 
without improvement of the Mean Squared Error (MSE) on the validation subset, or 
an MSE threshold of 10-2.  Momentum and learning rate were set respectively at 0.5 
and 0.1 as previously shown [13]. Training was repeated 50 times for each model, 
with MCCV applied prior to training to randomly split the patients in three different 
subsets; here the training set comprised 60% of the cases, and  validation and test sets 
contained 20% each.   
To define an interaction map for a given set of genes, the first input gene in the 
dataset was defined as an output.  All others were set as inputs and applied to the 
ANN architecture and algorithm described above.  The weights of the trained ANN 
model were stored.  This process was iteratively repeated for all inputs in the dataset, 
treating each one in turn as an output.  The weights relating a given input to a given 
output were then analyzed based on the sum of weights leading from an input to the 
output, to determine the intensity of the relationship between a source (input) and 
target (output). Analysis of the weights across all of the potential associations 
provided a rank order of their strength. 
2.4   Visualisation of Interaction maps 
The concept of the interaction mapping uses the network theory as described 
previously [3], where a single marker is symbolised by a node and any relation 
between two markers is represented with a directed edge, and/or an arrow setting one 
of the node as a source, and the other one as a target. Cytoscape® [17] was used for 
interaction visualisation. 
2.5   Filtering the interaction map to determine the key interactions for the 
metastatic risk system 
A matrix of interactions between variables was generated and extracted. Every 
association between any pair of variables contained in the dataset was investigated. 
Most interactions were found to be of non-significance. As this algorithm produces a 
huge amount of results (n inputs giving n(n-1) associations), non-significant 
associations were filtered out so that only the highest absolute values remained.  A 
filter value of 5 was used and the sign of the interaction was preserved so we could 
determine a direction for the mapped interaction indicating whether it was inhibitory 
or stimulatory. 
3   Results 
The approach was tested on the Van’t Veer dataset [1]. In the first instance this 
consisted of screening the rank order of genes in terms of strength of predicting 
metastasis.  The distribution of the genes ranked by their predictive error for test data 
was obtained (data not shown here), and clearly showed that the top genes have a 
higher ability to predict, and therefore are most relevant for the system being 
investigated by interaction analysis. The best predictor in the gene set was the mRNA 
sequence referred to as NM_001216 which codes for carbonic anhydrase IX (CA9), a 
protein involved in breast cancer prognosis and relapse [18]. 
To assess the interactions within the genes associated with prognostic outcome top 
100 predictors were submitted to the interaction analysis. These genes had a range of 
predictive ability for test data between 72% for the first gene to 62.7% for the 100th. 
Analysis of the resulting weights from the interaction analysis produced a matrix of 
9900 potential associations.  It clearly appears that no relevant information can be 
elucidated from this interaction map due to its high dimensionality and complexity. 
Figure 1 displays the distribution of the ranked interaction values.  The majority of 
the interactions have low absolute values ranging from -10.9 to +17.2. The 
distribution of interaction indicates that there are very few strong links compared to 
the overall population of links.  These warranted further investigation. 
During the interaction analysis, the overall predictive performance of the models 
was assessed to define the interaction map by determining the correlation coefficient 
between actual and predicted levels. Therefore, the error values of the model were 
constantly assessed to produce a level of confidence for the interactions identified. In 
this dataset the average r2 values was 0.665. 
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Fig. 1. Distribution of the interaction sorted by values. The interactions in dark grey at the 
extremities represent the strongest interactions at level 5. 
 
A filter removing links between -5 and +5 was applied which resulted in the 
number of links decreasing from 10,000 to 163 (1.63% of the original interactome).  
This greatly simplified the interaction map, facilitating interpretation and 
understanding of the key features within the global interaction map as shown in 
Figure 2. 
 
 
Fig. 2. Display of the interaction map reduced to level 5.  Red is a positive interaction 
(stimulation).  Blue is a negative interaction (inhibition). 
From this map, we could identify the highest positive interaction involving 
NM_016448 (Retinoic acid-regulated nuclear matrix-associated protein) which is 
known to have a role in cancer cell proliferation [19], and Contig42933_RC, which 
corresponds to the genbank accession number R73468, referring to an unknown gene 
which has already been strongly associated with metastasis in breast cancer [20]. In 
the opposite negative direction, the strongest interaction was between NM_016448 
and Contig55725_RC, the cell division cycle associated 7 (CDCA7). This has been 
shown to be over expressed in human tumours [21]. 
Moreover, we can clearly identify some key nodes involved in dense regions of 
interactions. Again, NM_016448 (Retinoic acid-regulated nuclear matrix-associated 
protein) appeared as a key feature within the whole interaction network, interacting 
strongly (within the strength of interactions over 5) with 35 other genes. Significantly, 
most of these interactions (33) have NM_016448 as the target. 
According to these preliminary observations it appears that Retinoic acid-
regulated nuclear matrix-associated protein has a key role in the whole interactome in 
this breast cancer study. This is in agreement with the literature which has 
demonstrated its implication in breast cancer [19] with the ability to decrease the 
expansion of cancer cells. Moreover, the mRNA sequence for CA9, previously 
identified in the screening step as the best predictor for metastasis in this case series, 
belongs to one of the features interacting with the Retinoic acid-regulated nuclear 
matrix-associated protein (NM_016448). In addition, we show an interaction between 
CA9 and the mRNA for phosphoglycerate kinase 1 (PGK1). Interestingly, 
interactions between both have already been described in relation to cancer [22].  
4   Discussion 
Within this study we have sought to develop an algorithm for the exploration of 
interactions within gene microarray data.  This algorithm uses a multifactorial ANN 
based approach to model interactions. 
4.1   Advances 
This approach, incorporating an ANN based interaction mapping, offers the potential 
to identify key components and interactions in a multifactorial fashion. This may 
overcome limitations from previous studies using simple pairwise interactions, or 
those based upon biomolecular function, thus facilitating the identification of 
unidirectional influences. Moreover, the robustness of ANNs allows us to incorporate 
multiplatform data for exploration, and therefore not only focus on a particular 
system, but investigate on a wider scale for cross-platform interactions.  
4.2   Validation 
Earlier using the data supplied by West et al. [2], we have demonstrated that we can 
identify a rank order of key genes of biological relevance [15].  Similarly we have 
found a rank order of genes of biological relevance to metastasis here.  CAIX, 
appeared as the strongest feature from the screening step, and was seen to have a 
strong interaction with PCK1, both already described to interact and to be involved in 
breast cancer [22]. Moreover, the retinoic acid-regulated nuclear matrix-associated 
protein, known to have a role in cancer cell proliferation [19], has been found to be 
strongly influenced within the whole interactome. We have shown other features with 
biological significance, confirming a level of confidence we can have for the model 
developed and the overall method.  
However, despite these initial promising results, further validation both from the 
literature (and databases such as Ingenuity, or KEGG) and utilising gene silencing 
techniques needs to be conducted. 
4.3   Limitations 
The method is without its limitations. Firstly, the main limitation may come from the 
origin of the data itself. We are well aware that the collection of experimental data 
involves a certain level of bias. However, as we can only investigate and explore for 
relative interaction, none of the interaction is absolute, but relative to all the others 
within the dataset. This limitation may have an increased influence once the approach 
is applied to a cross-platform dataset. 
Another important limitation comes from the complexity of the overall 
interactome obtained, and the relevance of the filtering strategy employed. It will be 
challenging to address a filtering strategy with an acceptable false discovery rate.  
4.4   Future work 
The filtering strategy will have a key role in the future development of the approach. 
New approaches are under consideration, such as monitoring the deviation that 
multiple models can have and therefore filtering out any interactions that are not 
consistent over multiple runs of the process. 
Further validation of the method is fundamental. This will involve databases 
queries and literature reviewing. Under consideration is an automatised process to 
query the databases and literature. In addition, comparison with other existing and 
validated methods will be key, in order to prove the efficiency of this approach. 
Several alternative methods are under considerations, such as Bayesian Networks 
[23]. 
An additional approach that could be further investigated is using the interaction 
mapping process to investigate the differences between the interactomes of two 
different classes, for example the metastatic versus the non-metastatic breast cancer 
patients.  This may elucidate further features of interest associated with the breast 
cancer interactome. 
5   Conclusion 
A novel ANN based approach to predict the interactions which may exist between 
the components in a given dataset coming from high-throughput technologies has 
been described. The main advantages of the approach being its multifactorial 
character, and its reliance upon ANNs to allow for the inclusion of highly 
dimensional and non-linear data. Furthermore, the approach allows us to employ 
cross-platform datasets, and therefore we can apply the method to a wider scale. 
Preliminary results show this to be a novel and powerful tool for interactions 
discovery, which will allow for the investigation of biological systems and potentially 
provide a greater understanding of the underlying processes with a view to novel 
targets discovery. 
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Abstract
Applications of genomic and proteomic technologies have seen a major increase, resulting in an explosion in the
amount of highly dimensional and complex data being generated. Subsequently this has increased the effort by the
bioinformatics community to develop novel computational approaches that allow for meaningful information to be
extracted. This information must be of biological relevance and thus correlate to disease phenotypes of interest.
Artificial neural networks are a form of machine learning from the field of artificial intelligence with proven pattern
recognition capabilities and have been utilized in many areas of bioinformatics. This is due to their ability to cope
with highly dimensional complex datasets such as those developed by protein mass spectrometry and DNA micro-
array experiments. As such, neural networks have been applied to problems such as disease classification and
identification of biomarkers. This review introduces and describes the concepts related to neural networks, the
advantages and caveats to their use, examples of their applications in mass spectrometry and microarray research
(with a particular focus on cancer studies), and illustrations from recent literature showing where neural networks
have performed well in comparison to other machine learning methods.This should form the necessary background
knowledge and information enabling researchers with an interest in these methodologies, but not necessarily from
a machine learning background, to apply the concepts to their own datasets, thus maximizing the information gain
from these complex biological systems.
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INTRODUCTION
The intention of this review is to provide researchers
with an understanding of the potential benefits
of using artificial neural network (ANN)-based
approaches within a biomedical context. They may
be applied for classification, predictive modelling and
biomarker identification within data sets of high
complexity. The focus within this review is on
transcript or gene expression data generated from
DNA microarray (MA) analysis, or peptide/protein
level data generated by mass spectrometry (MS). In
‘Artificial neural networks’ section the concepts
behind ANN learning will be introduced and
described detailing their advantages and disadvan-
tages. This will include details on how robust models
are generated, tested and validated using suitable
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cross validation approaches. In ‘Regularization’
section the reader will be made aware of techniques
that must be applied during the modelling process in
order to obtain reliable results, a principal considera-
tion in highly dimensional datasets. In ‘Experimental
methods requiring robust bioinformatics’ section the
MS and MA technologies will be outlined. In ‘Data
complications in proteomics and genomics’ section,
issues of high dimensional input data and the
importance of reproducibility will be examined. In
‘Recent applications’ section, examples of publica-
tions detailing how ANNs are currently being used
in genomic MA and proteomic MS studies will be
summarized. ‘Comparison to other machine learning
methods’ section provides highlighted case studies
where ANNs have performed favourably in com-
parison to other common statistical and machine
learning methodologies. ‘Future trends’ section
briefly outlines the advanced steps necessary once
a validated ANN biomarker signature has been
discovered. ‘Conclusions’ will sum up the review.
Researchers with an interest in the potential benefits
that ANN approaches may bring to their laboratories
should then be able to apply them to their own
datasets, maximizing the information to be gained
from the analysis of complex biological systems.
Background
There are a number of steps required in order
to identify and validate a biomarker so that it can
be used in a clinical setting [1], and despite the
increasing use of high-throughput technologies such
as MS and gene MAs, there remains a lack of
clinically useful biomarkers emerging for diseases
such as cancer. There may be several reasons for this,
such as the reported lack of reproducibility of these
approaches [2–5], and the sheer mass of data being
generated, which is often extremely noisy, and is
becoming progressively complex. This is particularly
true in the field of ‘-omics’, where for example, in
the recent Affymetrix GeneChip 1.0 ST MAs
(designed to target all known and predicted exons
in human, mouse and rat genomes), each individual
case studied contains information for approximately
1.2 million exon clusters corresponding to over 1.4
million probesets. Thus teasing out the key com-
ponents from these datasets requires the use of
mathematical models running on hardware capable
of efficient analyses. The discovery of new biomar-
kers could facilitate more reliable, efficient and less
subjective methods to assist the human expert in the
diagnosis of disease, as well as providing new
potential targets for future therapies.
With this in mind, it is clear that the identification
of new biomarkers still requires a concerted, multi-
disciplinary effort. This necessitates the requirement
for specific computational tools for data-mining, and
as such remains a major challenge in bioinformatics
[6]. One such tool are ANNs [7], a form of machine
learning from the field of artificial intelligence
utilized in many areas of bioinformatics and medicine
[8] due to their ability to cope with noisy, non-linear
and highly dimensional datasets, in particularly when
appropriate regularization strategies are employed
and when combined with appropriate feature
reduction methodologies or forward selection meth-
ods such as that proposed in [9]. Using ANNs, it is
possible to analyse these sophisticated datasets in
identifying novel gene or protein signatures
(biomarkers or fingerprints) of biological systems in
an endeavour to identify specific phenotypes for
diagnosis of disease, establishing a patient’s clinical
outcome, or even predicting a patient’s response to
therapy.
ARTIFICIALNEURALNETWORKS
ANNs are inspired by the way in which the
human brain learns and processes information, with
the ability to handle complex (non-linear) features
within data in order to generalise and predict well for
future cases. Their concept simulates the behaviour
of a biological neural network; in humans, learning
involves minor adjustments to the synaptic connec-
tions between neurons, in ANNs, the learning
process is based on the interconnections between
the processing elements that constitute the network
topology.
McCulloch and Pitts first described the concept of
the artificial neuron in 1943 as a mathematical
function derived from simulating the basic functions
of biological neurons [10]. This manuscript will focus
on ANNs in their most common form, the multi-
layer perceptron (MLP), but other ANN-based
approaches exist; for example radial basis function
networks and recurrent neural networks. In the
MLP, ANNs are organized into several layers, with
each layer having a number of respective neurons, or
processing elements, that constitute that layer
(Figure 1). Simply put, the majority of ANNs have
a similar topology consisting of an input layer, one or
more hidden layers and an output layer. The number
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of hidden layers and the number of neurons in each
layer is dependent on the complexity of the problem,
i.e. the number of input neurons. The input layer
interacts with the external environment to receive
the input data as a vector of predictor variables, each
represented as a node. This information is passed
through to the first hidden layer, and multiplied (thus
modified) by a set of associated weights. These
products are summed and fed through a non-linear
transfer function (e.g. sigmoid, hyperbolic tangent)
which scales and then produces an output, similar to
the axon of the neuron. The calculation of the
output for each neuron is then as follows:
vk ¼
Xn
i¼1
wkixi
and
yk ¼ ðvk þ vk0 Þ
where x1, x2. . .xn are the input signals converging to
neuron k.!k1, !k2. . .!kn are the weights connecting
neuron k. vk is the net input. yk is the output of the
neuron where vk0 is a bias term and (.) is the
activation function commonly of the form:
ðvÞ ¼ 1
1þ ev
for the sigmoid activation function and:
ðvÞ ¼ e
v  ev
ev þ ev
for the hyperbolic tangent activation function.
Ultimately this modified information reaches the
node(s) in the output layer, the result of which is the
output of the entire ANN, for example the predicted
class for a given case, or a continuous numerical
output in a regression model. In a two group
classification problem, the output in the training
examples is usually represented as 0 and 1, or 1 and
1. The interconnecting weights are crucial to the
system and also enable a variable strength to be given
to each input variable included in the model,
whether it is excitatory or inhibitory.
ANN learning
ANNs must be trained to efficiently compute the
gradient as to be capable of accurately modelling a set
of cases and predicting their output. There are two
major learning paradigms; supervised and unsuper-
vised. Supervised learning involves providing the
network with a set of cases that have values for the
inputs as well as the known desired outputs.
The output of the network is then compared with
the true output to calculate error by assessing the
network performance as learning progresses. The
interconnecting weights are initially randomized
(e.g. [1, 1]) so that predictions after completion
of the first training cycle are essentially random. One
of the most popular forms of supervised learning is to
compare the error between the true output and the
predicted output and then feed this error back
through the layers of the network. The weights are
adjusted so that after completion of the next training
cycle (or epoch) the error decreases according to:
!kiðÞ ¼ kxi
Each weight update !ki at the current (
th) cycle is
updated in proportion to the input value to which
the weight is applied xi, the error in the output
of the unit k and constants known as the learning
rate  [11]. The weight change of a neuron
is proportional to the influence an input had on
the error during training and the learning rate is a
constant which controls the size of these weight
changes. The larger the learning rate, the faster
learning will proceed; however too large a value may
lead to non-convergence of the model. Each time
a pattern is presented to the network, the weights
leading to an output node are modified slightly
during learning in the direction required to result in
a smaller error the next time the same pattern is
presented, until a target error is reached or no
improvement of the error is observed. The larger the
learning rate, the larger the weight changes and the
faster the learning will proceed. If the learning rate is
Figure 1: Architecture of a typical multi-layered
perceptron artifical neural network.
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too small, training will be slowed down, however,
oscillation or non-convergence can occur if the
learning rate is too large [12]. A momentum term, ,
may be applied to help prevent the network
becoming trapped in local minima, or being stuck
along flat regions in error space. This occurs with a
slight alteration to the weight update rule by making
the weight update on the th iteration depend on the
update that occurred during the ( –1th) iteration:
!kiðÞ ¼ kxi þ !kið  1Þ
This helps to speed up the time it takes for the
network to reach convergence by gradually increas-
ing the step size of the search in regions where the
gradient is not changing. As with the learning rate,
effectively choosing values for these constants
depends on the particular problem of interest and
experimentation is important here to find optimal
values. In our own experiences for MA and MS data,
a learning rate of 0.1 combined with a momentum of
0.5 has proved successful [9, 13]. The target error
that needs to be minimized is often determined
as the total sum-of-squares based on the difference
between the output and target vector as follows:
" ¼ 1
2
Xn
j¼1
ðdj  yjÞ2
where n is the number of cases, dj is the target
network output for case j and yj is the network
predicted output for case j. Alternative error
functions also exist, such as the mean squared error,
or the maximum conditional likelihood fitting, but
will not be dwelt upon here. This learning process is
an extension of the generalized delta rule, and is
commonly known as back-propagation [14–16].
It is crucially important that the data used in training
the network should be reasonably large in order
to contain all the information necessary to be able to
recognize which of the predictor variables are
important amongst the vast amounts of noise and
individual variation that is expected to cloud
important information in complex ‘-omics’ datasets.
If the network outputs fail to show good discrimina-
tion on an independent test dataset, over-fitting may
have occurred and training must be continued or
repeated. Over-fitting can occur when the number
of parameters in a model exceeds the number of
cases. It is in essence a memorization of the training
data (and any associated random noise) [17, 18]. In
order for the network to be trained to a satisfactory
level which maintains generalization for new data,
it is vital to employ an appropriate regularization
technique (discussed later in the review). Once
learning is complete the weights are stored and can
be used to predict future cases in separate test
datasets. Other learning algorithms have also been
proposed. These include (but are not limited to)
QuickProp [19], RPROP [20] and the Levenberg–
Marquardt algorithm [21, 22].
Unsupervised learning occurs when the network
attempts to map the inputs to outputs without any
external assistance. Therefore the network itself
governs how it groups the cases based upon the
input data. This is sometimes referred to as self
organization, and Kohonen’s self organizing maps
[23] are the most popular form of neural network-
based unsupervised learning. Other forms of unsu-
pervised learning include principal components
analysis, independent components analysis, hebbian
learning and autoassociators. Although unsupervised
learning algorithms are an active area of research, it is
beyond the scope of this review to explain and
review their application in detail and consequently
this manuscript will focus on the use of supervised
neural networks. For a more detailed discussion on
unsupervised pattern recognition in high-throughput
genomics and proteomics see [24].
Advantages and disadvantages of
artificial neural networks
As ANNs are loosely based on the way a biological
neuron is believed to organize and process informa-
tion, they have many advantages in their ability to
derive meaning from large complex datasets. First,
they do not rely on data to be normally distributed,
an assumption of classical parametric analysis
methods. They are able to process data containing
complex (non-linear) relationships and interactions
that are often too difficult or complex to interpret by
conventional linear methods. Another advantage is
that they are fault tolerant, i.e. they have the ability
of handling noisy or fuzzy information, whilst also
being able to endure data which is incomplete or
contains missing values. In addition to this (like other
machine learning methods), they are capable of
generalization, so they can interpret information
which is different to that of the training data, thus
representing a ‘real-world’ solution to a given
problem by their ability to predict future cases or
trends based on what they have previously seen.
Thus, trained ANNs can be used as standalone
executable systems in order to predict the class of an
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unknown case of interest, and therefore have the
potential application in diagnosis. Finally, there are
several techniques that can be used to extract
knowledge from trained ANNs, and the importance
of individual variables can be easily recovered using
various methods such as the analysis of interconnect-
ing network weights [25], sensitivity analysis and rule
extraction [26]. This, from a biological perspective, is
perhaps one of the most useful aspects of ANN
modelling. Gevrey et al. [27] review this subject in
more depth.
Like all approaches, ANNs also have their
limitations. Training of ANNs can potentially be
time consuming depending on the complexity of the
data being modelled, and as the number of hidden
layers required to capture the features of the data
increases, so does the time taken for training to
complete. As such, only one or two hidden layers are
commonly used. Over-fitting may be a problem in
ANNs, which is a memorization of the training cases
causing the network to perform poorly on future
cases. The one major barrier which researchers
usually associate with ANNs is that it is not always
apparent how they reach a solution, and because
of this they have been referred to as ‘black boxes’
[28–31].
Further limitations originate from the data itself.
Experimental data may suffer from high background
variation that is difficult for computational algo-
rithms to interpret. The challenges in terms of
reproducibility of some technologies has also been
investigated [18, 32–39], rendering validation with a
separate cohort of samples virtually impossible. The
old adage ‘garbage in, garbage out’ can be strongly
applied to modelling with ANNs, and thus the
quality of the model output is highly dependent
upon the quality of the input data. If the input data is
not representative of the ‘real world’ scenario, the
model is compromised. To overcome these issues,
several techniques for pre-processing the data have
been proposed, and the reader is referred to [40–45]
for more examples, and for a guide to considerations
regarding study design see [2].
Implementing artificial neural networks
Implementing ANNs is usually performed with
statistical computer software packages, or open
source equivalents in R (http://www.r-project.
org/index.html) and Weka (http://www.cs.waikato.
ac.nz/ml/weka/). A comprehensive list of ANN
software packages can be found at ftp://ftp.sas.com/
pub/neural/FAQ6.html#questions.
REGULARIZATION
Commonly the main purpose of modelling is to
simulate a real world system and therefore a model is
judged on its ability to generalize to new data. In
ANNs the risk of low generalization is mainly
attributed to over-training of the model, leading to
over-fitting and subsequently poor predictive per-
formance during independent validation. Due to the
fact that even a linear model would over-fit in high
dimensions, ANNs must be appropriately regularized
during training in order to achieve sufficiently high
predictive performances. In order to address this,
regularization techniques need to be applied during
training. Several options for regularization exist and
methods can be chosen according to the type of
data or generalization performance that is required.
This section will now briefly introduce some of the
most common forms.
Weight decay
One of the simplest regularization methods to
implement is weight decay. In weight decay, the
error function includes a penalty term, for example
the sum of squared weights and biases multiplied by
a decay constant that controls how much the
penalty term should affect the resulting error
function. Since over-fitted models are more likely
to contain unusually large weights, this approach
aims at penalizing such large weights, in order to
keep weight values smaller than they naturally
otherwise would converge at, thus keeping the
activation of the neurons in the linear range [7].
Resampling and early stopping
According to Ntzani and Ioannidis [46], independent
validation is only conducted in about 10% of MA
studies published. Given the fact that these complex
datasets are likely to be non-linear in nature, one
may not have prior information regarding the
intricacies of the data. As such it is vital to estimate
the performance of these models on new data in
order to be confident that over-fitting has been
avoided. It was stated earlier that the back-propaga-
tion algorithm should stop training once the network
has achieved an acceptable level, however, the
question remains as to what is considered to be an
acceptable level, and what can be done to ensure that
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the model will be capable of generalizing to
additional future cases. If training is terminated
solely on the basis of a set number of iterations the
model is at risk of over-fitting. The most universal
approach to address this problem is resampling.
Typically in ANN-resampling approaches, the data
is split into different subsets, where a percentage of
the total sample set is used to train and optimize the
ANN (the training set) and (sample size permitting)
the remaining are partitioned for validation during
training (the validation set) and external testing after
the modelling is complete (the test set). A crude
regularization technique known as the early stopping
mechanism monitors the network error with respect
to a validation or test dataset. This process signals to
stop training either when a predetermined number
of iterations have completed, or when the prediction
accuracy of the model begins to worsen for the
validation or test dataset, a sign of over-fitting. The
weights resulting in the minimum validation or
test error are then selected. Once the network has
completed the learning process, it is further validated
using the test data split, to give an unbiased
estimation of the networks likely performance on
future unseen cases. Examples of this approach
can be found in [8] and [12].
Bayesian regularization
The Bayesian regularization approach involves
modifying the target function (such as the sum of
squared errors) in order to improve the models
generalization ability. The Bayesian regularization
aims to smooth the cost function by adding to it
a regularization parameter based on the sum of
squared weights. To reduce bias, the weights and
variables of the network are assumed to follow a
Gaussian distribution and are assigned prior prob-
abilities, optimized according to the Bayesian
framework of Mackay [47]. Network training then
attempts to find the trade-off between minimizing
the model complexity and model error, as such
minimizing both the bias and variance [48]. Methods
such as automatic relevance determination will
identify and remove unnecessary parameters from
the model since the Bayesian approach provides
an estimate for the entire distribution of model
parameters rather than a single optimal set of
weights. Model comparison is based on highest
evidence, rather than cross validation, and as such
Bayesian regularization maximizes the data available
as it does not require a validation set since all the
training data can be used for model fitting. A review
of Bayesian methods for supervised neural networks
can be found in [49], and an example of its
application in a microarray study can be found
in [48].
Cross validation
There are a number of cross validation approaches
used to give an unbiased estimation of the error rate.
Examples of these will now be discussed.
First, in Monte Carlo resampling, a training,
validation and test set are randomly constituted, with
a predetermined number of cases in each subset. All
three sets may be randomized, or alternatively the
test subset may be kept constant, with the training
and validation sets drawn at random a number of
times, to enable comparison between models for
validation data [7].
Bootstrapping has been shown to be an effective
strategy for estimating the error of predictive values
in neural network models, and therefore is a reliable
approach in determining generalization of the net-
work [50]. In bootstrapping, rather than repeatedly
analysing subsets of data (as in the Monte Carlo
approach), subsamples of the data are analysed,
where many ‘pseudo-replicates’ are created by
resampling the original data. Here, cases are drawn
at random from the data set, with equal probability,
in order to replicate the process of sampling multiple
datasets. The 0.632 bootstrap error estimator has
been preferred in small sample microarray classifi-
cation [51, 52].
k-fold validation is an effective approach when
the number of samples is not efficient enough to split
the data into three subsets. In a widely used version
of this called leave one out cross validation [53, 54],
N divisions are made (where N is the total number of
cases in the dataset) and in each division the network
is trained on all of the samples except one, which is
set aside for test purposes. This process is repeated so
that all of the samples are used once for testing.
Tenfold validation is commonly used when the
number of samples is relatively high (e.g. >100)
whilst leave-one-out methods are useful when the
training set is lower (e.g. <100) or when the number
of features is higher than the number of examples.
This multiple cross validation helps to minimize
overlap of the test set compared to resampling. For
an overview of assessing the accuracy of prediction
algorithms for classification problems, the interested
reader is directed to [55].
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EXPERIMENTALMETHODS
REQUIRING ROBUST
BIOINFORMATICS
The advent of these high-throughput techniques
has increased the potential for identification of
new biomarkers massively. These methods facilitate
the comprehensive profiling of samples representing
disease states. The hurdle to overcome with these
technologies is now the sheer complexity of the data
generated. This complexity is necessary to represent
coverage (or even partial coverage given current
technological limitations) of the genome or pro-
teome. MAs are one of the methods commonly used
for the high throughput sample profiling at the
transcript level, whilst MS is being used to detect
changes at the protein level. These technologies are
therefore complementary to one another in describ-
ing biological systems, and the basic principles will
be briefly outlined.
Microarrays
A DNA MA consists of a solid surface, onto which
DNA molecules have been chemically bonded. The
purpose of MAs is to detect the presence and
the abundance of labelled nucleic acids in a given
biological sample, which will then hybridize to the
DNA on the array, and become detectable via the
label. The source of the labelled nucleic acids is
the mRNA of the sample of interest, so therefore the
purpose of a MA is to measure gene expression. As
there may be thousands of different DNA molecules
bonded to an array, it is possible to measure the
expression of many thousands of genes simulta-
neously, leading to the potential for extremely high
throughput analysis. There are two major types
of MA technology used today; firstly cDNA and
secondly oligonucleotide arrays, such as those
marketed by Affymetrix. For a more detailed
explanation of the technology, the reader is referred
to [56], or more specifically [57] and [58] for cDNA
and oligonucleotide MAs respectively.
Mass spectrometry
MS approaches, more specifically MALDI (matrix-
assisted laser/desorption ionization) and a modifi-
cation of this named SELDI (surface enhanced laser
desorption/ionization) TOF (time of flight) MS
are now being readily used to generate proteomic
profiles of biological samples. Simply, a mass spectro-
meter consists of an ion source, a mass analyser to
measure the mass/charge ratio (m/z) of the analytes
which have been ionized (mass spectrometers do not
measure mass directly, but rather the mass to charge
ratio of ions formed), and finally a detector that
records the number of ions at each m/z value. This
generates a spectrum according to the time of
flight of the ion, directly related to its mass, or a
‘fingerprint’ for the sample being analysed. For an
overview of the method see [59]. These analyses
have an inherent ability to generate profiles consist-
ing of hundreds of thousands of points, with each
point representing a protein mass, a peptide mass or a
fragment of the above. This high dimensionality
provides an obstacle and limits many analysis
methods.
DATACOMPLICATIONS IN
PROTEOMICSANDGENOMICS
Dimensionality and complexity
Biological ‘-omics’ datasets are unusual in that there
is a very large p (input variables) and relatively
small n (cases). As the dimensionality of the input
data space (p n) increases, it becomes exponentially
more difficult to find a global optimum for the
parameter space. This has been termed ‘the curse of
dimensionality’ [60], and often leads to an input
space with many irrelevant or noisy inputs, which
coupled with the wide heterogeneity commonly
found in biological samples, make it difficult to
identify the truly important markers with predictive
algorithms performing badly as a result of them
modelling extraneous portions of the data space.
Conventional statistical theory would indicate that
for a valid representation of the population one
should have a model where n> p, and some rules
state that to have confidence in results there should
be at least 10 events for each variable [61]. Clearly
some form of dimensionality reduction/variable
selection algorithm is required to satisfy this, because
acquiring a data set containing hundreds of thousands
of samples is not feasible. Ma and Huang [62] review
the topic of feature selection in bioinformatics, and
for a review to approaches for dimensionality
reduction in biomarker studies the reader is referred
to [63].
Reproducibility
Superimposed on the dimensionality issues are those
of data quality. In order to identify biomarkers the
data should be reproducible within samples, between
sample runs and across multiple instruments (at least
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instruments of the same model) [64]. This can be
optimized through the use of technical and experi-
mental replicates, where filtering and averaging of
samples are methods which are commonly used to
assess reproducibility and increase the confidence in
the profiles for comparison. Technical replicates
provide information on the variability that occurs
when performing a particular assay, whilst experi-
mental (or biological) replicates give a measure of the
natural sample to sample variation. Lack of reprodu-
cibility decreases the validity of markers and makes
validation and ultimately clinical use difficult [65].
Low reproducibility within the data adds to the issues
of dimensionality by making the relevant features
within data sparser with respect to the overall noise.
Low replication and poor data quality can lead to the
introduction of features not representative of disease,
but of sample run, sample collection, storage and
preparation. This introduces random, noisy and
unimportant features within the data, further
increasing the problem of data analysis.
RECENTAPPLICATIONS
This section will now highlight recent applications
of ANN technologies in MAs and MS. Since the
majority of studies involving the use of ANNs are in
tumour diagnosis, the following will focus on the
field of cancer. Table 1 summarizes the majority of
studies using ANNs with these technologies since
2001, and a selection of these will now be discussed
in more detail.
Genomics
The seminal paper by Khan et al. [66] was perhaps
the first major application showing the potential
advantages of using ANNs for these complex
datasets. Here they used principal components
analysis (PCA) followed by ANNs to classify 88
round blue-cells tumours into four diagnostic
categories based on cDNA MA analysis of over
6000 genes. Due to the high accuracy of the models
developed the authors eluded to the potential use of
ANN-based methodologies ‘as an adjunct to routine
histological diagnosis’. This dataset was made avail-
able for the scientific community to download and
has since formed the basis for several more studies
using various ANN-based algorithms in the success-
ful classification of these samples [67–70].
In [71], Gruvberger and colleagues used PCA for
dimensionality reduction followed by ANN analysis
to predict the oestrogen receptor (ER) status of
58 tumours from their gene expression profiles.
Here they performed a series of classifications using
different sets of 100 genes and showed the ANN
performance to be good discriminators on this data.
As a result of using ANNs, they hypothesized that
the classification was not only controlled by a few
differentially expressed genes, but a more complex
expression pattern existed involving a larger number
of genes.
In predicting long term survival of 40 patients
with large B-cell lymphoma, O’Neill and Song [72]
used the data generated by Alizadeh et al. [73]
containing 12 078 transcripts representing expression
levels for 4026 genes. This was the first time ANNs
were shown to have the ability to perfectly classify
(100% accuracy) this type of high dimensional data,
and also provided a robust solution for reducing
Table 1: Cancer studies using artificial neural networks
to analysemicroarray andmass spectrometry data since
2001
Platform Cancer type Number
of cases
Number
of classes
References
MA Astrocytoma 65 2 [86]
MA Astrocytoma 60 2 [69]
SELDI-TOF Astrocytoma 12 2 [80]
MA Breast 58 2 [68, 71]
MA Breast 10 2 [87]
MA Breast 49 2 [9]
MA Breast 78 2 [69, 88]
MA Breast 15 2 [69]
SELDI-TOF Breast 40 2 [89]
SELDI-TOF Breast 82 2 [90]
MA Colorectal 62 2 [69, 91]
SELDI-TOF Colorectal 147 2 [82, 92]
SELDI-TOF Colorectal 93 2 [83]
MA Oesophageal 28 2 [93]
MA Leukaemia 72 2 [94]
MA Leukaemia 64 2 [95]
MA Leukaemia 38 2 [69]
MA Leukaemia 57 3 [69]
MALDI-TOF Liver 132 2 [84]
SELDI-TOF Liver 106 2 [96]
SELDI-TOF Liver 182 2 [97]
MA Lung 32 2 [69]
MA Lymphoma 40 2 [72]
MA Lymphoma 220 2 [75]
MALDI-TOF Melanoma 100 2 [65]
SELDI-TOF Melanoma 205 2 [85]
MA Myeloma 105 2 [77]
MA Neuroblastoma 56 2 [76]
MA Ovarian 54 2 [98]
MA Prostate 102 2 [69]
SELDI-TOF Renal 138 2 [81]
MA SRBCT 88 4 [66^70]
SRBCT: small round blue cell tumours.
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unknown noise and redundancies in datasets whilst
maintaining correct classifications.
Using the data made accessible by Rosenwald
et al. [74], Ando and co-workers [75] described the
use of fuzzy neural networks as an approach to
variable selection in the expression profiling of 220
diffuse large B-cell lymphoma patients in an effort to
predict survival from 7384 genes. Here, using just
four genes, ANNs were shown to predict outcome
with a classification accuracy of 73%. The analysis in
the original manuscript achieved a lower accuracy
using more genes in a Cox model. Moreover, the
authors showed that by increasing the number of
genes in their model to 35 (many of which were
clinically relevant to the prognosis of lymphoma),
the accuracy increased to 91%. They were able to
extract informative rules from their models, with a
view to using these approaches in future approaches
focused on personalized medicine.
Wei et al. [76] used cDNA MAs to analyse 56
tumour samples from patients with neuroblastoma.
Total 37 920 data points for each of the samples
remained to be analysed after the removal of poor
quality data. Due to this complexity, the authors
chose to utilize the power of ANNs in order to
develop a predictor of survival. Using all of the data
in a model, high accuracies were achieved (88%).
What is more, they proposed an ANN base gene
minimization strategy and identified a signature of 19
genes, some of which had previous affiliations as
prognostic markers. This subset of 19 genes had the
ability to correctly classify 98% of the patients
and further partition the patients into subgroups
according to survival status. They concluded that
ANN-based approaches such as this would allow
therapies to be tailored in a patient specific manner
according to their gene expression profiles.
Using ANNs to analyse a 7129 gene expression
dataset derived from 74 patients diagnosed with
multiple myeloma and 31 normal bone marrow
cases, Narayanan et al. [77] showed how genes that
were consistently positive or negatively expressed
could be identified from large datasets. They
achieved this by using the interconnecting weights
of the trained ANN model, and demonstrated how
ANNs could be utilized as a powerful method for
dimensionality reduction by identifying 39 genes
with 100% generalization on unseen cases. Many of
these genes had been previously linked to cancer.
Furthermore, the authors described how symbolic
knowledge can be extracted from these trained
ANN models in order to create simple rules. For
example, if gene x is present then myeloma, and if
gene y is absent then normal. This made clear the
potential for the use of ANNs in a clinical setting.
In one of our own studies [9], we presented
a novel stepwise algorithm using ANNs so that
optimal predictive gene signatures can be identified
from highly complex, noisy and heterogeneous
datasets. Using the dataset published by West et al.
[78] we identified gene subsets highly predictive
for ER status and lymph node status in 49 breast
cancer cases analysed by MA containing 7129 gene
transcript intensities per patient. As with other studies
using ANNs, many of these genes had previously
been associated with cancer. When the models were
applied to a completely separate 88-patient cohort
dataset made available by Huang etal. [79], accuracies
of 88% and 83% were seen for predicting ER and
lymph node status respectively. This manuscript also
showed how ANNs could be used in the interroga-
tion of predictive biomarkers to provide an insight
into how the increased or decreased expression
affects the class of interest, enabling rules for
molecular classification to be derived.
Proteomics
One of the first major applications of ANNs for
the analysis of MS data was in the classification of
astrocytoma by Ball et al [80]. They showed the early
promise of utilizing SELDI-TOF MS technology
combined with intensive computer algorithms
for protein expression screening in cancer patients.
Here ANNs were used to screen 100 000 data
points generated by SELDI-TOF MS, and by
scrutinizing the interconnecting network weights,
the authors were able to assign a relative importance
value to each ion in terms of its contribution to the
classification. The top 50 ions were identified, which
could be grouped into several sub-groups according
to their mass. Furthermore, an additive approach was
performed in order to find the optimal combination
of ions in terms of predictive ability. This led to
the identification of two ions that in combination
were able to predict tumour grade with an accuracy
of 94%.
Rogers et al. [81] also used SELDI-TOF MS in
their study on urinary proteins in renal cancer. Here,
ANNs were utilized in an effort to detect early onset
of disease, and identify indicative biomarkers.
Following pre-processing using peak identification,
ANN models were built and trained using several
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types of controls (healthy controls and benign cases
combined with healthy controls). Both peak pre-
sence/absence (categorical), as well as actual peak
intensities (continuous) were used, with the latter
shown to be more efficient. This highlighted
the importance and extra information gain that is
achieved using actual intensity data to capture the
heterogeneity in biological systems rather than peak
presence/absence. Moreover, this study utilizing
ANNs achieved superior results to the urinary
protein assays that were available at the time for
bladder cancer.
With a current lack of reliable biomarkers for
colorectal cancer, Chen etal. [82] proposed the use of
proteomics combined with ANN analysis for
the discovery of key proteins able to distinguish
colorectal cancer patients from a healthy population.
To achieve this, MS profiles were generated by
SELDI-TOF MS for an age and gender matched
cohort of 55 colorectal cancer cases and 92 healthy
controls. Initially analysis by cluster analysis showed
54 peaks of interest, culminating in the identification
of four candidate biomarkers significantly elevated in
colorectal cancer patients. These four ions were then
used in an ANN model to build a classifier and
discriminate healthy controls from cancer. Here,
this approach was shown to outperform discriminant
analysis and achieve a sensitivity of 91% and
specificity of 93%.
Similarly, Ward et al. [83] were also interested
in data mining SELDI-TOF MS data for reliable
biomarkers of colorectal cancer. They performed
proteomic profiling on 62 colorectal cancer patients
and 31 non-cancer controls. First, feature selection
by t-test was conducted, with statistically significant
differentially expressed peaks selected for ANN
training. The final ANN model included seven
peaks and was able to classify with high sensitivity
(95%) and specificity (91%), and outperformed CEA
(a marker of proven benefit in prognosis and benefit)
in discriminating colorectal cancer.
In an effort to improve the prognosis of breast
cancer patients through early diagnosis, Hu et al. [54]
also used SELDI-TOF-MS to explore for reliable
tumour markers in serum. They performed screening
of the serum proteome in 49 breast cancer patients,
51 patients with benign breast diseases and 33
healthy controls. Total 253 mass peaks were
identified using discriminant analysis in classifying
between breast cancer and benign, and also between
breast cancer and benign plus controls. Using a
stepwise approach to assess the predictive ability for
each peak, an ANN was able to narrow down the
number of markers of interest to just four peaks.
These were able to accurately predict the outcome of
cancer with a sensitivity of 76% and specificity of
90% for the blind test set. This four-peak model did
not result in a statistically significant reduction
predictive performance compared to the 253 peak
model, and therefore the four-peak model was
shown to be more parsimonious in discriminating
cancer patients from healthy controls.
Luk et al. [84] focused their work on hepatocel-
lular carcinoma biomarkers, investigating differ-
entially expressed proteins between tumour and
adjacent healthy liver tissue. Here, proteomic
profiling was performed using MALDI-TOF MS
and 2D gel electrophoresis followed by analysis by
ANNs and decision trees. Both techniques proved
to be excellent discriminators of the two pheno-
types, with ANNs superior in both training and
validation data.
Mian et al. [85] were interested in profiling the
serum proteome in the classification of early and late
stage melanoma, and also predicting disease progres-
sion. Here, screening of the patients’ proteome was
performed with MALDI-TOF MS, showing an
interesting signal with significantly higher intensity in
25% of the stage IV samples. ANN modelling in
the lower mass range of the spectrum was shown
to accurately classify between disease stages and
also between progressors and non-progressors.
Interestingly, when predicting disease progression,
this ANN approach was shown to outperform S100-
, a widely utilised correlate of tumour burden in
melanoma.
COMPARISON TOOTHER
MACHINE LEARNINGMETHODS
There have been a number of studies comparing
ANNs with other statistical and machine learning
approaches to data analysis. Some of these will now
be briefly reviewed, outlining how ANNs have
performed compared to other statistical and machine
learning methods when applied to biological data.
This brief discussion will include but will not be
focused singly on MA and MA methodology
benchmarking studies, as few have been published.
Dreiseitl et al. [99] compared the ability of KNN,
logistic regression, ANNs, decision trees and SVMs
in classification of skin lesion data. The authors found
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logistic regression, ANNs and SVMs to give almost
identical results, with k-nearest neighbours and
decision trees performing the worst. Interestingly,
even the worst of the five methods (decision trees)
achieved sensitivity and specificity values comparable
to human experts indicating these approaches may
be of use to assist human decisions in the medical
arena.
Sargent [100] carried out a review on 28 cases
comparing ANNs with other statistical approaches
when applied to medium and large data sets with
more than 200 cases. ANNs outperformed regression
in 36% of the studies, and was outperformed in 14%
of the studies, with the results being similar in the
remaining cases.
Pal et al. [67] used an ANN-based approach in
categorizing subgroups of cancer from microarray
data. They identified a smaller number of biomarkers
when compared to other machine learning tool such
as SVMs whilst performing equally well, suggesting
ANNs found a more parsimonious solution. The
study performed in [101] was a direct comparison of
SVMs and ANNs in the detection of mammographic
CAD. Overall, the authors found a similar perfor-
mance between the two techniques, with ANNs
slightly outperforming SVMs in detection and
diagnosis in the test set of data.
Song and co-workers [102] compared various
machine learning techniques to more classical
statistical approaches in the prediction of outcome
in two datasets. They used ANNs (single and multi-
layered), logistic regression, least squares linear
separation and support vector machines (SVMs)
to determine the risk of death in a population of
patients with cardiac problems. They found the
multi layered ANN to be consistently better than the
other approaches, suggesting that the ability of the
ANN to model non-linear data was providing
additional information regarding the datasets leading
to higher predictive capabilities [103].
Eftekhar and colleagues [104] made a comparison
between ANNs and logistic regression models to
study patients with head injury trauma. It was
reported that ANNs significantly outperformed the
logistic models in discrimination and calibration
(goodness of fit) in 77.8% of cases but under-
performed in 68% of cases when comparing model
accuracies.
In the study by Hu et al. [54] the authors
compared their ANN model with other commonly
used machine learning techniques such as SVMs and
decision trees. They showed ANNs to be more
reliable than the other methods in the discrimination
of cancer patients from normal controls from mass
spectrometry data.
Shen and Tan [105] used different coding
strategies and feature selection methods in comparing
SVMs to other machine learning methods on two
cancer microarray datasets. Here, ANNs achieved
similar results to SVMs and outperformed K-nearest
neighbour and C4.5 decision tree approaches.
Another direct comparison between ANNs and
SVMs was performed by Romero and Toppo on
a variety of benchmark datasets [106]. Overall,
ANNs obtained similar accuracies to SVMs and the
two approaches remained competitive across the
different datasets.
In 2008, Peterson and co-workers [69] performed
a comparison of a large number of machine learning
methods (including ANNs, SVMs, K-nearest neigh-
bour, linear discriminant analysis and logistic regres-
sion) in the classification of DNA microarrays in
cancer research. One of the main findings here was
that at the greatest level of sample size ANNs
out-performed all other methods resulting in the
greatest area under the curve.
Judson et al. [107] performed a comparison of six
machine learning approaches in complex simulated
datasets. They showed that, particularly when using
a large number of features, ANNs and SVMs
were always the top performers, whereas recursive
partitioning and regression trees and K-nearest
neighbours were always the poorest.
In a study investigating heart rate variability
before a Paroxysmal atrial fibrillation event using
ANNs and SVMs [108], Chesnokov showed ANNs
provided better results in terms of sensitivity,
specificity and positive predictive value compared
to SVM which became biased towards positive cases.
Muselli and co-workers [109] proposed an
ANN-based method for gene selection microarray
data. In both the artificial and the real gene
expression data, they showed that SVMs exhibited
poor performance compared to the ANN-based
method.
FUTURETRENDS
As with the development of a novel therapeutic
agent, model systems representing novel biomarker
expression signatures (be it gene or protein expres-
sion) must be validated carefully and extensively in a
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medical setting. Trained models of these biomarker
signatures need to be incorporated into simple
software solutions so that medical practitioners
who are unsavvy in machine learning techniques
can simply enter the biomarker profiles from their
patients and receive an instant prediction with an
acceptable degree of confidence. If it can be shown
that the application of such models leads to an
improvement in medical care towards the holy grail
of cost effective ‘personalized medicine’, then these
ANN software applications may be more widely
acceptable and made more readily available to assist
patient care in a larger number of hospitals and
clinics.
CONCLUSIONS
Rapidly advancing technologies in genomics and
proteomics have increased the complexity of data
being generated, and with that the requirement for
robust data mining approaches in order to analyse
and extract panels of biomarkers from biological
systems. This review introduces one such approach,
artificial neural networks, as a robust tool able to
digest these datasets and identify the key components
(biomarkers), thus providing an increased under-
standing of the biological system being modelled
whilst also pointing out potential therapeutic targets
for focusing future research. Representative works in
this field and comparisons with other popular
statistical and machine learning techniques are
highlighted to provide the interested reader with
the sufficient background information required so
that they can utilize the potential power of these
approaches in the modelling of their own complex
datasets.
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